The role of the CXCL12 – CXCR4 chemokine ligand – receptor

interaction in the metastasis of prostate cancer by Arya, M.
 1 
The role of the CXCL12 – CXCR4 
chemokine ligand – receptor 
interaction in the metastasis of 
prostate cancer 
 
by 
 
Manit Arya 
 
 
 
 
 
 
 
 
A thesis submitted in fulfilment of the 
requirements for the degree of MD(Res),  
Division of Surgery and Interventional Science, 
University College London. 
 
 
 
 2 
DECLARATION 
This work has not previously been accepted in substance for any degree and is not being 
concurrently submitted in candidature for any degree.  
This thesis is the result of my own investigations, except where otherwise stated.  
I hereby give consent for my thesis, if accepted, to be available for photocopying and for 
inter-library loan, and for the title and summary to be made available to outside 
organisations.  
Signed…Manit ARYA………………………………… (candidate)  
Date…10TH Sept 2010…………………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
ABSTRACT 
 
 
 
The aim was to investigate whether chemokine ligand – receptor interactions are involved 
in the chemotaxis of prostate cancer to favoured metastatic sites.   
 
Initially, chemokine receptor mRNA expression, CXCR and CCR groups, was 
determined using conventional RT-PCR in cell lines derived from prostate cancer 
metastases, DU145, LNCaP and PC3, the primary prostate cancer cell line 1542 CPT3X 
and the normal prostate epithelial/ stromal cell lines 1542 NPTX, Pre 2.8 and S2.13. It 
was observed that in the cell lines derived from prostate cancer metastases, CXCR4 
mRNA expression was relatively high. Using real-time quantitative PCR it was 
subsequently established that in DU145, LNCaP and PC3 cells, CXCR4 mRNA 
expression was 1287, 407 and 21 times respectively that of 1542 CPT3X. 1542 NPTX 
and 1542 CPT3X had similar levels of CXCR4 mRNA (the former had only twice that of 
the latter) and Pre 2.8 had no detectable CXCR4 mRNA expression. In laser 
microdissected patient primary tumour samples and patient benign tissue specimens 
CXCR4 mRNA expression was higher than that of the metastatic cell lines. Flow 
cytometry analysis showed that significantly higher levels of the CXCR4 protein were 
present on the cell membrane of the three metastatic cell lines. Cell migration assays 
revealed that chemotaxis of the metastatic cell lines PC3 and DU145 was enhanced by 
CXCL12 ligand and inhibited anti-CXCR4 antibody.  
 
We have demonstrated that human prostate cell lines derived from metastases express 
functional CXCR4 receptor and that CXCL12 ligand enhances their migratory 
capabilities. Also, primary patient tumours and patient benign tissue specimens express 
CXCR4 mRNA at high levels (it is suggested that in vivo post-transcriptional 
modification and/ or regulation of CXCR4 receptor at the protein stage may significantly 
affect cellular protein levels). These results suggest that the CXCL12-CXCR4 axis may 
be involved in the metastasis of prostate cancer to preferred organs.  
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ABBREVIATIONS 
 
A – adenosine 
Ab – antibody 
AIDS – acquired immune deficiency syndrome 
AC – adenyl cyclase 
ADC – analog to digital converter 
AR – androgen receptor 
ATCC – The American Type Culture Collection 
 
BLAST – basic local alignment search tool 
BMP – bone morphogenetic protein 
bp – base pairs  
BPE – bovine pituitary extract 
BPH – benign prostatic hyperplasia 
BSA – bovine serum albumin 
BSA-PBS – bovine serum albumin in phosphate buffered saline 
 
0C – degrees Celsius 
cAMP – adenosine 3’, 5’-cyclic-monophosphate 
CAMs – cell adhesion molecules  
CCD – charge-coupled device 
CD – cluster of differentiation  
cDNA – complementary (to RNA) deoxyribonucleic acid 
c-Met – Met tyrosine kinase 
CSC – cancer stem cells 
Ct – threshold cycle  
 
DAG – diacyl-glycerol 
dATP – deoxyadenosine triphosphate 
dCTP – deoxycytidine triphosphate 
ddNTPs – di-deoxynucleoside triphosphates 
DEPC – diethylpyrocarbonate 
dGTP – deoxyguanosine triphosphate 
DNA – deoxyribonucleic acid 
dNTPs – deoxynucleoside triphosphates 
dsDNA – double stranded deoxyribonucleic acid 
DTT – dithiothreitol 
dTTP – deoxythymidine triphosphate 
dUTP – deoxyuridine triphosphate 
 
e value – expectation value 
EB buffer – elution buffer 
ECL – extracellular loop 
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ECM – extra-cellular matrix 
EDTA – ethylenediaminetetraacetic acid 
EGF – epidermal growth factor 
EGFR – epidermal growth factor receptor 
ELR – glutamic acid-leucine-arginine  
EPC – endothelial progenitor cells 
ERK – extracellular signal-regulated kinase 
ET-1 – endothelin-1 
ETV4 – Ets variant 4 (part of Ets family of transcription factors) 
Ets – E twenty-six family of transcription factors 
 
FACS – Fluorescence Activated Cell Sorter 
FAM – 6-carboxyfluorescein 
FBS – foetal bovine serum 
FDA – Food and Drug Administration 
FGF – fibroblast growth factor 
FITC – fluorescein isothiocyanate 
FRET – fluorescence resonance energy transfer 
FS – fluorescent sequencing 
 
GA1000 – gentamicin, amphotericin B 
GAPDH – glceraldehyde-3-phosphate dehydrogenase 
GDF-9 – growth differentiation factor 9 
GDP – guanosine diphosphate 
GI number – GenInfo Identifier sequence identification number 
GITC – guanidine isothiocynate 
GMFI – geometric mean fluorescent intensity 
GTP – guanosine triphosphate 
 
HAEC-I – immortalised human aortic endothelial cells 
hASCs – human adipose tissue derived stem cells 
HBME – human bone marrow endothelial cells 
HDMVEC – human dermal microvascular endothelial cells 
hEGF – human epidermal growth factor 
HEX – hexachloro-6- carboxyfluorescein 
HGF – hepatocyte growth factor/ scatter factor 
HIF-1 – hypoxia-inducible factor-1 
HIV - human immunodeficiency virus 
HPF – high power field 
HSC – haematopoietic stem cell 
HUVEC – human umbilical vein endothelial cells 
 
IGF – insulin-like growth factor  
IL – interleukin 
IP3 – inositol-1,4,5-triphosphate 
IUIS – International Union of Immunological Societies 
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JOE – 6-carboxy-4,5-dichloro-2,7-dimethoxyfluorescein 
 
kb – kilobase pairs 
kDa – kilodalton 
Keratinocyte-SFM – keratinocyte serum free medium 
KSHV-GPCR – Kaposi's sarcoma herpesvirus-G protein-coupled receptor 
 
M – molar 
MAP kinase – mitogen-activated protein kinase 
mg – milligrams 
ml – millilitres 
mM – millimolar 
MMP – matrix metalloproteinase  
mRNA – messenger ribonucleic acid 
 
NCBI – National Centre for Biotechnology Information 
ng – nanograms 
NK cells – natural killer cells 
nM – nanomolar 
nmol – nanomoles 
NSCLC – non-small cell lung cancer 
NTC – no template control 
 
OD – optical density 
oligodT – oligodeoxythymidine 
OPG – osteoprotegerin 
 
p – probability 
32P – radioactive isotope of phosphorus 
PBS – phosphate buffered saline 
PCR – polymerase chain reaction 
PDGF – platelet derived growth factor 
PE – phycoerythrin 
PE buffer – wash buffer 
PE–CY5 – phycoerythrin and cyanine-5 conjugate 
PGE2 – prostaglandin E2 
PI – propidium iodide 
PI3K – phosphphatidylinositol-3-OH-kinase 
PIP2 – phosphatidylinositol-4,5-biphosphate 
PKB – protein kinase B 
PKC – protein kinase C 
PLA2 – phospholipase A2 
PLC – phospholipase C 
pmol – picomoles 
PMT – photomultiplier tube 
PrEGM – prostate epithelial specific growth medium 
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PSA – prostate specific antigen 
PTHrP – parathyroid hormone-related peptide  
PYK – proline-rich tyrosine kinase 
 
QG buffer – solubilisation buffer 
 
R110 – rhodamine 110 
R6G – rhodamine 6G 
RANKL – receptor activator of NF-kappaB ligand 
RCC – renal cell cancer 
RLT buffer – guanidine isothiocynate containing lysis buffer 
Rn – normalised reporter signal 
RNA – ribonucleic acid 
Rnb – fluorescence emission of the baseline 
Rnp – fluorescence emission of the product 
ROX – passive reference dye  
RPMI – Roswell Park Memorial Institute Medium 
rRNA – ribosomal ribonucleic acid 
RT – reverse transcriptase 
RT-PCR – reverse transcriptase polymerase chain reaction 
 
SCID – severe combined immune deficiency 
SCLC – small cell lung cancer  
SD – standard deviation 
SDF – 1 - stromal cell derived factor 1 
SE – standard error  
SEER – Surveillance Epidemiology and End Results  
Ser – serine 
STR – short tandem repeat 
SYBR Green – Synergy Brands, Inc Green 
 
T – thymidine 
TAE – tris acetate EDTA buffer 
Taq – Thermus aquaticus 
TAMRA – tetramethyl-6-carboxyrhodamine 
TAMs – tumour associated macrophages 
TET – tetrachloro-6 carboxyfluorescein 
TGF – transforming growth factor 
Thr – threonine 
Tm – melting temperature of primers 
TNF – tumour necrosis factor 
TCSC – tissue-committed stem cell 
TRIS – tris – (hydroxymethyl) – aminoethane 
Tween 20 – polyoxyethylene-sorbitan monolaurate 
 
µg – micrograms 
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µl – microlitres 
µm – micrometre 
µM – micromolar 
UNG – uracil DNA glycosylase (uracil N-glycosylase) 
uPA – urokinase type plasminogen activator 
uPAR – urokinase type plasminogen activator receptor 
UV – ultraviolet radiation 
 
V – volts 
VEGF – vascular endothelial growth factor 
VCAM – vascular cell adhesion molecule  
VIC – fluorescent reporter dye (composition not released by Applied Biosystems)  
VHL – von Hippel-Lindau 
 
WHO – World Health Organisation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 10 
TABLE OF CONTENTS 
                                                                                                                   Page 
 
CHAPTER 1: INTRODUCTION                                                             19 
 
Section 1.1: The epidemiology and the spread of prostate                20 
cancer          
 
Section 1.2: The theory of metastasis and prostate cancer                22 
 
Section 1.3: Chemokines and their structure                                     37 
 
Section 1.4: The role of chemokines and their receptors in               56 
cancer  
 
Section 1.5: Hypothesis and aims                                                      78 
 
 
 
CHAPTER 2: THEORY OF TECHNIQUES                                          80 
 
Section 2.1: Polymerase chain reaction and reverse                          81 
transcriptase-polymerase chain reaction   
 
Section 2.2: Real-time quantitative PCR                                           82 
Section 2.3: Flow cytometry                                                            103 
Section 2.4: Cell migration assays                                                   118 
 
 
 
CHAPTER 3: MATERIALS AND METHODS                                     120 
 
Section 3.1: Materials and methods used in chapter 4:                    121 
Elucidation of chemokine receptor mRNA  
                    expression (CXCR and CCR groups) in prostate  
                    cell lines 
 
 
 
 11 
Section 3.2: Materials and methods used in chapter 5:                    138 
Quantitation of CXCR4 mRNA expression in cell  
lines and patient prostate tissue samples  
 
Section 3.3: Materials and methods used in chapter 6:                    145 
Elucidation of cell membrane CXCR4 chemokine  
receptor (protein) expression in prostate cell lines 
 
 
Section 3.4: Materials and methods used in chapter 7:                    151 
Establishing that the CXCR4 receptor is functional in  
cell lines derived from prostate cancer metastases 
 
 
CHAPTER 4: ELUCIDATION OF CHEMOKINE RECEPTOR       154         
mRNA EXPRESSION (CXCR AND CCR GROUPS) IN  
PROSTATE CELL LINES 
Section 4.1: Introduction and Aims                                                  155 
Section 4.2: Results                                                                          156 
Section 4.3: Discussion                                                                    168 
 
 
CHAPTER 5: QUANTITATION OF CXCR4 mRNA                          173 
EXPRESSION IN CELL LINES AND PATIENT  
PROSTATE TISSUE SAMPLES 
 
Section 5.1: Introduction and Aims                                                  174 
Section 5.2: Results                                                                          176 
Section 5.3: Discussion                                                                    189 
 12 
CHAPTER 6: ELUCIDATION OF CELL MEMBRANE                    192  
CXCR4 CHEMOKINE RECEPTOR (PROTEIN)  
EXPRESSION IN PROSTATE CELL LINES 
 
Section 6.1: Introduction and Aims                                                  193 
Section 6.2: Results                                                                          195 
Section 6.3: Discussion                                                                    217 
 
 
CHAPTER 7: ESTABLISHING THAT THE CXCR4                         223  
RECEPTOR IS FUNCTIONAL IN CELL LINES  
DERIVED FROM PROSTATE CANCER METASTASES 
 
Section 7.1: Introduction and Aims                                                  224 
Section 7.2: Results                                                                          226 
Section 7.3: Discussion                                                                    233 
 
 
CHAPTER 8: FURTHER DISCUSSION                                               235 
 
Section 8.1: Results summary and evaluation                                  236                  
 
Section 8.2: Confirmatory studies of CXCL12 – CXCR4               242 
interaction in the migration and dissemination 
of prostate cancer 
 
Section 8.3: The importance of the CXCL12 – CXCR4 axis in      246    
tumour cell migration 
 
 
 13 
Section 8.4: Therapeutic implications                                              256 
 
Section 8.5: Concluding remarks                                                     264 
 
 
 
REFERENCES                                                                                          265 
 
 
 
APPENDIX: ABSTRACTS OF ARTICLES                                          308 
PUBLISHED FROM THESIS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14 
LIST OF FIGURES 
 
                                                                                                                                      Page 
CHAPTER 1 
Figure 1.1: The metastatic cascade                                                                                  24        
Figure 1.2: Structural classification of the chemokine family                                         40 
Figure 1.3: Diagrammatic representation of the chemokine receptor CXCR4                46  
                    (Fusin) 
 
Figure 1.4: The chemokine receptor signal transduction pathway in leucocytes             49  
 
 
CHAPTER 2 
Figure 2.1: The polymerase chain reaction                                                                       81 
Figure 2.2: The Taqman real time quantitative PCR assay (hydrolysis probes)              85 
Figure 2.3: The ABI PRISM® 7700                                                                                 88 
 
Figure 2.4: Model of a single amplification plot illustrating the nomenclature               91 
        commonly used in real-time quantitative PCR 
Figure 2.5: Emission spectra for 3 common fluorochromes                                           107 
 
Figure 2.6: The coaxial stream                                                                                       109 
 
Figure 2.7: Basic optics of a flow cytometer                                                                  110 
 
 
CHAPTER 3 
Figure 3.1: Optimisation of GAPDH PCR cycles                                                          132         
 
Figure 3.2: Costar Transwell culture chamber                                                            151 
 
 15 
CHAPTER 4 
Figures 4.1a – n: The expression of CXCR and CCR chemokine receptors                  158  
        and CXCL12 ligand in cell lines using standard RT-PCR 
                    performed at 35 cycles  
 
Figure 4.2: Nucleotide sequence electropherogram obtained by extracting the             167  
       CXCR4 PCR product from an agarose gel using the DU145 cell  
        line 
        
 
 
CHAPTER 5 
Figure 5.1: Optimisation of CXCR4 primer concentrations                                           177 
                     
Figure 5.2: Optimisation of starting RNA quantity                                                        178 
             
Figure 5.3: Relative amplification efficiency scatter plot                                               180                            
       
Figure 5.4a and b: Relative CXCR4 mRNA expression in cell lines and                186-87 
       patient samples using real-time (Taqman) quantitative RT-PCR 
                    
 
 
CHAPTER 6 
 
Figures 6.1a – e: Representative flow cytometry histograms and dot plots            198-202 
                    for the results of differential primary anti-CXCR4 antibody 
                    binding to DU145 cells using five different primary antibodies 
                     
Figures 6.2a – e: Dot plots demonstrating autofluorescence and non-specific              205
                    binding of secondary antibody 
 
Figures 6.3a – h: Representative flow cytometry histograms and dot plots             207-14 
                    are shown for cell membrane CXCR4 receptor expression in  
                    each cell line 
 
                   
                               
CHAPTER 7 
 
Figure 7.1: Photograph of migrating cells in one high power field in a                         227 
                   Transwell well at x200 magnification 
                     
 16 
Figure 7.2a-c: Effect of CXCL12α on chemotaxis of prostate cell lines                  229-31 
 
 
 
CHAPTER 8 
Figure  8.1: A summary of the pathophysiological role of CXCL12 – CXCR4            247  
                    interaction in cellular migration/ chemotaxis 
 
Figure 8.2: The hypoxic control of CXCR4 expression in renal carcinoma                  251  
       cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 17 
LIST OF TABLES 
                                                                                                                                      Page 
Chapter 1 
Table 1.1: Chemokine nomenclature                                                                                42 
Table 1.2: The four classes of chemokine receptors and their ligands                             44 
 
 
 
Chapter 2 
 
Table 2.1: A summary of the primer and probe design guidelines used by the              101 
      primer/probe design program, Primer Express, for real-time  
      quantitative Taqman PCR  
 
Table 2.2: Universal Thermal Cycling Parameters for real-time quantitative                102 
      TaqMan PCR 
 
Table 2.3: Photomultiplier detection of light emission produced by common               112 
      fluorochromes/ dyes in the Becton Dickinson FACScan  
 
 
 
Chapter 3 
 
Table 3.1: Details of continuous human cell lines used                                                  123 
 
Table 3.2: Details of chemokine receptor primers used in PCR                                     126 
 
Table 3.3: Constituents of a 20µl reverse transcriptase reaction                                    130 
 
Table 3.4: PCR master mix for 1x 50µl reaction                                                            131 
 
Table 3.5: CXCR4 Primers, Probe and Amplicon Details (designed using                    139 
     Primer Express® software and supplied by Applied Biosystems)  
 
Table 3.6: Clinically localized patient primary prostate tumour and benign                  141 
      prostate samples - summary of available information (all tissue  
      derived from frozen fresh radical prostatectomy specimens)  
       
Tables 3.7a and b: Details of primary and secondary antibodies used                     147-48 
 
 18 
Chapter 4 
 
Table 4.1: Summary of CXCR and CCR receptor and CXCL12 ligand                        165 
      expression observed in cell lines  
 
 
 
Chapter 5 
 
Table 5.1: Combination of CXCR4 forward and reverse primer concentrations           176 
      for optimisation (all primer concentrations are nM solutions) 
 
Table 5.2a: Calculation of relative CXCR4 mRNA quantitation, using the                   183 
                    comparative threshold (2-∆∆Ct) method, for one experiment 
        consisting of three samples for each cell line  
        
Table 5.2b: Mean relative CXCR4 mRNA expression in cell lines (with standard       184 
        deviation) for the three samples run in experiments 1, 2 and 3  
 
Table 5.2c: Represented here are the results of the mean relative CXCR4 mRNA       185 
                   expression for the laser microdissected patient samples, numbered 
                   1 to 18 
 
 
 
Chapter 6 
 
Table 6.1: The results of differential primary antibody binding to the cell                    197 
      membrane  CXCR4 receptor in the DU145 cell line using each 
      of five different primary anti-CXCR4 antibodies 
       
Table 6.2: This table summarises the results data from figure 6.3 and shows               206 
                  the results from one experiment elucidating cell membrane CXCR4  
                  receptor expression in cell lines  
 
Table 6.3: The overall mean GMFI +/ - standard deviation has been calculated           216 
from 3 separate flow cytometry experiments investigating CXCR4 
receptor expression in each cell line   
 
 
 
Chapter 7 
 
Table 7.1: Results of cell migration assays                                                                     228 
 19 
CHAPTER 1 
 
 
INTRODUCTION and HYPOTHESIS 
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SECTION 1.1 
The epidemiology and the spread of prostate cancer 
The burden of prostate cancer in the community 
Prostate cancer is one of the most frequently diagnosed cancers in Western men, 
with the incidence rate increasing in most countries since the 1980s. The highest 
incidence rates are reported in the USA, where in 2003 - 2007 the annual age adjusted 
incidence rate was 150.4 per 100,000 caucasian men and 234.6 per 100,000 men of Afro-
Carribean descent, using the Surveillance Epidemiology and End Results (SEER) data 
[www.seer.cancer.gov/statfacts/ accessed June 2010]. In 2000, prostate cancer became 
the most frequently diagnosed cancer in men in the UK, surpassing both lung and 
colorectal cancer. This trend has continued and in England alone in 2007 there were 
30,201 newly diagnosed patients registered with prostate cancer [www.statistics.gov.uk 
accessed June 2010]. The overall age standardised incidence rate of prostate cancer in 
England in 2007 was 97.2 per 100,000 men. The incidence rates increase with age; the 
rate is 10.0 per 100,000 in men aged 45–49 years, rising to 737.4 per 100,000 in men 
aged ≥85 years [www.statistics.gov.uk accessed June 2010]. Additionally, similarly to 
the USA, prostate cancer is the second leading cause of cancer associated death, and in 
the latest figures provided for England, by the Office for National Statistics, there were 
9,157 deaths from prostate cancer in 2008 with an age standardised mortality rate of 240 
per 1 million population [www.statistics.gov.uk accessed June 2010]. It has been 
estimated that that the lifetime risk of a man developing clinically significant prostatic 
cancer is 10% and the risk of dying from prostate cancer is 3% [Melia J 2005]. 
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The spread of prostate cancer  
a) Local invasion - in prostate adenocarcinomas, extraprostatic extension 
preferentially occurs posteriorly and posterolaterally, which parallels the location of most 
neoplasms. Further local spread of tumour can result in invasion of the muscular wall of 
the seminal vesicle and also the rectum.  
b) Metastasis - the most frequent sites of metastatic prostate carcinoma are lymph 
node and bone. As regards the lymphatic dissemination, prostate cancer initially spreads 
to the obturator, external iliac, internal iliac, presacral, and lateral sacral (presciatic) 
lymph nodes [Breyer BN et al 2008, Brossner C et al 2001, Heidenreich A et al 2002, 
Wawroschek F et al 2001]. 
Prostate cancer metastasizes to bone more frequently than does any other solid 
tumour [Arya M et al 2006, Coleman RE 2001]. In a comprehensive autopsy study of 358 
patients who died from cancer between 1927 and 1941, Walther HE 1948 found that bone 
was the most common site of metastases for prostate cancer. In this series, the frequency 
of bone metastasis in prostate cancer was about 60% although several other autopsy 
series have since put the frequency closer to 80–90% [Cumming J et al 1990, Shah RB et 
al 2004, Rana A et al 1993]. Metastasis to bone usually occurs as a result of the 
haematogenous dissemination of cancer cells and this represents the major cause of 
morbidity (including impaired mobility, pathological fracture, spinal cord compression) 
and mortality in this disease. In fact, after diagnosis of bone metastasis, median survival 
is approximately 2 to 3 years [Coleman RE 1997, Nørgaard M et al 2010], depending on 
the hormone responsiveness of the disease. However, in spite of the severe complications 
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of prostate cancer skeletal metastasis, there have not been many therapeutic advances to 
prevent or diminish these lesions.   
The development of efficacious therapies to decrease or prevent lymph node and 
particularly skeletal metastasis in prostate malignancy has been hampered up till now by 
the lack of an adequate understanding of the mechanisms of organ specific metastasis in 
cancer. The molecular genetics and pathophysiology of these processes are now being 
elucidated and this will help to provide the basis for creating strategies to prevent or 
diminish their occurrence and associated complications.  
 
 
 
SECTION 1.2 
 
The theory of metastasis and prostate cancer 
 
The leading cause of death from cancer is tumour metastasis. Metastasis is 
defined as the process by which a malignant cell leaves the primary tumour, travels to a 
distant site via the circulatory system, and establishes a secondary tumour. This is a 
multi-step process, which consists of a series of sequential events involving complex 
interactions between the cancer cell and its surroundings in the host [Mundy GR 2002, 
Geiger TR and Peeper DS 2009]. Not all cancer cells have the ability to metastasise due 
to the great difficulties involved in the process. Additionally, it has been shown that 
metastasis is an inefficient process with only a minority of the cells leaving the primary 
organ (such as the prostate) having the potential to establish colonies in secondary sites 
(such as lymph nodes and bone marrow) and eventually proliferating into clinically 
detectable metastatic neoplasms. This was demonstrated in the study by Rosol TJ et al 
 23 
2003, who performed intracardiac injection of luciferase-labelled PC3 prostate cancer 
cell line cells into immunocompromised mice. Neoplastic cells were localised, using non-
invasive imaging, in the lungs, kidneys and long bones 15 minutes after injection. 
However, 24 hours later, no viable cells were detected signifying that most of the injected 
cells were either dead or metabolically inactive. In another study Luzzi KJ et al 1998 
used videomicroscopy of various types of cancer, and showed that only 2% of cancer 
cells formed micrometastases.  Other groups have demonstrated that only 1% of these 
micrometastatic deposits eventually develop into larger established tumours, despite a 
significant number of undivided solitary cells remaining in tissues several months after 
injection [Naumov GN et al 2001 and 2002, Macdonald IC et al 2002, Townson JL and 
Chambers AF 2006]. In renal cancer radical nehrectomy patients, Glaves D et al 1988 
estimated the rates at which cancer cells were released directly into the renal vein. They 
found that cancer cells were released as single cells and multi-cell emboli in 8 of 10 
patients, in numbers varying between 14 and 7,509 emboli per millilitre of blood. Despite 
a calculated median input into the circulation of 3.7 x 107 cancer cells per day for ≥180 
days, only 3 of 10 patients had metastases before surgery, and only 1 of the remaining 
disease-free patients subsequently developed distant metastases over a maximum 35 
month period. 
After the initial transformation of the cells, metastasis is thought to involve the 
following steps shown in figure 1.1. Completion of all steps in sequential order is 
required for successful metastasis [Chambers AF et al 2002, Fidler IJ 2003, Geiger TR 
and Peeper DS 2009].  
 
 24 
Figure 1.1: The metastatic cascade  
 
(Initial neoplastic transformation of prostate cells) 
 
 
Tumour neoangiogenesis/ lymphangiogenesis and cancer growth 
 
 
 
Loss of local cell adhesion and detachment of cells from primary tumour 
 
 
Local invasion of host stroma (extracellular matrix) 
 
 
Escape of tumour cells into vasculature or lymphatics 
 
 
Cancer cell avoidance of immune system attack and turbulence of circulation 
 
 
The non-random (with random) homing of neoplastic cells to specific 
metastatic sites 
 
 
Extravasation of tumour cells into secondary organ and proliferation  
                                     and growth at this site                                                                                                                         
 
 
Of particular interest to this thesis is the non-random homing of cancer cells to 
specific metastatic sites and their survival in specific organs. This is due to: 
• Directional migration of cancer cells down a chemotactic gradient to organs 
exhibiting peak levels of the chemoattractant.  
• Capillary bed arrest of tumour cells in receptive organs/ cancer cell endothelial 
interactions. 
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• Extravasation from the capillaries into the surrounding host tissue, proliferation 
within the host organ microenvironment resulting in the establishment of 
micrometastases. 
These final steps of the metastatic cascade have been grouped together, as 
collectively, they play a key role in the appreciation of metastasis as an organ-specific, 
non-random process. Factors that affect the directional migration of cancer cells, the 
capillary bed arrest of tumour cells in target organs, extravasation from the capillaries 
into the surrounding tissue, proliferation within specific host organs, or formation of new 
blood vessels to support growth in host organs could all result in potentiation of site 
specific metastasis.  
It is well established that different cancer types have preferred metastatic sites. 
Breast cancer favours regional lymph nodes, bone marrow, lung and liver. Malignant 
melanoma has a similar pattern but also has a high incidence of skin metastasis. Prostate 
cancer particularly favours the bone marrow as well as lymph nodes. Several 
explanations for these metastatic patterns have been proposed. 
In 1889, Stephen Paget, an English surgeon, studied autopsy records of 735 
women who died of breast cancer [Paget S 1889]. He noticed that the majority of 
metastatic deposits were in the liver and that metastasis to the spleen was extremely 
uncommon. In contrast to this, autopsy cases of patients who died of sepsis demonstrated 
that abscesses occurred in similar frequency in both the liver and spleen. Paget suggested 
that the difference in the number of metastases could not be explained simply by 
circulatory patterns because the liver and spleen received approximately the same volume 
of blood. Paget’s findings were published in a seminal article in the “Lancet” [Paget S 
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1889]. Based on these observations, Paget proposed the “seed and soil” hypothesis, 
stating that certain tumours, the “seeds”, have specific metastatic affinity for particular 
organs, the “soil”. He hypothesised that it was the compatibility between the “seed” and 
the “soil” that determined whether tumours could survive and grow at a distant site. 
Forty years later, in 1928, an American pathologist, James Ewing, proposed an 
alternative theory to the “seed and soil” hypothesis. He postulated that neoplastic cells 
grew specific sites because they were directed to these sites by the direction of blood 
flow and lymphatics [Ewing J 1928]. He stated that “the mechanisms of circulation will 
doubtless explain most of peculiarities, for there is as yet no evidence that any one 
parenchymatous organ is more adaptable than others to the growth of embolic tumour 
cells.” However, Ewing also noted there was an exception in that “the spleen seems to 
escape with peculiar frequency.” 
It is likely that these two theories are not mutually exclusive. Fidler IJ 2002 
combined the two theories and defined the modern seed-and-soil hypothesis consisting of 
three principles. First, cancerous tissues contain heterogeneous subpopulations of cells 
with different angiogenic, invasive, and metastatic properties. Second, the metastatic 
process is selective for the small subpopulation of cells that have survived the long 
journey to a distal organ. Third, the success of the metastatic cells depends on their 
ability to interact and utilize the ‘‘soil’’ provided in their new microenvironment [Fidler 
IJ 2002]. These heterogenous subpopulations of cells within a tumour can be seen on co-
culture of an isolated mouse femur with PC-3 human prostate cancer cells. On a scanning 
electron micrograph after 3 days of culture, cells exhibiting diverse phenotypes are 
attached to the bone. It has been hypothesized that these variable morphologies may 
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represent the heterogeneous population of prostate cancer cells that differentially respond 
to growth on bone [Tantivejkul K et al 2004].  
However, Fidler’s modern seed-and-soil hypothesis does not entirely incorporate 
the growing evidence for the ‘homing’ theory, which states that different organs have 
special abilities to attract, through chemotactic factors, specific types of cancer cells 
[Moore MA 2001, Muller A 2001, Ben-Baruch A et al 2008]. It is likely that a 
combination of all these factors is likely to be involved and there is evidence supporting 
all these theories in the organ-specific metastasis of prostate cancer. This evidence is now 
presented: 
i) Vascular flow patterns  - there is some supporting evidence for Ewing’s theory 
that cancer cell delivery to the bone is related to only the volume of blood flow [Ewing J 
1928], but this explanation is not widely acknowledged in the metastasis of prostate 
cancer. Batson first confirmed the existence of a portal-like venous system between the 
prostate and the lower lumbar vertebrae [Batson OV 1940].  Early researchers suggested 
that prostate cancer cells migrated to the bone because of venous drainage through the so 
called Batson’s Plexus. However, this hypothesis did not explain the high occurrence of 
prostate cancer metastases outside the vertebral column and bony pelvis nor did it 
account for the low incidence of prostate cancer metastases to the lungs. More recently 
there has been further support of this theory. In a review of bone scans from 27 patients 
with limited skeletal involvement, the distribution pattern of early prostate cancer 
metastases was similar to the distribution of normal adult bone marrow [Imbriaco M et al 
1998]. More importantly, Bubendorf L et al 2000 studied more than 19,000 male 
autopsies, of which 1589 had prostate cancer. The group observed that there was an 
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increased incidence of bone metastases in prostate cancer patients in comparison with 
those who had kidney or bladder neoplasms. Additionally, in prostate cancer patients, 
there was also a high prevalence of expected peri-aortic and pelvic lymph node 
metastases, and there was a strong association between the presence of lymphatic 
metastasis and haematogenous (skeletal and visceral) metastases. Greater than 90% of the 
patients with haematogenous metastasis had skeletal metastases. The highest frequency 
of metastases was noted in the lower lumbar spine followed by higher vertebral levels, 
and then ribs, long bones, and skull suggesting an upward metastatic spread along spinal 
veins after initial lumbar deposits. More detailed scrutiny confirmed that involvement of 
these levels almost certainly proceeded in a step-wise fashion as it was very rare for the 
less frequently affected bones to be involved without simultaneous disease in the more 
regularly affected bones. Interestingly, patients with lung metastases were noted to have a 
statistically reduced chance of skeletal metastasis. It was concluded that these results 
supported the theory that a portal venous circulatory system existed between the prostate 
and lower lumbar vertebrae leading to a higher delivery of circulating prostate cancer 
cells flowing to these vertebrae. Another method of haematogenous spread would be the 
flow of prostatic venous blood directly into the inferior vena cava: this would account for 
the investigators’ finding of an inverse correlation between lung and skeletal metastasis 
because caval blood has to circulate through the lungs before systemic dissemination. 
Cancer cells in the lymphatic system can also move directly into Batson’s plexus 
due to the presence of potential lymphatic-blood vessel shunts present at this site (these 
shunts are also present at the primary tumour site). Alternatively, the lymphatic system 
converges with the bloodstream via the thoracic duct. 
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ii) Chemotactic gradients and homing of cancer cells - there is increasing support 
for the “homing” theory to explain the directional cell migration of malignant cells to 
specific organs which exhibit peak expression of chemoattractant molecules. When 
prostate carcinoma cells are injected adjacent to adult human bone implanted in SCID 
mice, the prostate carcinoma cells migrate towards the adult human bone [Tsingotjidou 
AS et al 2001]. This observation provides evidence that bone provides chemotactic 
factors for prostate carcinoma cells. Using in-vitro assays, Jacob K et al 1999 found that 
extracts from bone promoted an increase in chemotaxis and invasion by PC-3 cells 
compared with brain and other tissue extracts, thus demonstrating that bone contains 
significant migration and chemoinvasion promoting factors for prostate cancer cells. The 
purified active chemoattractant factor was found to be the minor bone matrix protein 
osteonectin (also known as SPARC or BM-40). Osteonectin also enhanced matrix 
metalloproteinase activity in the prostate cancer cells. It has also been shown that the 
cytokine TGFβ1, which is secreted by osteoblasts, stimulated the chemotaxis (as well as 
invasion and integrin expression) of PC3 cells [Festuccia C et al 1999, Ding Q et al 
2010].  
Furthermore, epidermal growth factor (EGF) was noted to be expressed at 
favoured sites of prostate cancer metastasis in the stroma of both lymph nodes and 
medullary bone [Rajan R et al 1996]. EGF resulted in increased motility and enhanced 
the chemomigration of PC3 prostate cancer cells in Boyden chambers [Festuccia C et al 
2005, Jarrard DF et al 1994] and increased their invasion through Matrigel [Festuccia C 
et al 2005, Unlü A and Leake RE 2003]. Also, it was demonstrated that inhibition of the 
EGF receptor decreased the chemotaxis and invasion of PC3 cells [Festuccia C et al 
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2005, Unlü A and Leake RE 2003]. These results support the hypothesis that bone and 
lymph nodes are the preferred site for prostate cancer metastasis due to a chemoattractant 
mechanism involving EGF [Lu X and Kang Y 2010]. Additionally, these observations 
have implications for therapeutic intervention as does the finding that the Rho-kinase 
inhibitor, Y-27632, inhibited in vitro PC3 cell chemotactic migration to bone marrow 
fibroblast conditioned media and their metastatic growth in immune compromised mice 
[Somlyo AV et al 2000]. 
Iincreased chemotaxis has also been shown to occur in DU145, PC3 and LNCaP 
cells in migration assays, in response to insulin-like growth factors 1 and 2 (IGF1 and 2), 
which are known to be produced by bone cells [Marelli MM et al 2006, Ritchie CK et al 
1997]. Gmyrek GA et al 2001 observed that HGF (scatter factor) acting via its receptor, 
Met tyrosine kinase (c-Met), induced the migration of DU145 cells in-vitro. Recently 
these results have been consolidated by Dai Y and Siemann DW 2010, who demonstrated 
BMS-777607, a small-molecule met kinase inhibitor, suppressed HGF-stimulated cell 
migration in c-Met-expressing PC-3 and DU145 prostate cancer cells. Other bone factors, 
which may be involved in the chemomigration of prostate cancer include type 1 collagen 
peptides (which are bone stromal factors); these have been revealed to be 
chemoattractants for bone derived metastatic prostate cancer cell lines VCaP and PC3 
[Cooper CR et al 2003].  
Recently, an exciting body of evidence has emerged that has implicated 
chemokines and their receptors as having a pivotal role in the chemotaxis of cancer cells 
to specific organs such as bone and lymph nodes. This will be discussed in the later 
section titled “Chemokines and their role in cancer”. 
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iii) Interaction with the endothelium - tumour cells, in order to develop a cancer at 
secondary sites, must arrest in the capillary beds of distant organs, and extravasate 
through the vessel wall. Evidence suggests that only endothelium-attached cancer cells 
can give rise to metastases [Al-Mehdi AB et al 2000, Bussard KM et al 2008]. In prostate 
cancer it has been hypothesised that prostate carcinoma metastasis to bone is mediated, at 
least in part, by the cancer cells’ preferential adhesion to bone marrow endothelium as 
opposed to endothelium from other sites. This was observed in studies showing that PC3 
prostate carcinoma cells adhered preferentially to immortalized human bone marrow 
endothelial (HBME) cells as compared to human umbilical vein endothelial cells 
(HUVEC), immortalized human aortic endothelial cells (HAEC-I), and immortalized 
human dermal microvascular endothelial cells (HDMVEC) [Cooper CR et al 2000, Lehr 
JE and Pienta KJ 1998]. This adhesion was promoted when HBME cells were cultured on 
bone extracellular matrix components [Cooper CR et al 2000]. Romanov VI et al 2004 
indicated that this preferential binding of prostate cancer C4-2B cells to bone marrow 
endothelium is related to PSA expressed as secreted and surface-associated molecules in 
the C4-2B cells. The interaction of the cancer cells with the endothelium may occur via 
the “dock and lock” mechanism [Honn KV and Tang 1992, Miles FL et al 2008], which 
is comparable to leucocyte trafficking and extravasation at areas of inflammation. Both of 
these processes involve the arrest of circulating cells on the endothelium by low-affinity 
binding, induction of a firmer cell adhesion, extravasation, and subsequent invasion of 
the surrounding matrix. The cell adhesion molecules (CAMs) involved in the “docking” 
phase may include P-selectin, which can be found on activated endothelial cells and 
which binds to its ligand sialyl LewisX carbohydrate antigen located on the cell surface of 
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cancer cells or platelets. Expression of sialyl LewisX by prostate cancer cells is associated 
with a poor prognosis [Martensson S et al 1995]. 
Kierszenbaum AL et al 2000 identified a potential cell membrane receptor in 
prostate cancer cells that mediated the binding of the tumour cells to bone marrow 
endothelium. The galactosyl receptor, a C-type lectin that binds to specific sugar moieties 
via a specific carbohydrate recognition domain, was demonstrated to be present on both 
normal and PC3 cells. Blocking this receptor with antibodies that bind to the 
carbohydrate recognition domain prevented the adhesion of the malignant PC3 cells to 
the endothelium [Kierszenbaum AL et al 2000]. Also, prostate cancer cells express 
Thomsen-Friedenreich glycoantigen (Galb1-3GalNAc), which has been discovered to 
bind with β-galactoside binding lectin, galectin-3, expressed on microvascular 
endothelium of metastatic tissues [Ellerhorst J et al 1999, Glinsky VV et al  2001, 
Glinsky VV et al 2003, Nangia-Makker P et al 2002]. Najy AJ et al 2008 have suggested, 
using an SCID mouse model of human prostate cancer metastasis, that the disintegrin 
ADAM15, supports prostate cancer metastasis by modulating tumour cell-endothelial cell 
interaction. Other CAMs thought to be involved in prostate cancer cell “docking” on the 
endothelium include vascular cell adhesion molecule (VCAM), CD11a (alpha-L), CD18 
(beta-2), and leucocyte functional antigen – 1 pectin [Morrissey C and Vessella RL 2007, 
Pienta KJ et al 1995]. 
In a similar manner to the inflammatory response of leucocytes, the ‘‘locking’’ of 
prostate cancer cells to endothelial cells is attained via the complex collaboration of 
integrins. This is illustrated by the finding that antibodies to the β1 integrin subunit  
inhibited adhesion of PC-3 cells to bone marrow endothelial cells [Scott LJ et al 2001] 
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and cooperativity between αvβ3, α5β1 and α3β1 integrins is necessary for PC-3 and 
DU145 cell adhesion to interleukin-1-stimulated HUVEC [Romanov VI and Goligorsky 
MS 1999]. Prostate cancer cell binding to the endothelium may aid extravasation as it can 
result in retraction of endothelial cells in preclinical models [Sikes RA et al 2004]. 
iv) Interaction between tumour cells and tumour microenvironment at the 
metastatic site - as recognised originally by Paget S 1889 and then reinforced more 
recently by Fidler IJ 2002 the establishment of successful cancer metastasis depends on a 
“fertile soil” at the metastatic site. In the case of prostate cancer many factors potentially 
contribute to cancer cell growth, particularly in the bone. It has been hypothesized that 
prostate cancer cells are “osteomimetic” [Josson S et al 2010, Koeneman KS et al 1999, 
Rucci N and Teti A et al 2010]. In other words they develop properties similar to bone 
cells upon entering the bone marrow. This is also known as epithelial-mesenchymal 
transition and refers to epithelial cells losing their epithelial features and acquiring 
mesenchymal characteristics. This process occurs mainly during embryogenesis and 
allows the epithelial cells to migrate to a new environment and differentiate into a distinct 
cell type by the reverse process of mesenchymal-epithelial transition. However, in cancer 
cells, epithelial mesenchymal transition confers the invasive phenotype. The process is 
partly illustrated by LNCaP cell derivatives, which like osteoblasts, synthesize and 
deposit bone matrix proteins such as osteopontin, osteocalcin, osteonectin, and bone 
sialoprotein when in the bone [Gardner TA et al 2009, Zhau HE et al 2000]. Typically, 
external stimuli are needed to initiate epithelial-mesenchymal transition and in the bone 
microenvironment these include extracellular matrix components, and soluble factors 
including members of the TGFβ superfamily, FGF family, EGF, HGF, IGF-2 and 
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proteins of the Wnt and Hedgehog families. Additionally, many of the growth factors, 
which may be secreted by a variety of cells including osteoblasts, stromal cells and the 
cancer cells themselves, have been demonstrated to stimulate prostate carcinoma growth 
in vitro. For example, prostate carcinoma cells have IGF receptors [Cohen P et al 1991, 
Hellawell GO et al 2002] and proliferate in response to IGF [Gennigens C et al 2006, 
Ritchie CK et al 1997]. Transfection of LNCaP cells with FGF-8 expression vector 
induced an increased growth rate, higher soft agar clonogenic efficiency, enhanced in 
vitro invasion, and increased in vivo tumourigenesis [Song Z et al 2000].  
The interactions between tumour cells and host microenvironment contribute 
greatly to the formation of osteoblastic lesions. Bone morphogenetic proteins (BMPs) are 
known to contribute to bone formation. Bentley H et al 1992 first reported that the 
expression of BMP-6, a member of the TGF-β superfamily, was detected in prostate 
tissue samples of over 50% of patients with clinically defined metastatic prostate cancer, 
but not non-metastatic or benign prostate samples. Subsequent studies have confirmed the 
increased expression of BMP-6 in metastatic prostate cancer cells [Autzen P et al 1998, 
Dai J et al 2005, Thomas BG and Hamdy FC 2000]. It is believed that secretion of BMP-
6 by prostate cancer cells contributes to osteoblastic lesions because BMP-6 stimulates 
osteoblastic differentiation of pluripotent mesenchymal cells [Ebisawa T et al 1999]. 
Another BMP, GDF-9, has been shown to promote the growth rate of both PC-3 and DU-
145 cells by protecting them from apoptosis [Bokobza SM et al 2010]. 
Endothelin-1 (ET-1), a potent vasoconstrictor, is produced by tumour cells and is 
also a direct mitogen for osteoblast progenitors in vitro [Takuwa Y et al 1990] and in 
vivo [Nelson JB et al 1999, Tsukahara H et al 1998]. Patients with osteoblastic prostatic 
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metastasis have high serum levels of ET-1 [Nelson JB et al 1995]. Administration of an 
ET-1 receptor antagonist in vivo resulted in both decreased tumour burden and 
osteosclerotic features of the metastatic bone lesions [Yin JJ et al 2003]. 
There is evidence that the presence of prostate cancer cells in bone stimulates 
bone matrix formation (osteoblastic activity; apparent as osteosclerotic lesions on 
imaging) as well as bone matrix degradation (osteolytic activity). The majority of bone 
matrix degradation caused by prostate cancer cells is thought to be due to enhanced 
osteoclast activity, but there is increasing evidence that prostate cancer cells directly 
participate in the process by producing and secreting matrix degrading enzymes. 
Sanchez-Sweatman OH et al 1998 observed that PC3 cells and their conditioned medium 
are able to degrade non-mineralized bone matrix. Furthermore, the cells themselves 
degraded mineralized bone matrix directly. This activity was correlated with production 
and secretion of matrix metalloproteinases (MMPs) because it was found that the matrix 
degrading activity could be reduced by inhibition of metalloproteinase activity. It is 
thought that bone matrix degradation can in fact release embedded growth factors and 
cytokines that may in turn stimulate the proliferation of prostate cancer cells. Thus, if 
prostate cancer cells participate in bone degradation, a vicious cycle is set up whereby the 
cancer cells stimulate bone turnover and bone turnover stimulates the cancer cell 
proliferation [Chung LW 2003].  
Parathyroid hormone-related peptide (PTHrP) is secreted by the majority of solid 
osteotropic cancers and plays a significant role in the development of osteolytic features 
of metastatic bone lesions. PTHrP, produced by tumour cells in the bone 
microenvironment, stimulates osteoclast generation and recruitment (osteoclastogenesis) 
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by inducing the secretion of receptor activator of NF-kappaB ligand (RANKL), which 
binds to the RANK receptor present on osteoclast precursors [Guise TA et al 1996]. 
Additionally, PTHrP simultaneously decreases secretion of the molecule osteoprotegerin 
(OPG) by osteoblastic cells, which also results in osteoclast differentiation as OPG 
normally binds to RANK and thus prevents RANKL/RANK interaction on osteoclast 
progenitors [Guise TA et al 1996]. Studies in prostate cancer patients have reported data 
suggesting a positive association between the presence of metastatic disease and raised 
OPG levels [Brown JM et al 2001] and in one study, serum OPG levels showed the best 
discriminatory power to differentiate between patients with and without bone metastases 
[Jung K et al 2004]. This association provides an attractive explanation for the 
osteosclerotic nature of prostatic cancer metastases. 
Another factor contributing to the “fertile soil” in bone is collagen type 1, the 
main component of bone, which has been reported to increase the proliferation rate of 
prostate cancer cells compared with cells cultured on plastic or fibronectin [Kiefer J et al 
2004]. A component of the non-collagenous extracellular matrix of bone is osteopontin, 
which has been shown to stimulate proliferation and anchorage-independent growth of 
human prostate cancer cell lines [Elgavish A et al 1998, Thalmann GN et al 1999]. 
Castellano G et al 2008 have correlated activation of the osteopontin/ MMP-9 pathway 
(osteopontin activates MMPs) with prostate cancer progression using patient samples. 
The factors involved in the interaction of the lymph node microenvironment in 
relation to prostate cancer (or other neoplasms) have not been extensively studied. 
However, Chu JH et al 2006 orthotopically implanted prostate cancer PC-3 cells into 
nude mice and subsequently compared the gene expression patterns of cells harvested 
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from the primary site versus those from spontaneous lymph node metastasis. A 
complementary DNA array platform containing 96 human tumour metastasis-related 
genes was used. Among them, 10 were upregulated in lymph node metastasis. These 
could be divided into 4 categories: extracellular matrix degrading enzymes (cathepsin B, 
D, and L, and MMP16), adhesion molecules (integrins  α5 and α6), transcription factors 
(Ets1, Ets2, and ETV4), and cell surface receptors (uPA receptor). These genes and their 
products may well be involved in enhancing the metastasis of prostate cancer to lymph 
nodes, perhaps by regulating the host microenvironment at this site. 
There is evidence supporting all the above-mentioned theories in the organ-
specific metastasis of prostate cancer and it is likely that the process involves a 
combination of all the hypotheses discussed. However, there is increasing evidence for 
the “homing” theory of metastasis. Importantly, it is now postulated that chemokines and 
their receptors are involved in all aspects of tumour development, progression and 
migration with an essential and exciting role in the homing and organ-specific metastasis 
of cancer cells. Prior to discussing this, we must address the issue of chemokine / 
chemokine receptor nomenclature, structure and their physiological role. 
 
 
SECTION 1.3 
 
Chemokines and their structure 
 
What are chemokines? 
 
Cytokines are a category of signaling molecules which are important in 
intercellular communication. More than 200 of these polypeptides regulate cell 
proliferation, differentiation, maturation and death. The cytokine network includes 
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several cytokine families (lymphokines, interleukins, chemokines) that can be classified 
in terms of ligand and receptor structure, although most cytokines have little homology in 
their DNA or amino acid sequence [Baird PN et al 1995, Cohen MC and Cohen S 1996, 
Germano G et al 2008]. One exception to this is the family of chemoattractant cytokines 
or chemokines. With approximately 50 closely related members and at least 19 receptors, 
chemokines are now the largest known cytokine family. 
The history of chemokines began over two decades ago when investigators 
discovered a factor produced by lipopolysaccharide-stimulated monocytes, later named 
interleukin-8 (IL-8; the only chemokine originally named an interleukin), that showed 
chemotactic activity for neutrophils [Yoshimura et al 1987, Walz et al 1987]. Since this 
discovery, interest in chemokines and their receptors has greatly increased and in the 
Third International Symposium on Chemotactic Cytokines in 1992, the term 
“chemokines” was introduced for this large and growing family of structurally related 
proteins, which were recognized mainly for their ability to act as chemoattractants (as 
well as activators) of specific types of leucocytes in a variety of immune and 
inflammatory responses. Similar to other cytokines, the chemokines are secretory 
proteins produced by leucocytes and tissue cells either constitutively or after induction, 
and many of their effects are exerted locally in a paracrine or autocrine fashion. However, 
chemokines are much smaller than other cytokines (8-14kDa) and act via heptahelical G-
protein coupled receptors.  
Chemokines can be made by virtually every nucleated cell type under appropriate 
conditions [Gale LM and McColl SR 1999, Hippe A et al 2010]. Most chemokines are 
expressed in response to a stimulus, but some are constitutively expressed in a tissue-
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specific manner. Therefore, the distinction between inducible and constitutive expression 
might depend only on the origin of the cells under study. For example, the chemokine 
CXCL14 (originally named BRAK because of its expression in breast and kidney) is 
constitutively expressed at high levels in normal squamous epithelium, but might require 
a stimulus to be expressed by inflammatory cells (and certain cancers) [Frederick MJ et al 
2000]. 
  The main function of chemokines is in leucocyte chemotaxis or migration, in 
addition to leucocyte activation, in both physiological and pathological conditions. They 
control leucocyte circulation, homing, extravasation and recirculation between the blood 
vessels, lymphatic vessels and lymphoid organs and tissues [Baggiolini M et al 1997, 
Hippe A et al 2010, Mantovani A 1999, Murphy PM et al 2000, Rollins JB 1997]. In 
addition to their traditional chemotactic effects in the immune system, chemokines have 
been implicated in the modulation of cell adhesion, phagocytosis, apoptosis, 
angiogenesis, proliferation and viral pathogenesis [Baggiolini M et al 1997, Hippe A et al 
2010, Murphy PM et al 2000, Rollins JB 1997]. Additionally, chemokines and their 
receptors are essential for normal embryological development because based on knock-
out studies of mice, lack of the chemokine ligand CXCL12 (SDF-1) or its receptor, 
CXCR4, resulted in impaired foetal development of the cerebellum, the cardiac septum, 
gastric vasculature, and B-cell lymphopoesis. These mice died either in utero or at birth 
[Raz E and Mahabaleshwar H 2009, Tachibana K et al 1998, Zou YR et al 1998]. 
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Chemokine structure and nomenclature  
Chemokines consist of approximately 70-130 amino acids and are divided into 
four subfamilies defined by the arrangement of the conserved N-terminal cysteine (C) 
residues of the mature proteins. The first three classes all have 4 conserved cysteines 
whereas the fourth has only two (Figure 1.2) [Bajetto A et al 2001]: 
the CXC or α chemokines have one amino acid residue separating the first two conserved 
cysteine residues near the amino or N-terminus;  
the CX3C or δ chemokines have three amino acid residues between the first and second 
cysteines near the N-terminus; 
the CC or β chemokines in which the first two conserved cysteine residues near the N-
terminus  are adjacent;  
the C or γ chemokines which lack two (the first and third) of the four conserved cysteine 
residues 
Figure 1.2. Structural classification of the chemokine family  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 Fig. 1.2: Structural classification of the chemokine family  
 
CHEMOKINE                                                                      STRUCTURE 
GROUP 
C:              …………...C…………..……………..C……. 
CC:         ……C------C…………C…………….C……. 
CXC:       ……CX----C…………C…………… C……. 
CX3C:      ……CXXXC…………C…………….C……. 
 
Footnote: C – cysteine; X - an amino acid other than cysteine  
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The conserved cysteines are important in creating the tertiary structure of chemokines as 
they form disulphide bonds between themselves (C1 to C3 and C2 to C4), which 
subsequently results in the characteristic three-dimensional folding of the chemokines. 
The disulphide bonds keep two amino-terminal regions together that are essential for 
receptor recognition and biological activity.  
As new chemokines were discovered, they were named by the individual 
laboratories that identified and/or characterized them. Therefore a single chemokine often 
had many names, which resulted in much confusion. As a result of this a new 
nomenclature system was developed several years ago, in which the chemokine structural 
code (CXC, CC, CX3C, or C) is followed by the letter ‘L’ (ligand) for each chemokine 
(as in CXCL1) or by the letter ‘R’ (receptor) for each receptor (as in CXCR1) [Zlotnik A 
and Yoshie O 2000]. Table 1.1 is an extensive list of the chemokines identified to date 
together with their synonyms and official names. 
It is important to note that within the CXC subfamily, the chemokines are further 
divided structurally (and functionally) into two groups. One group of the CXC 
chemokines have the characteristic three amino acid sequence, glutamic acid-leucine-
arginine (ELR) motif, immediately before the first cysteine residue of the CXC motif 
near the amino terminus. A second group of CXC chemokines lack such an ELR domain. 
The CXC chemokines with the ELR domain (including CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL8) act mainly as chemoattractants of neutrophils (and promote 
angiogenesis in wound healing and tumours). The CXC chemokines without the ELR 
domain (including CXCL4, CXCL9, CXCL10), are chemoattractants primarily for T-
lymphocytes and monocytes (and are non or antiangiogenic). However, one exception is  
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Table 1.1: Chemokine nomenclature 
 
New official name   Alternative/original name (other names may exist) 
 
CXCL1     GROα – growth related oncogene α 
CXCL2     GROβ – growth related oncogene β 
CXCL3    GROγ – growth related oncogene γ 
CXCL4    PF-4 – platelet derived factor 4 
CXCL5     ENA-78 – epithelial cell derived neutrophil activating factor 78 
CXCL6     GCP-2 – granulocyte chemoattractant protein 2 
CXCL7     NAP-2 – neutrophil activating protein 2 
CXCL8     IL-8 – interleukin 8 
CXCL9     MIG – monokine induced by γ-interferon 
CXCL10    IP-10 – γ-interferon inducible protein 10 
CXCL11    I-TAC – interferon inducible T cell α-chemoattractant 
CXCL12    SDF-1 – stromal cell derived factor 1 
CXCL13    BCA-1 – B cell activating chemokine 1 
CXCL14    BRAK – breast and kidney chemokine 
CXCL15    Lungkine  
CXCL16    SR-PSOX– scavenger receptor that binds phosphatidylserine and oxidized lipoprotein 
CXCL17                                                  VCC-1 – vascular endothelial growth factor correlated chemokine - 1                                                                                                            
CCL1     I-309 
CCL2     MCP-1 – monocyte chemoattractant protein 1 
CCL3     MIP-1α – macrophage inflammatory protein 1α 
CCL4     MIP-1β – macrophage inflammatory protein 1β 
CCL5     RANTES – regulated on activation, normally T cell expressed and secreted 
CCL6     Unknown 
CCL7     MCP-3 – monocyte chemoattractant protein 3 
CCL8     MCP-2 – monocyte chemoattractant protein 2 
*CCL9/ CCL10    MIP - 1γ – macrophage inflammatory protein 1γ 
CCL11     Eotaxin 
CCL12     MCP-5 – monocyte chemoattractant protein 5 
CCL13     MCP-4 – monocyte chemoattractant protein 4 
CCL14     HCC-1 – haemofiltrate CC chemokine 
CCL15     Lkn-1 – leukotactin 1 
CCL16     LEC – liver expressed chemokine 
CCL17     TARC – thymus and activation regulated chemokine 
CCL18     PARC – pulmonary and activation regulated chemokine 
CCL19     ELC – Epstein–Barr virus induced receptor ligand chemokines 
CCL20     LARC – liver and activation regulated chemokine 
CCL21     SLC – secondary lymphoid tissue chemokine 
CCL22     MDC – macrophage derived chemokine 
CCL23     MPIF-1 – myeloid progenitor inhibitory factor 1 
CCL24     MPIF-2 -–myeloid progenitor inhibitory factor 2 
CCL25     TECK – thymus expressed chemokine 
CCL26     Eotaxin-3 
CCL27     ESkine 
CCL28    MEC – mucosa-associated epithelial chemokine 
XCL1     Lymphotactin-α 
XCL2     Lymphotactin-β 
CX3CL1    Fractalkine 
 
 
*CCL9 has also been designated CCL10 but the latter term is no longer in use 
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CXCL12 (stromal cell derived factor 1; SDF-1), which lacks the ELR domain but induces 
neovascularisation in vivo (discussed in next section). 
The CC chemokines induce the migration of various cell types including 
monocytes, dendritic cells, basophils, eosinophils, natural killer (NK) cells and T 
lymphocytes [Baggiolini M et al 1997, Hippe A et al 2010] . The C chemokine subfamily 
is represented by only two members, XCL1 and 2 (lymphotactin-α and β respectively), 
which specifically promote the chemotaxis of T-lymphocytes [Kelner GS et al 1994, 
Kennedy J et al 1995, Hippe A et al 2010]. 
Additionally, CX3CL1 (fractalkine), is the only member of the CX3C chemokine 
group. Unlike other chemokines it exists as a membrane bound glycoprotein with the 
chemokine atop an extended mucin-like stalk. It promotes the chemotaxis and adhesion 
of monocytes, NK cells and T-lymphocytes to endothelial, epithelial and dendritic cells 
[Bazan JF et al 1997]. 
 
Chemokine Receptors 
The specific effects of chemokines on their target cells are mediated by members 
of a family of 7-transmembrane-domain, G-protein-coupled receptors (also known as 
serpentine receptors). These chemokine receptors are part of a much bigger superfamily 
of G-protein-coupled receptors that include receptors for hormones, neurotransmitters, 
paracrine substances and inflammatory mediators [Murphy PM et al 2000]. To date 
19 human chemokine receptors have been identified (table 1.2). Among the 7 receptors 
that selectively bind certain CXC chemokines are chemokine receptors CXCR1 to 
CXCR7, whereas the CC receptor family consists of 10 receptors, CCR1 to CCR10. The  
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Table 1.2 The four classes of chemokine receptors and their ligands* (some chemokines 
may bind other receptors) 
 
Chemokine receptor  Chemokine ligand 
 
CXCR1    CXCL6, CXCL8  
CXCR2    CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, CXCL8 
CXCR3     CXCL4, CXCL9, CXCL10, CXCL11 
CXCR4     CXCL12 
CXCR5     CXCL13 
CXCR6    CXCL16 
CXCR7                                             CXCL11, CXCL12, ?non-signaling scavenger receptor 
 
CCR1     CCL3, CCL4, CCL5, CCL7, CCL8, CCL9/CCL10, CCL14, CCL15, CCL16, CCL23 
CCR2     CCL2, CCL6, CCL7, CCL8, CCL12, CCL13, CCL16 
CCR3     CCL7, CCL8, CCL11, CCL13, CCL15, CCL24, CCL26, CCL28 
CCR4     CCL3, CCL5, CCL17, CCL22  
CCR5     CCL3, CCL4, CCL5, CCL8, CCL13, CCL16 
CCR6     CCL20 
CCR7     CCL19, CCL21 
CCR8     CCL1, CCL16 
CCR9     CCL25 
CCR10     CCL27, CCL28 
 
XCR1     XCL1, XCL2 
 
CX3CR1    CX3CL1 
 
*Chemokines also interact with another receptor having seven transmembrane regions, the Duffy 
receptor – this is a non-signalling receptor and therefore is not included in this table 
 
 
receptor for CX3CL1 (fractalkine) is CX3CR1, and XCR1 is the receptor for XCL1 and 2 
(lymphotactin). Another chemokine receptor, known as the Duffy antigen receptor for 
chemokines (DARC) has been shown to bind to both CXC and CC chemokines. 
However, this is a non-signalling receptor as no function has been observed on 
chemokine ligand binding. The relationship between chemokines and their receptors is 
termed promiscuous, with each receptor being able to bind to more than one chemokine 
and each chemokine being able to use more than one receptor. However, monogamous 
chemokine ligand – receptor interactions have been thought to exist eg. CXCL12 – 
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CXCR4, CCL25 – CCR9, CXCL13 – CXCR5, but this is being disputed as more 
chemokines and chemokine receptors are being discovered.  
Chemokine receptors have been exploited by intracellular pathogens as cell entry 
and disease transmission factors. The most striking examples of this are the promiscuous 
chemokine binding protein DARC which is used as a portal of entry into human 
erythrocytes by the malarial parasite Plasmodium vivax [Horuk R 1994], and the 
chemokine receptors CCR5 and CXCR4 which are used as co-receptors by the HIV-1 
virus to promote cellular fusion and infection which results in the disease AIDS [D'Souza 
MP and Harden VA 1996]. 
Figure 1.3 shows a diagrammatic representation of CXCR4 and exemplifies the 
basic structure of chemokine receptors [Lodowski DT and Palczewski K et al 2009]. 
Characteristic features of chemokine receptors include: they measure approximately 
350 amino acids in length and require the introduction of few gaps in the primary 
sequence to be aligned to other chemokine receptors; a short N-terminus sequence, which 
is extracellular and is acidic overall and which may be sulfated on tyrosine residues and 
contain N-linked glycosylation sites; an intracellular C-terminus contains serine and 
threonine residues that act as phosphorylation sites for receptor regulation; 7 hydrophobic 
-helical transmembrane domains - with 3 intracellular and 3 extracellular connecting 
loops composed of hydrophilic amino acids - are oriented perpendicularly to the plasma 
membrane; a disulfide bond links highly conserved cysteines in extracellular loops 1 and 
2; G-proteins are coupled through the C-terminus segment and possibly through the third 
intracellular loop.  
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Figure 1.3: Diagrammatic representation of the chemokine receptor CXCR4 
(Fusin).CXCR4 is a 352 amino acid protein. Extracellular cysteine residues are indicated 
by an asterisk. The two potential N-linked glycosylation sites are shown. By analogy with 
other chemokine receptors, the cysteine residues in extracellular loops 1 and 2 form a 
disulfide bond. Ser - serine. Thr – threonine  
Diagram modified from Berson JF et al 1996.  
 
 
 
 
 
Signal Transduction (figure1.4) 
 
The first study on chemokine signaling was performed in human neutrophils 
stimulated by CXCL8 (IL-8; the only chemokine originally named as an interleukin). It 
showed that functional responses were prevented by pretreatment of the cells with 
Bordetella pertussis toxin, indicating that the receptor was coupled to GTP-binding 
proteins of the Gi-type, which eventually turned out to be the rule for all chemokine 
receptors [Thelen M et al 1988]. These G-proteins are inactive when GDP is bound to the 
G-protein subunit. However, on chemokine ligand binding, the chemokine receptors 
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associate with the Bordetella pertussis toxin-sensitive heterotrimeric (i.e. consists of three 
subunits) G-protein, which facilitates the exchange of guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP), resulting in G-protein activation. On activation, the G-
proteins dissociate into the GTP-bound Gα and Gβγ subunits. This results in the 
following effects: 
a) Gα subunit dependent effects: this results in the direct inhibition of adenyl cyclase 
activity leading to decreased intracellular cAMP levels [Bajetto A et al 1999, Zheng J et 
al 1999]. Evidence also suggests that the Gα subunit may activate tyrosine kinases 
[Thelen M 2001]. 
b) Gβγ subunit dependent effects:  
 
i) activation of the cell membrane associated enzyme phospholipase C (PLC), which 
cleaves phosphatidylinositol-4,5-biphosphate (PIP2) yielding the two second messengers, 
inositol-1,4,5-triphosphate (IP3) and diacyl-glycerol (DAG).  
IP3 triggers the release of calcium from intracellular stores, resulting in a transient 
rise in free intracellular calcium, whereas DAG, acting in conjunction with calcium, 
activates the enzyme protein kinase C (PKC). The former has been used widely to test the 
responsiveness of chemokine receptors to different chemokines [Baggiolini M et al 1997] 
and the latter is stimulated by almost any surface receptor and is therefore not a 
characteristic event in chemokine–induced signal transduction. The rise in intracellular 
calcium activates proline-rich tyrosine kinases (PYK2) which activate MAP kinases. The 
MAP kinases in turn activate phospholipase A2 (PLA2). 
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DAG, intracellular calcium, PKC, PLA2 and decreased cAMP all interact with 
specific cell activation mechanisms leading to cell motility, degranulation, release of 
superoxide anions and modification of integrin avidity (latter are part of family of 
CAMs). 
ii) another well established effector of Gβγ subunits is phosphphatidylinositol-3-OH-
kinase (PI3K) which activates protein kinase B (PKB). This results in a chemotactic cell 
response. 
After GTP hydrolysis, the GDP-bound Gα subunit re-associates with the G γ 
subunit; this then terminates signaling. Additionally, after activation, chemokine 
receptors become either partially or totally desensitized to repeated stimulation with the 
same or other agonists. This process is thought to involve both phosphorylation of serine 
and threonine residues in the C-tail of the chemokine receptor by G-protein-coupled 
receptor kinases (eg. PYK2 activated by the rise in intracellular calcium), and also 
receptor sequestration by internalization. Desensitization is thought to be important in 
maintaining the capacity of the cell to sense a chemoattractant gradient [Thelen M 2001]. 
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Figure 1.4: The chemokine receptor signal transduction pathway in leucocytes.  
AC – adenyl cyclase, cAMP – cyclic AMP, PI3K – phosphphatidylinositol-3-OH-kinase, 
PKB – protein kinase B, PLC – phospholipase C, DAG – diacylglycerol, PKC – protein 
kinase C, IP3 – inositol triphosphate, PYK2 – proline-rich tyrosine kinase, MAPK – 
mitogen-activated protein kinase, PLA2 – phospholipase A2  
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CXCR Receptors – history, location and physiological role in leucocytes 
 
 
CXCR1 and CXCR2 - receptors for CXCL8 (IL-8; the only chemokine 
originally named as an interleukin) were first shown to be present on the surface of 
neutrophils by Peveri P et al 1988. However, two types of CXCL8 binding sites were 
elucidated, one of which bound CXCL7 and CXCL1, 2, and 3 with high affinity and 
one of which bound these ligands with low affinity [Besemer J et al 1989]. Both, 
however, had high affinity for CXCL8 [Lee J et al 1992, Moser B et al 1991]. Eventually, 
2 receptors for CXCL8 i.e. CXCR1 and CXCR2 were cloned. 
CXCR1 was originally cloned by Holmes et al 1991. CXCR2 was simultaneously 
cloned by Murphy PM and Tiffany HL 1991. CXCR1 and CXCR2 bind all known N-
terminal Glu-Leu-Arg (ELR) positive, CXC chemokines. They do not bind other types of 
chemokines. CXCR1 and CXCR2 are expressed on all granulocytes, monocytes, and mast 
cells and on some T-cells and NK cells [Chuntharapai A et al 1994].  
 
 
CXCR3 - CXCR3 binds the non-ELR-containing CXC chemokines, CXCL9 and 
CXCL10 [Loetscher M et al 1996], CXCL11 [Cole KE et al 1998] and CXCL4 [Lasagni 
L et al 2003]. The receptor is expressed by IL-2-activated T-lymphocytes [Loetscher M et 
al 1996]. Two isoforms have been established [Lasagni L et al 2003].  
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CXCR4 - CXCR4 (Fusin) was first cloned by Loetscher M et al 1994 as an 
orphan chemokine receptor (that is, a receptor whose ligand has not yet been discovered) 
and was given the acronym LESTR. It was found to be expressed on neutrophils, myeloid 
cells, and T lymphocytes [Loetscher M et al 1994]. LESTR was subsequently discovered 
to be a necessary co-receptor for the entry of T-tropic HIV-1 and HIV-2 into CD4+-
expressing cells [Feng Y et al 1996]. When CXCL12 (SDF-1) was identified as the ligand 
for LESTR, the receptor was renamed CXCR4 [Bleul CC et al 1996, Oberlin E et al 
1996]. CXCR4 gene deletion in mice results in impaired B lymphopoiesis, myelopoiesis, 
hematopoiesis, impaired cerebellar neurone migration, cardiac defects and defective 
formation of large vessels supplying the gastrointestinal tract [Ma Q et al 1998, 
Nagasawa T et al 1996, Tachibana K et al 1998, Zou YR et al 1998] suggesting that 
CXCL12 and CXCR4 have significantly different functions from those of other 
chemokines and their receptors.  
 
 
CXCR5 - BLR1, an orphan receptor expressed in Burkitt's lymphoma cells and B 
lymphocytes, was noted to have significant homology with other CXC receptors [Dobner 
T et al 1992]. Subsequently, CXCL13, a chemokine with strong B-cell-attracting/ 
activating functions, was found to bind BLR1 [Legler DF et al 1998], and thus BLR1 was 
reclassified as CXCR5. 
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CXCR6 - this was originally identified as an orphan receptor in 1997 until it was 
demonstrated that it bound CXCL16, at which time it was renamed CXCR6 [Matloubian 
M et al 2000, Murphy PM 2002, Wilbanks et al 2001]. CXCR6 is expressed mainly on T 
lymphocytes [Kim CH et al 2001, Tabata S et al 2005, Unutmaz D et al 2000] and 
binding of the ligand, CXCL16, results in chemotaxis of these cells in the inflammatory 
process [Tabata S et al 2005].  
 
 
CXCR7 - the orphan receptor, RDC-1, was demonstrated by Balabanian K et al 
2005,  to result in the chemotaxis of T lymphocytes by binding CXCL12 (thought 
previously to be the only ligand for CXCR4). Therefore the group proposed naming this 
orphan receptor, CXCR7. There is no information publicly available at this time to 
confirm whether this designation has been accepted by the International Union of 
Immunological Societies (IUIS) / World Health Organisation (WHO) Subcommittee on 
Chemokine Nomenclature. This receptor also has high affinity for CXCL11. The function 
of this receptor is currently controversial as some studies suggest it is a non-signaling 
scavenger receptor for CXCL11 and CXCL12 [Naumann U et al 2010]. 
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CCR Receptors – history, location and physiological role in leucocytes 
 
 
 
CCR1 - CCR1 was the first CC chemokine receptor to be identified [Neote K et 
al 1993]. Ligands for CCR1  include CCL3, CCL5, CCL7 and CCL8 [Ben-Baruch A et al 
1995, Combadiere C et al 1995, Gong X et al 1997].  Subsequently, CCL14, CCL15 and 
CCL23 were shown to bind to this receptor [Tsou CL et al 1998, Youn BS et al 1998]. 
CCR1 is expressed by monocytes [Sica A et al 1997], neutrophils [Bonecchi R et al 
1999] and activated T cells [Loetscher P et al 1996, Perera LP et al 1999]. 
 
 
 
 
CCR2 - two groups simultaneously discovered CCR2. Yamagami S et al 1994 
identified CCR2B but Charo IF et al 1994 discovered two isoforms of CCR2 - CCR2A 
and CCR2B. CCR2 binds the the monocyte chemotactic proteins (MCPs) [Baggiolini M 
et al 1994] and thus ligands for CCR2 include CCL2, CCL7, CCL8, CCL13 and CCL16 
[Combadiere C et al 1995, Gong X et al 1997, Nomiyama H et al 2001].  
 
 
CCR3 – Daugherty BL et al 1996 and Kitaura M et al 1996 both initially 
identified CCR3, which is found predominantly on eosinophils but also on basophils and 
T cells [Gerber BO et al 1997, Uguccioni M et al 1997]. Ligands include CCL11, CCL24, 
CCL5, CCL7, CCL13, CCL15 and CCL28 [Daugherty BL et al 1996, Forssmann U et al 
1997, Uguccioni M et al 1997, Pan J et al 2000]. 
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CCR4 - Power et al 1995 identified CCR4. CCR4 binds CCL3, CCL5, CCL17 
and CCL22 [Imai T et al 1997, Imai T et al 1998]. The latter two ligands both activate T 
lymphocytes.  
 
 
CCR5 – this was discovered by Samson M et al 1996. Ligands include CCL3, 
CCL4, CCL5, CCL8 [Ruffing N et al 1998] and also CCL13 and CCL16 [Blanpain C et 
al 1999].  CCR5 is found in peripheral T lymphocytes and macrophages [Raport CJ et al 
1996]. Importantly, CCR5 (and also CXCR4) has been shown to be the major co-
receptor, in association with CD4, for HIV-1 entry into permissive cells [Doranz BJ et al 
1996].  
 
 
CCR6 – this was initially cloned as an orphan receptor by a few laboratories. 
When Baba M et al 1997 discovered that CCL20 specifically bound to this receptor, it 
was renamed CCR6. The receptor is expressed by memory T cells, B lymphocytes, and 
dendritic cells [Liao F et al 1999].  
 
CCR7 – initially cloned as an orphan receptor, this was named CCR7 when it 
was found that it specifically bound CCL19 [Yoshida R et al 1997]. It also binds CCL21 
[Campbell JJ et al 1998]. CCR7 is known to be expressed on activated T and B 
lymphocytes and dendritic cells [Yoshida R et al 1997, Yanagihara S et al 1998].  
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CCR8 – when Roos RS et al 1997 and Tiffany HL et al 1997 established that 
several orphan receptors specifically bound CCL1, they were all renamed CCR8. The 
receptor also binds CCL16 [Howard OM et al 2000]. CCR8 is significantly expressed in 
thymus T lymphocytes and monocytes [Tiffany HL et al 1997]. Similarly to CXCR4 and 
CCR5, CCR8 is a cofactor in the infection of permissive cells with the HIV-1 virus 
[Horuk R et al 1998].  
 
 
CCR9 – when Zaballos A et al 1999 found that CCL25 bound a known orphan 
receptor, this was reclassified as CCR9. This receptor is expressed on both immature and 
mature T cells [Zaballos A et al 1999].  
 
 
CCR10 – this receptor was first cloned by Marchese A et al 1995. It binds the 
ligands CCL27 [Baird JW et al. 1999, Homey B et al. 2000] and CCL28 [Wang W et al 
2000]. 
 
 
CCR11 – this has been disqualified as a chemokine receptor [Murphy PM 2002]. 
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SECTION 1.4 
 
The role of chemokines and their receptors in cancer 
 
Over the past decade it has become clear that chemokines are not only involved in 
foetal development, mobilization of haematopoietic stem cells and inflammatory 
processes by trafficking of naive lymphocytes, but they may be pivotal at all stages of 
malignant development, including initiation of neoplasia, growth of tumour and 
progression to invasion and metastasis.  
 
 
Chemokines in cellular transformation 
There is increasing evidence that chemokines are implicated in the neoplastic 
transformation of cells. The chemokine receptor CXCR2 shares a high degree of 
homology to the G-protein-coupled receptor ORF74 or Kaposi's sarcoma herpesvirus-G 
protein-coupled receptor (KSHV-GPCR), encoded by Kaposi’s sarcoma-associated 
herpes virus-8 [Bais C et al 1998]. This is an agonist-independent receptor whose 
signalling is further upregulated by binding of CXC chemokines CXCL8 and CXCL1 
(GROα). Yang TY et al 2000 showed that over-expression of this receptor within 
haematopoietic cells of transgenic mice led to the development of angioproliferative 
lesions resembling Kaposi’s sarcoma. Furthermore, Burger M et al 1999 demonstrated 
that a point mutation of CXCR2 leads to constitutive signalling of the receptor and 
cellular transformation of transfected NIH 3T3 cells (a fibroblast cell line derived from 
mouse embryo) comparable to results seen with KSHV-GPCR. This work with others 
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suggests that CXC chemokines (CXCL8 and CXCL1) continually stimulate certain cells 
expressing the CXCR2 receptor by autocrine and paracrine mechanisms, ultimately 
leading to promotion of oncogenic cellular transformation. 
Using ovarian cancer cell lines, it has been shown that the presence of the 
receptor CXCR2 promoted cell cycle progression by modulating cell cycle regulatory 
proteins and inhibited cellular apoptosis, thus implicating this receptor in the 
carcinogenesis of ovarian neoplasms [Yang G et al 2010]. 
Wang D et al 2000 have established that over-expression of human CXCL1, 
CXCL2 and CXCL3 (GROα, β, γ) in immortalised murine melanocytes enables these 
cells to form tumours in SCID and nude mice and additionally they have established that 
the malignant transformation of the melanocytes by these chemokines requires Ras 
activation.  
Other chemokines might play similar role in neoplastic transformation. CXCL13, 
the only chemokine known to specifically chemoattract B lymphocytes, has been shown 
to be highly expressed in Helicobacter pylori-induced gastric lymphoma [Mazzucchelli L 
et al 1999], suggesting a role for CXCL13 in the localization of the tumor as well as 
possibly in the oncogenic event itself. More recently, using a mouse model, Popivanova 
BK et al 2009, identified CCL2 as a crucial mediator of the initiation and progression of 
chronic colitis-associated colon carcinogenesis. 
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Chemokines and leucocyte recruitment in tumours 
The production of inflammatory chemokines by tumour cells (or stromal cells) 
results in the presence of various types of leucocytes in the tumour tissue. The leucocytes 
secrete a variety of molecules including cytokines, chemokines and proteases, which 
affect tumour growth and invasion. However, there is great debate as regards to the role 
of infiltrating leucocytes in the cancer micoenvironment and their relevance to cancer 
growth and progression [Allavena P et al 2008, Whiteside TL 2006, Yang L and Carbone 
DP 2004].  
Many tumours and metastatic deposits contain numerous macrophages as the 
major leucocyte component of the cancer stroma. These macrophages are referred to as 
tumour associated macrophages (TAMs) and most are derived from peripheral blood 
monocytes recruited into the neoplastic mass [Mantovani A et al 1992]. The role of 
TAMs in tumours is contentious but they are mostly associated with tumour progression 
and metastasis although in a significant number they result in cancer regression [Allavena 
P et al 2008, Bingle L et al 2002, Whiteside TL 2006, Yang L and Carbone DP 2004]. 
This effect of TAMs is thought to be regulated by modulation of the host immune system. 
TAMs demonstrate tumour cell growth-promoting effects through release of various 
cytokines (including chemokines), growth factors, inflammatory mediators and 
proteolytic enzymes. Once within the tumour, the tumouricidal activity of the 
macrophages seems not to be activated. Also, macrophages have been shown to suppress 
many T cell and NK cell anti-tumour responses and also lead to generalised 
immunosuppression in the host (eg. by secretion of IL-10 and prostaglandin-E2 by 
TAMs) [Balkwill F 2004a, Elgert KD et al 1998]. On the other hand, tumour growth 
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reduction by TAMs can be mediated by non-specific anti-tumour cytotoxic mechanisms 
or induction of specific cell lytic effects. Thus some studies suggest the presence of 
tumour-associated macrophages is associated with a worse prognosis whereas others 
show a better or no prognostic significance [Allavena P et al 2008, Bingle L et al 2002, 
Whiteside TL 2006]. The determinants of the role of TAMs in each tumour are, as yet, 
poorly understood. 
In the seminal work by Mantovani’s group they described a tumour-derived 
chemotactic factor for monocytes produced by human and mouse cancer cell lines 
[Bottazzi B et al 1983], that was later identified as the chemokine CCL2 (MCP-1), which 
binds to the CCR2 receptor [Bottazzi B et al 1990]. The chemokine CCL2 has since been 
shown to induce recruitment of macrophages in many malignancies and furthermore, the 
levels of this chemokine are further amplified by its secretion by the TAMs. In cancer of 
the oesophagus, CCL2 expression correlates positively with the level of macrophage 
infiltration, tumour angiogenesis, and invasion indicating that tumour associated 
macrophages may promote tumour progression. However, Monti P et al 2003 observed 
that CCL2 is secreted by pancreatic carcinoma cells and is released into the patient 
circulation. Serum CCL2 levels were found to be positively correlated with intratumoural 
macrophage infiltration but inversely correlated with tumour cell proliferative activity. 
Also, patients with high circulating levels of CCL2 had significantly longer survival than 
those with low levels. Gene transfer of CCL2 into cancers has also demonstrated 
confusing results with some studies showing reduced tumorigenicity whilst others have 
shown increased rates of neoplastic growth and metastases [Conti I et al 2004].  
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Examples of other tumour secreted chemokines associated with an increased 
infiltration of macrophages in the neoplasm include CCL5 (RANTES), which is secreted 
by breast cancer cells and whose level of expression correlates with the extent of 
macrophage infiltration and progression and lymph node metastasis [Azenshtein, E et al. 
2002]. More recently it has been shown that co-culture with macrophages increased the 
expression of CXCL8 (IL-8) in a glioma cell line and that in 43 human glioma specimens 
IL-8 mRNA expression and microvessel count in glioma surgical specimens correlated 
positively with the density of TAMs [Hong TM et al 2009]. It was suggested that 
macrophages could play a role in promoting glioma growth and angiogenesis by inducing 
IL-8 expression in glioma cells via inflammatory stimuli or the nuclear factor kappa B 
pathway. 
CCL2, with a number of other chemokines, also aids in the recruitment of 
dendritic cells into neoplasms [Sozzani S et al 2000]. Dendritic cells play a vital role of 
antigen-presentation and stimulation of naive T cells that function in the adaptive arm of 
the immune system; thus it follows that CCL2 recruitment of these antigen presenting 
cells could promote tumour immunity. However, once again, the role of dendritic cells is 
not as straightforward as it seems and it is not clear whether their presence is associated 
with a beneficial or adverse outcome. Data indicate that if dendritic cells were to be 
recruited into tumours in an immature form they may actually prime the immune system 
to be tolerant of the tumour antigens rather than immunogenic. There is clear data on the 
infiltration of cancers by dendritic cells [Chaput N et al 2008, Lespagnard L et al 1999, 
Vicari AP and Caux C 2002, Whiteside TL 2006] but further work is required to clarify 
these contradictory findings and understand the intricate balance between immunogenic 
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induction and toleration of tumours, which occurs within this population of cells 
[Bennaceur K et al 2008, Hackstein H et al 2001] 
 
Chemokines as tumour growth factors 
It is widely known that cells respond to growth factors in an autocrine and 
paracrine manner, which in turn can induce cells to enter and proceed through the G1 
phase of cell cycle. This growth regulation has been observed in a number of tumour 
systems and highlights the important role for chemokines.  
CXCL8 has been established as an essential autocrine growth factor for some 
human melanoma cell lines and acts via CXCR1 or CXCR2 receptors, which have also 
been shown to be present in melanoma cell lines [Payne AS and Cornelius LA 2002, 
Satyamoorthy K et al 2003, Schadendorf D et al 1993, Varney ML et al 2003]. These 
findings have been more recently confirmed by Gabellini C et al 2009, who also 
demonstrated that CXCL8 was as an autocrine/ paracrine growth factor in melanoma cell 
lines acting via CXCRI and CXCR2 (CXCL8 also induced angiogenesis via this route). 
However, this group also observed that only CXCR2 receptor plays an important role in 
regulating the CXCL8-mediated invasive and migratory behaviour of human melanoma 
cells. 
  Zhu YM et al 2004 demonstrated that in the non-small cell lung cancer 
(NSCLC) cell lines, H460 and MOR/P, cell proliferation could be induced by CXCL8 
and constitutive proliferation could be inhibited by neutralizing antibodies against 
CXCL8 ligand or CXCR1 receptor. This indicated that constitutive CXCL8 and CXCR1 
protein expression enabled an autocrine growth mechanism in these cells. Using similar 
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methodology, it has been observed that an autocrine mitogenic effect due to CXCL8 
occurs in human epidermoid carcinoma cell lines A431 and KB, but this is via the 
CXCR2 receptor [Metzner B et al 1999]. Interestingly, Luppi F et al 2007, discovered 
that CXCL8 stimulates cell proliferation in NSCLC cell lines through epidermal growth 
factor receptor (EGFR) transactivation. 
In vitro studies on androgen-independent PC3 cells have confirmed the mitogenic 
activity of CXCL8, increasing the rate of cell proliferation through activation of both 
CXCR1 and CXCR2 receptors [Murphy C et al 2005]. Using CXCL8 LNCaP 
transfectants Araki S et al 2007 showed that CXCL8 induced cell proliferation was 
mediated through CXCR1 and was independent of androgen receptor (AR) i.e. CXCL8 is 
a molecular determinant of androgen-independent prostate cancer growth and 
progression. 
Other tumour cell lines in which CXCL8 acts as an autocrine growth factor are 
those obtained from human cancers of the colon, stomach, liver, pancreas, and Kaposi’s 
sarcoma [Brew R et al 2000, Fujisawa N et al 2000, Kamohara H et al 2007, Kitadai Y et 
al 2000, Li A et al 2001, Miyamoto M et al 1998, Takamori H et al 2000, Masood R et al 
2001]. CXCL8 has additionally been found to inhibit TNF-related apoptosis in the 
ovarian cancer cell line OVCAR3 [Abdollahi T et al 2003]. These findings are reinforced 
in hepatocellular, gastric, pancreatic and prostate cancers, in which CXCL8 and its 
receptor(s) have been found on immunohistochemistry of surgically resected neoplasms 
[Akiba J et al 2001, Eck M et al 2003, Hussain F et al 2010, Kuwada Y et al 2003, 
Murphy C et al 2005]. Additionally, in biopsy tissue obtained from human ovarian 
carcinomas, neuroblastomas and squamous cell carcinomas of the head and neck, both 
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CXCL8 and its receptor, CXCR2 are expressed by malignant cells. This suggests CXCL8 
could also function in an autocrine pathway for these tumours [Ferrer FA et al 2000, 
Ivarsson K et al 2000, Richards BL et al 1997]. 
  CXCL1 (GROα) was originally identified and purified from serum-free culture 
supernatants of a malignant melanoma cell line, Hs294T, and characterized as an 
autocrine growth factor for melanoma cells [Bordoni R et al 1990, Richmond A and 
Thomas HG 1986]. Two highly related CXC chemokines CXCL2 (GROβ) and CXCL3 
(GROγ) have additionally been shown to be involved in melanocyte transformation and 
tumour growth [Owen JD et al 1997]. All three share the receptor CXCR2. CXCL1 has 
also been shown to act as an autocrine growth factor for some human adenocarcinoma 
cell lines derived from the lung and stomach [Fujisawa N et al 2000] and in human 
malignant colonic, pancreatic, and oesophageal cell lines [Li A et al 2004, Takamori H et 
al 2000, Wang B et al 2006]. In a murine model CXCL1 is an autocrine mitogenic agent 
for squamous cell carcinoma [Loukinova E et al 2000]. In gastric carcinoma further 
verification has been provided by immunohistochemistry on patient samples [Eck M et al 
2003, Junnila S et al 2010].  
CXCL12 has been found to stimulate glioblastoma cell proliferation [Barbero S et 
al 2003]. The expression of the receptor for CXCL12 ligand, CXCR4, has been observed 
to be upregulated in human glioblastomas and inhibition of this receptor blocks tumour 
cell proliferation [Barbero S et al 2003, Seghal A et al 1998, Seghal A, Ricks S et al 
1998]. Interestingly, Bajetto A et al 2001 and Bajetto A, Bonavia R et al 2001 
demonstrated the concomitant expression of the CXCL12 ligand (SDF-1) with its 
receptor CXCR4 leads to autocrine and paracrine regulation of cell growth in cultured 
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astrocytes. Also, using 12 primary cultures from human meningioma tissue Barbieri F et 
al 2006 established that CXCL12 - CXCR4 interaction stimulated meningioma cell 
proliferation through the extracellular signal-regulated kinase (ERK) - 1/2 pathway. Kang 
H et al 2005 have established the role of the autocrine CXCL12 – CXCR4 pathway in the 
proliferation of breast cancer cell lines; Marchesi F et al 2004 and Sutton A et al 2007 
have confirmed the same axis in pancreatic and hepatocellular cancer respectively using 
cell lines and human tissue. 
In prostate cancer cell lines, PC3, DU145 and LNCaP, CCL5 (RANTES) was 
confirmed to promote cell proliferation via the CCR5 receptor in an autocrine fashion, 
which could be inhibited by a CCR5 antagonist [Vaday GG et al 2006, Zhang X et al 
2010 ]. Both CCL5 and CCR5 were also detected in human prostate cancer tissues 
[Vaday GG et al 2006].Additionally,  Lu Y et al 2006, demonstrated CCL2 (MCP-1) 
acted as a paracrine and autocrine growth factor in prostate cell lines. 
 
Chemokines in the modulation of angiogenesis and angiostasis 
Angiogenesis is a normal physiological process that takes place during embryonic 
development and wound healing. It is also required for solid tumours to grow beyond 1 
mm in diameter and for their subsequent rapid growth [Folkman J 1995, Foulds L 1964, 
Gimbrone M et al 1974]. CXCL4 (PF-4) and CXCL8 are members of the CXC 
chemokine subfamily, but they differ in that CXCL8 contains the ELR motif (ELR+; 
Glu-Leu-Arg) at its NH2 terminus. It has been demonstrated that CXCL4 has angiostatic 
properties, which was initially demonstrated by Maione TE et al 1990, who observed that 
it inhibited endothelial cell proliferation, angiogenesis in the chick chorioallantoic 
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membrane assay and tumour growth in immunodeficient mice. Lewis lung carcinoma 
cells transfected with human CXCL4, when injected intravenously, had significantly 
impaired ability to form lung metastases due to inhibition of neovascularisation in vivo 
[Yagamuchi K et al 2005]. In fact a variant of CXCL4 has been discovered, known as 
CXCL4-L1 or PF-4var, which differs from CXCL4 in only three amino acids, but is 
much more potent in inhibiting angiogenesis in tumours such as melanoma and lung 
carcinoma [Struyf S et al 2004, Struyf S et al 2007]. It has been established that it is the 
short terminal COOH fragment or terminal peptides of both CXCL4 and CXCL4L1 that 
determine the potent antiangiogenic effect of these molecules [Hagedorn M et al 2002, 
Vandercappellen J et al 2010]. Also of interest is the fact that CXCL4 is able to inhibit 
the migration and proliferation of lymphatic endothelial cells in a dose dependent manner 
in vitro, suggesting that it may be implicated in the control of lymphangiogenesis [Shao 
XJ and Xie FM 2005]. 
In contrast, CXCL8 was the first chemokine shown to stimulate endothelial cell 
chemotaxis, proliferation and in vivo angiogenesis (using a rat corneal micropocket 
assay) [Koch AE et al 1992]. In human umbilical vein endothelial cells (HUVECs) and 
human dermal microvascular endothelial cells, recombinant human CXCL8 induced 
endothelial cell proliferation and capillary tube organization (via CXCR2 and CXCR1) 
whilst neutralization by anti-CXCL8 antibody blocked capillary tube organization [Li A 
et al 2003]. Incubation of endothelial cells with CXCL8 inhibited endothelial cell 
apoptosis [Li A et al 2003]. CXCL8 is critical to glial tumour [Brat DJ et al 2005] and 
melanoma [Gabellini C et al 2009] neovascularity (via CXCR2 and CXCR1) and in glial 
neoplasms levels of the chemokine correlate with histological grade in glial neoplasms 
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[Brat DJ et al 2005]. In prostate cancer, CXCL8 has been particularly well studied as 
regards its role in neoangiogenesis and prognosis. Significant levels of CXCL8 are 
observed in prostate tumour cells, but not in normal or benign hyperplastic cells [Ferrer 
FA et al 1998]. Antibody to CXCL8 secreted by the cell line PC-3 has been shown to 
reduce tumour growth and tumour-related angiogenesis in a SCID mouse model [Moore 
BB et al 1999]. In LNCaP cells CXCL8 confers androgen-independent growth [Araki S 
et al 2007, Lee F et al 2004] and Aalinkeel R et al 2004 have suggested that the 
metastatic potential of prostate cancer cells in vitro correlates with the expression of 
proangiogenic factors including CXCL8. Clinically, serum CXCL8 (ELR+) is elevated in 
prostate cancer patients [Veltri RW et al 1999] with a significant elevation of CXCL8 in 
men with bone metastases when compared to men with localised disease [Lehrer S et al 
2004]. Additionally, CXCL8 mRNA levels in radical prostatectomy specimens are 
positively correlated with an advanced pathologic stage [Uehara H et al 2005] and 
cytoplasmic expression of this chemokine has been established to correlate with 
microvessel density on immunohistochemistry [Murphy C et al 2005]. In pancreatic 
cancer, Matsuo Y et al 2009 measured ELR+ CXC chemokine levels in supernatants 
from multiple pancreatic cell lines and confirmed significantly higher expression from 
those derived from malignant cells. Paracrine effects of these ELR+ chemokines on 
human umbilical vein endothelial cells (HUVEC) was investigated and results confirmed 
significantly enhanced proliferation, invasion, and tube formation of HUVEC. These 
biological effects were significantly inhibited by treatment with a neutralizing antibody 
against the CXCR2 receptor. 
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Strieter RM et al 1995 hypothesised that the presence of the ELR motif is critical 
for determining the effect a CXC chemokine has on angiogenesis. They showed that 
substitution of the ELR motif in CXCL8 with the amino acids TVR (Thr-Val-Arg) or 
DLQ (Asp-Leu-Gln) resulted in an ELR– mutated CXCL8 that was unable to stimulate 
endothelial chemotaxis or in vivo angiogenesis. The mutated CXCL8 actually inhibited 
angiogenesis. In contrast, the addition of ELR to CXCL9 (MIG), an ELR– chemokine, 
resulted in its conversion from an angiostatic to an angiogenic agent. The angiogenic 
members of the CXC chemokine family include CXCL1, CXCL2, CXCL3, CXCL5, 
CXCL6, CXCL7 and CXCL8, which are all ELR+. Only CXCL8 and CXCL6 
specifically bind to to the receptor CXCR1, whereas, all ELR+ CXC chemokines bind to 
CXCR2 [Addison CL et al 2000, Strieter RM et al 2004]. The ability of all ELR+ CXC 
chemokine ligands to bind to CXCR2 supports the notion that this receptor mediates the 
angiogenic activity of ELR+ CXC chemokines. The angiostatic ELR- CXC chemokines 
such as CXCL4, CXCL9, CXCL10 and CXCL11 mediate their activity through the 
CXCR3 receptor [Strieter RM et al 2004]. 
Luan J et al 1997 tested the biological consequence of overexpression of CXCL1, 
CXCL2, CXCL3 (GROα, GROβ, GROγ: all ELR+) chemokines following their 
transfection of non-tumourigenic immortalised mouse melanocytes. This resulted in the 
formation of highly vascular tumours in nude mice. Antibodies to these three proteins 
slowed or inhibited the formation of tumours in the SCID mouse model (accompanied by 
a reduction in the number of viable endothelial cells in tumours) and blocked the 
angiogenic response to conditioned medium from tumourigenic transfectants in the rat 
corneal micropocket assay. In colorectal cancer, CXCL1 released from carcinoma cells 
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induced microvascular endothelial cell migration and tube formation in vitro [Wang D et 
al 2006]. Furthermore, PGE2 (a proinflammatory mediator) promoted tumour growth in 
vivo by induction of CXCL1 expression, which resulted in increased tumour microvessel 
formation vitro [Wang D et al 2006]. A correlation between CXCL1 cytoplasmic 
immunostaining and microvessel density was revealed in a series of human oral 
squamous cell carcinomas [Shintani S et al 2004] and it has been noted that in patients 
with metastatic renal cell cancers CXCL1 and CXCL3  levels are raised (as well as 
several other proangiogenic chemokines) [Mestas J et al 2005]. Collectively, these results 
indicate that CXCL1 inhibitors in particular should be evaluated further as potential anti-
angiogenic agents for treatment of cancers. 
Amongst the angiostatic chemokines the most studied has been CXCL10 (IP-10), 
which is ELR–. This molecule inhibits growth of new blood vessels stimulated by either 
vascular endothelial growth factor (VEGF) or angiogenic CXC chemokines in the rat 
corneal micropocket assay [Belperio JA et al 2000]. Using a mouse matrigel 
neovascularisation model, CXCL10 was shown to inhibit angiogenesis stimulated by 
basic fibroblast growth factor in vivo [Angiolillo AL et al 1995]. In HUVECs, CXCL10 
resulted in dose-dependent and selective inhibition of proliferation and countered the 
proliferative effects of vascular endothelial growth factor as well as leading to potent and 
selective induction of apoptosis [Feldman ED et al 2006]. Treatment of endothelial cells 
with CXCL10 in the presence of VEGF inhibited endothelial cell tube formation in vitro 
and significantly inhibited VEGF-induced endothelial motility, via the CXCR3 receptor 
[Bodnar RJ et al 2006]. Burkitt’s lymphoma cells transfected to overexpress CXCL10 
had reduced ability to form subcutaneous tumours in nude mice, which was attributed to 
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its ability to decrease tumour angiogenesis [Sgadari C et al 1996]. Similarly, in 
melanoma, CXCL10 resulted in decreased tumour growth and microvessel density in 
vivo by binding the CXCR3 receptor [Yang J and Richmond A 2004]. In renal cancer, 
intratumour CXCL10 mRNA levels were inversely correlated with microvessel density in 
patient samples and thus high CXCL10 expression levels were a favourable prognostic 
factor [Kondo T et al 2004].  
Interestingly, one ELR– CXC chemokine actually stimulates, rather than inhibits, 
angiogenesis: SDF-1 or CXCL12. Gupta SK et al 1998 demonstrated that the CXCR4 
receptor is expressed on endothelial cells and that its ligand CXCL12 was an efficacious 
chemoattractant for these cells. Additionally, CXCL12 induces angiogenesis from cross-
sections of leukocyte-free rat aorta in vitro [Salcedo R et al 1999] and the formation of 
capillary-like structures by endothelial cells in culture [Molino M et al 2000]. Endothelial 
progenitor cells (EPC) from healthy volunteers also express the CXCR4 receptor and 
anti-CXCR4 antibodies significantly inhibited CXCL12 induced EPC migration, EPC 
induced angiogenesis as well as reducing EPC incorporation and impairing blood flow 
recovery in ischaemic hind limbs of nude mice [Walter DH et al 2005]. Related to this, 
Ara T et al 2005 have observed that CXCL12 acts on arterial endothelial cells of large 
arteries to up-regulate CXCR4 and mediate the connection between the larger artery and 
neighbouring capillary plexus. Recently, using in vitro experiments in glioma cells, 
VEGF has been shown to exert its effects by upregulation of CXCL12 and CXCR4 
expression [Hong X et al 2006], and in ovarian carcinoma it was shown that VEGF 
upregulates CXCR4 expression on vascular endothelial cells and synergises CXCL12 
mediated vascular endothelial cell migration in vivo [Kryczek I et al 2005]. Additionally, 
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CXCL12 synergised VEGF mediated vascular endothelial cell expansion and hypoxia 
induced both tumour CXCL12 and VEGF production. This suggests that hypoxia 
triggered tumour CXCL12 and VEGF form a synergistic angiogenic axis in vivo 
[Kryczek I et al 2005]. From this evidence, it is likely that anti-VEGF treatments, which 
have been introduced, act partly via down-regulation of the CXCL12 – CXCR4 axis. 
Interestingly, using tumor xenografts of the C6 glioma cell line containing cancer stem 
cells (CSC; which are predicted to be critical drivers of tumour progression due to their 
self-renewal capacity and limitless proliferative potential) Folkins C et al 2009 
demonstrated that that CSC contribute to tumour angiogenesis by promoting both local 
endothelial cell activity and systemic angiogenic processes involving bone marrow-
derived endothelial progenitor cells. This was found to be the result of increased VEGF 
and CXCL12 by the CSC. It should be noted that there is now some emerging evidence 
that CXCL12 exerts its biological effects in endothelial cells through a receptor different 
from CXCR4 [Hatse S et al 2006]. 
These studies suggest the presence of both stimulators and inhibitors of 
angiogenesis among the CXC chemokine subfamily. It is postulated that CXC 
chemokines form a balanced network of angiogenic and angiostatic regulators that are 
disrupted in cancer. Importantly, the balance of ELR+ and ELR– chemokines produced 
by a tumour and its stroma may determine the degree of angiogenesis surrounding the 
tumour and thus, the consequent invasiveness of the tumour [Moore BB et al 1998, 
Strieter RM et al 2004]. 
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Chemokines in local tumour invasion and adhesion 
Several studies have shown that chemokines are important in stimulating cancer 
cells to produce and secrete protease enzymes, which aid invasiveness through the ECM. 
For example, CXCL8 expression by human melanoma cells induces transcriptional 
activation of expression of the gene encoding MMP-2 and augmented collagenase 
activity in these tumour cells, which leads to increased invasiveness [Luca M et al 1997]. 
In prostate cancer, CXCL8 over-expression induces the expression of MMP-9, 
leading to increased tumour cell invasiveness and metastatic potential in nude mice 
[Inoue K et al 2000a]. Invasion through ECM components by malignant prostate cell 
lines (LNCaP and/ or PC3) in response to CXCL12 was shown to be a result of increased 
MMP expression (specifically MMP-1, MMP-2, MMP-3, MMP-9, MMP-14) [Chinni SR 
et al 2006, Hu W et al 2008, Singh S et al 2004a]. CXCL12 – CXCR4 interaction, 
resulting in increased MMP-9 and MMP-2 expression, has been implicated in perineural 
invasion of prostate cancer using human tissue and cell lines [Zhang S et al 2008]. Hu W 
et al 2008 suggested that exogenous CXCL16 interacted with the CXCR4 receptor in 
prostate cancer cells to promote significant MMP-9 and MMP-2 activity in LNCaP but 
not in PC3. Additionally, the CCL25 ligand has been shown to enhance expression of 
MMP-2 and MMP-9 in prostate cancer cells in vitro, via the CCR9 receptor, resulting in 
increased invasive capacity [Singh S et al 2004b].  
In bladder cancer it has been suggested that CXCL8 exerts its action through an 
autocrine and paracrine loop by inducing adjacent tumour cells and stromal cells to 
express increased levels of MMP-2 and MMP-9, which facilitates tumour invasion, and 
metastases [Inoue K et al 2000b]. Also Eisenhardt A et al 2005 noted a distinct rise in 
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intracellular actin stress fibre formation, chemotactic activity and invasion through 
matrigel coated membranes in the bladder cancer cell lines J82 and T24 upon stimulation 
with CXCL12, which was blocked in the presence of a specific CXCR4 receptor 
antibody. More recently, Kawanishi H et al 2008, once again using the highly invasive 
human bladder cancer cell line T24 in addition to the poorly invasive human bladder 
carcinoma cell line RT112, demonstrated that CXCL1, secreted from malignant cells, 
promoted cancer cell invasiveness via the increased expression of MMP-13. They also 
showed that urinary CXCL1 levels were significantly higher in patients with invasive 
bladder cancer (pT1-4) than those with non-invasive pTa tumours and normal control, 
thus suggesting its use as a potential urinary biomarker for invasive bladder cancer. 
Tang CH et al 2010 found that human chondrosarcoma tissues had significant 
expression of the chemokine ligand CCL5 and its receptor CCR5, which was higher than 
that in normal cartilage. They also found CCL5 increased MMP-3 expression in human 
chondrosarcoma cells (JJ012 cells). Interestingly, it has been noted that human adipose 
tissue derived stem cells (hASCs), when co-cultured with breast cancer cells in vitro, 
resulted in increased neoplastic cell invasion through matrigel due to secretion of CCL5 
by hASCs, which resulted in raised MMP-9 activity in cancer cells [Pinilla S et al 2009].  
Chemokines are also implicated in mediating the expression of integrins, which as 
discussed earlier, are involved in the formation of tumour cell – ECM or tumour cell – 
endothelial cell adhesions during invasion and migration. For example, increased tumour 
cell adhesion to the fibronectin of ECM is related to the CXCL12 stimulation of 
numerous ovarian cancer cell lines to upregulate ß1-integrin [Scotton CJ et al 2001]. In 
small cell lung cancer cells (SCLC) CXCL12 stimulation has been demonstrated to 
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induce firm adhesion to marrow stromal cells via activation of α4β1 integrin and also 
induce SCLC cell invasion into the ECM [Burger M et al 2003]. In the B16 melanoma 
experimental metastasis model, CXCR4 transfected cells were observed to enhance 
adhesion to dermal and pulmonary microvascular endothelial cells [Murakami T et al 
2002]. Under flow conditions, these transfected cell lines showed no evidence of rolling 
before arrest and adhesion was dependent on β1 integrin expression and adhesion of 
transfectants to endothelial cells both in vitro and in vivo was inhibited by anti-β1 
antibodies [Cardones AR et al 2003]. Engl T et al 2006 have established that CXCL12 – 
CXCR4 interaction resulted in enhanced expression of α5 and β3 integrins in LNCaP and 
DU145 cell lines, which enabled increased adhesion of these cells to human endothelium 
or to ECM proteins (laminin, collagen, fibronectin), thereby promoting tumour invasion. 
Also it has been noted that lung derived CXCL12 (chondrosarcoma shows a predilection 
for metastasis to lungs) enhances the invasiveness of chondrosarcoma cell lines by 
increasing α5β3 integrin expression through the CXCR4/ ERK/ NF-kappaB signal 
transduction pathway [Lai TH et al 2009]. 
Additionally, Singh S et al 2009a, established that in prostate cancer, CXCL13, 
the only ligand for CXCR5, was produced by human bone marrow endothelial (HBME) 
cells, and was able to able to induce prostate cancer cell line adhesion to HBME cells 
and also increase their invasive ability in a CXCR5-dependent manner. This CXCL13 – 
CXCR5 interaction promoted the clustering of α5β3 integrin in the prostate cancer cells. 
CXCL13-mediated prostate cancer cell adhesion to HBME cells and α5β3 clustering was 
abrogated by CXCR5 blockade. 
 
 74 
Chemokines in the organ specific directional migration of cancer cells 
As discussed in an earlier section, metastasis is not a random process and different 
cancer types have specific metastatic sites. There is increasing support for the “homing” 
theory of organ specific metastasis stating that different organs have special abilities to 
attract, through chemotactic factors, specific types of cancer cells [Moore MA 2001, 
Muller A 2001, Ben-Baruch A et al 2008]. Importantly there is growing evidence that 
chemokines and their receptors play a pivotal role in this directional migration of cancer 
cells. 
In a seminal publication by Muller A et al 2001, they researched into the 
mechanisms involved in the metastasis of breast cancer to specific organs. They found 
that amongst 17 different chemokine receptor genes, CXCR4 and CCR7 were highly 
expressed in human breast cancer cells lines, malignant breast tumours and metastases 
relative to the levels in normal mammary epithelial cells. They then screened a panel of 
normal human organs for the ligands of these receptors, CXCL12 and CXCL21 
respectively, and found they exhibited peak levels of expression in organs preferred for 
breast cancer metastases. In vitro, using breast cancer cell lines, these ligands stimulated 
pseudopodia formation and directional migration in cells in addition to local invasion 
through extracellular matrix and basement membrane. Also, extracts of organs targeted 
by breast cancer (lung, liver, bone marrow and lymph node) had chemotactic activity for 
breast cancer cells that could be neutralised by anti-CXCR4 antibody, thus suggesting 
CXCL12 was the active agent. Neutralising anti-human CXCR4 monoclonal antibody 
suppressed lymph node and lung metastases in a metastatic model of human breast cancer 
(MDA-MB-231 cell line injected either orthotopically into the mammary fat pad or 
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intravenously in immunodeficient SCID mice). The same group found that melanoma cell 
lines express receptors CCR7 and CCR10 and that skin and lymph nodes, the two major 
sites of metastatic melanoma, selectively express ligands for both these receptors. At the 
time of this discovery CXCL12 (SDF-1) had already been well known for its homing 
effect on immature (CD34-positive) progenitor cells in the process of bone marrow 
repopulation [Aiuti A et al 1997].  
CXCR4 is, in fact, the chemokine receptor most commonly found in human and 
murine cancer cells [Balkwill F 2004a and b] and its involvement in directional 
metastasis has been suggested in a variety of tumours, including small-cell lung cancers, 
pancreatic cancers, astrogliomas, myelomas, B cell lymphomas, chronic lymphocytic 
leukaemias, kidney cancer and rhabdomyosarcoma [Balkwill F 2004b]. Studies have also 
reported that VEGF induces CXCR4 expression in tumour cells [Bachelder RE et al 
2002]. This observation raises the possibility that anti-VEGF agents may exert their anti-
tumour effects partly through CXCR4. The evidence for the role of the CXCL12 – 
CXCR4 axis in the directional migration of a variety of cancers is discussed in detail in 
the final chapter.   
Wiley H et al 2001 have reported that transfection of a normally non-metastatic 
melanoma cell line with CCR7 rendered it able to migrate to the lymph nodes in vivo. 
Takanami I 2003 reported the expression of CCR7 correlated highly with the ability of 
non-SCLC to metastasize to the regional lymph nodes. CCR7 negative tumours, in 
contrast, very rarely were found in the regional lymph nodes. CCR7 positive gastric 
carcinoma cells have a high incidence of lymph node metastasis, and patients with 
CCR7-positive tumours have a significantly poorer prognosis than those with CCR7-
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negative tumours [Mashimo K et al 2002]. Similar observations have been made in 
oesophageal carcinoma patients [Ding Y et al 2003] and it has also been noted that in an 
analysis of 78 human oesophageal squamous cell cancers, high CCR7 mRNA expression 
in neoplastic cells was found to be an independent predictive factor for lymph node 
metastases [Ishida K et al 2009]. CCR7 expression by malignant cells has additionally 
been implicated in the metastasis of SW620 colon cancer cells in vitro and in vivo [Yu S 
et al 2008]. It is suggested that CCR7 is a key receptor in determining lymph node 
metastasis in particular [Takanami I 2003]. Interestingly, Kochetkova M et al 2009, using 
breast cancer cell lines, reported a novel property of the chemokine receptors CCR7 and 
CXCR4 (both expressed on malignant breast cells) in inhibiting detachment-induced cell 
death - anoikis, which is believed to be one of the major blocks in the metastatic spread 
of various neoplasms. 
Other chemokine receptors implicated in chemokine dependent tumour cell 
attraction to certain tissues include CCR4, which is often expressed in adult T-cell 
leukaemias that preferentially invade the skin, where one of the CCR4 ligands, CCL17 
(TARC), can be expressed [Ishida T et al 2003]. Lee JH et al 2009 found that 6 out of 8 
gastric carcinoma cell lines expressed functional CCR4, as demonstrated by migration 
assays using its ligand CCL17; migration was inhibited by anti-CCR4 antibodies. 
Additionally, human CCR4 positive gastric tumours had a significantly poorer patient 
prognosis.  
Using immunohistochemical techniques, a unique cohort of 21 primary lung 
cancers with matched adrenal metastases were studied for chemokine receptor expression 
[Raynaud CM et al 2010]. It was discovered that CCR6 was clearly overexpressed in 
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adrenal metastases, compared with corresponding primary tumors. Moreover, CCL20, the 
ligand of CCR6, was preferentially expressed in adrenal tissues that developed metastases 
[Raynaud CM et al 2010].   
CCR3 has been demonstrated to be expressed in CD30+ cutaneous lymphomas, 
and its ligand CCL11 (eotaxin) is often expressed in the tumour cells and tumour 
associated skin lesions [Kleinhans M et al 2003]. In prostate cancer cells CCR9 
expression also correlates with enhanced chemotaxis and directional migration when 
induced by the ligand of CCR9, CCL25. Inhibition of CCL25 – CCR9 interactions 
effectively reduced the migration (and invasive competence) of LNCaP and PC3 cells 
[Singh S et al 2004b]. 
Of the CXCR group of receptors (excluding CXCR4, whose role in metastasis is 
discussed in detail in the final chapter), CXCR2 or CXCR3 have recently been verified in 
the organ specific metastasis of human melanoma [Singh S et al 2009b], colon cancer 
[Cambien B et al 2009] and osteosarcoma [Pradelli E et al 2009]. 
In prostate cancer , the chemokine ligand CCL2 has been implicated in promoting 
metastatic activity [Mizutani K et al 2009, Zhang J et al 2010], which can be significantly 
decreased in vitro by curcumin (the active phytochemical ingredient of turmeric and a 
dietary supplement, which is often self-prescribed to promote prostate health) [Herman 
JG et al 2009]. Also, in four hepatoma cell lines, following CCL3 stimulation, obvious 
pseudopodia formation as well as increased cell migration of hepatoma cells was 
observed, as a result of CCL3 interaction with its receptor CCR1, found on malignant 
cells [Yuan Y et al 2010]. CCL3 facilitated the migration of hepatoma cells by increasing 
the concentration of intracellular calcium. 
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All of these studies mentioned support the hypothesis that certain chemokine 
ligands and their receptors are involved in the homing of metastatic tumour cells to 
specific organs. 
 
 
SECTION 1.5 
Hypothesis and aims 
It was hypothesised that chemokine ligand - receptor interactions may be 
important in the non-random and organ selective metastasis of prostate cancer. 
This hypothesis was structured after studying the literature on the role of 
chemokines and their receptors in all aspects of cancer development, progression and 
migration and especially following the publication of the seminal paper in “Nature” by 
Muller A et al 2001, which demonstrated that the chemokine receptor : ligand 
interactions CCR7 : CCL21 and particularly CXCR4 : CXCL12 had a critical role in the 
directional migration of malignant breast cancer cells to specific metastatic sites such as 
bone marrow and lymph nodes. 
In order to test this hypothesis we had the following aims: 
1) The first aim was to perform a semi-quantitative analysis, at mRNA level, using RT-
PCR, of the chemokine receptors in the CXCR and CCR groups in prostate cell lines 
derived from normal prostate epithelium and stroma, primary prostate cancers and 
metastatic prostate cancers. 
2) If the pattern of expression of any chemokine receptor was found to be of interest in 
the prostate cell lines (eg. upregulation in metastatic cells), the next aim was to perform a 
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more accurate quantitative analysis of the mRNA of the specific receptor of interest in the 
prostate cell lines and in benign and malignant tissue derived from human prostates. 
3) Following this, the next step was to demonstrate protein expression of the receptor of 
interest in prostate cells. 
4) Once protein expression of chemokine receptor was established, the subsequent aim 
was to determine whether the receptor was functional (using prostate cell lines) by 
stimulating the receptor with its appropriate ligand.  
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SECTION 2.1 
Polymerase chain reaction and reverse transcriptase – polymerase chain 
reaction  
The polymerase chain reaction (PCR) is a technique which allows the exponential 
amplification of a specific region of DNA by repeating a 3 step process: denaturation, 
annealing and synthesis (extension). This process is shown in figure 2.1. 
Reverse transcriptase – PCR (RT-PCR) investigates gene expression at the mRNA level. 
The enzyme reverse transcriptase synthesizes a complementary DNA (cDNA) strand 
from a RNA strand. This cDNA is then used as a template for PCR analysis.  
Figure 2.1: The polymerase chain reaction 
1) The template DNA is 
denatured by heating to 950C, 
disrupting the hydrogen bonds 
between the base pairs 
resulting in two single strands 
of DNA from the one double 
stranded template DNA
Figure 2.1: The Polymerase Chain Reaction
2) After denaturation the temperature is 
reduced to approximately 600C to allow 
primers to bind with high specificity to 
their complementary bases on the 
template DNA. Annealing temperature 
varies depending on the nucleotide 
composition of the primer selected
3) After annealing the primers, the temperature is 
increased to 72-740C, the optimal temperature for Taq 
DNA polymerase activity. Beginning at the primer 
annealing site, Taq DNA polymerase synthesises new 
DNA by adding complementary nucleotide bases to 
the denatured single stranded template DNA resulting 
in two double stranded DNA molecules identical to the 
initial template DNA.
4) The 3 step process of 
denaturation, annealing and 
extension is typically repeated 
for 25-35 cycles. At the end of 
30 cycles there will be up to 
230 double stranded DNA 
molecules identical to the 
initial template DNA 
fragment.
950C
2 minutes
950C
45 seconds
600C
45 seconds
45 seconds
740C 740C
7 minutes
35 cycles
13
 
720C 
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SECTION 2.2 
 
Real-time quantitative PCR 
 
Methodology background 
Theoretically one copy of a specific sequence can be amplified and detected in 
PCR. The PCR reaction generates copies of a DNA template exponentially. This results 
in a quantitative relationship between the amount of starting target sequence and amount 
of PCR product accumulated at any particular cycle. Due to inhibitors of the polymerase 
reaction found with the template, reagent limitation or accumulation of pyrophosphate 
molecules, the PCR reaction eventually ceases to generate template at an exponential rate 
(i.e., the plateau phase) making the end point quantitation of PCR products unreliable. 
Therefore, duplicate reactions may generate variable amounts of PCR product. Only 
during the exponential phase of the PCR reaction is it possible to extrapolate back in 
order to determine the starting quantity of template sequence. The measurement of PCR 
products as they accumulate (i.e., real-time quantitative PCR) allows quantitation in the 
exponential phase of the reaction and therefore removes the variability associated with 
conventional PCR.  
Since the first documentation of real-time PCR [Higuchi R et al 1993], it has been 
used for an increasing and diverse number of applications including mRNA expression 
studies, DNA copy number measurements in genomic or viral DNAs [Gómez-Curet I et 
al 2007, Gubina NE et al 2010, Murata H et al 2009], allelic discrimination assays 
[Castillejo A et al 2007], expression analysis of specific splice variants of genes [Dales 
JP et al 2010] and gene expression in paraffin-embedded tissues [Harbeck N et al 2008] 
and laser captured microdissected cells [Hoffmann AC et al 2009]. 
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Fluorogenic probes and the Taqman real-time assay 
Real-time quantitative PCR allows the reliable detection and measurement of 
products generated during each cycle of the PCR process which are directly proportional 
to the amount of template prior to the start of the PCR process. Holland and coworkers 
demonstrated that the thermostable enzyme Thermus aquaticus (i.e., Taq) DNA 
polymerase had 5´ to 3´ exonuclease activity [Holland PM et al 1991]. This group also 
showed that cleavage of a target probe during PCR by the 5´ nuclease activity of Taq 
polymerase can be used to detect amplification of the target-specific product [Holland 
PM et al 1991]. An oligonucleotide probe, which was designed to hybridize within the 
target sequence, was introduced into the PCR assay. This probe was labeled with 32P at 
its 5´ end and was nonextendable at its 3´ end to ensure it could not act as a primer. 
Annealing of probe to one of the PCR product strands during the course of amplification 
generated a substrate suitable for exonuclease activity. Also, during amplification, the 5´ 
to 3´ exonuclease activity of Taq DNA polymerase (when the enzyme extended from an 
upstream primer into the region of the probe) degraded the probe into smaller fragments 
that could be differentiated from undegraded probe. This dependence on polymerization 
ensured that cleavage of the probe occurred only if the target sequence was being 
amplified. After PCR, cleavage of the probe was measured by using thin-layer 
chromatography to separate cleavage fragments from intact probe. 
The introduction of dual-labeled oligonucleotide fluorogenic probes allowed the 
elimination of post-PCR processing for the analysis of probe degradation [Lee LG et al 
1993]. The probe has a reporter fluorescent dye at the 5´ end and a quencher dye attached 
to the 3´ end. Whilst the probe is intact, the close proximity of the quencher significantly 
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decreases the fluorescence emitted by the reporter dye. A fluorescence signal is only 
emitted on cleavage of the probe, based on the fluorescence resonance energy transfer 
(FRET) principle [Cardullo RA et al 1988]. 
In the real-time quantitative TaqMan® assay a fluorogenic non-extendable probe, 
termed the “TaqMan” (hydrolysis) probe is used in conjunction with a forward and 
reverse primer (figure 2.2) [Heid CA et al 1996]. The probe has a fluorescent reporter dye 
covalently bonded to its 5´ end and a quencher dye at its 3´ terminus. Various fluorescent 
reporter dyes are in use including 6-carboxyfluorescein (FAM), 6-carboxy-4,5-dichloro-
2,7-dimethoxyfluorescein (JOE), tetrachloro-6-carboxyfluorescein (TET),  
hexachloro-6-carboxyfluorescein (HEX), or VIC (this is an acronym – Applied 
Biosystems have not released the chemical composition of this dye). Quenchers include 
either 6-carboxytetramethylrhodamine (TAMRA) or 4-(dimethylaminoazo)benzene-4-
carboxylic acid (DABCYL). If the target sequence is present, the fluorogenic probe 
anneals downstream from one of the primer sites and is cleaved by the 5´ nuclease 
activity of the Taq polymerase enzyme during the extension phase of the PCR [the most 
commonly used enzyme is Taq polymerase (Holland PM et al 1991) but any enzyme with 
5´ nuclease activity can be used (Gut M et al 1999)]. 
Whilst the probe is intact the proximity of the reporter and quencher dyes permits 
FRET and the fluorescence emission of the reporter dye is absorbed by the quenching 
dye. Cleavage of the probe by Taq polymerase during PCR separates the reporter and 
quencher dyes, thereby increasing the fluorescence emission from the former. 
Additionally, cleavage removes the probe from the target strand, allowing primer 
extension to continue to the end of template strand, thereby not interfering with the 
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exponential accumulation of PCR product. Additional reporter dye molecules are cleaved 
from their respective probes with each cycle, leading to an increase in fluorescence 
intensity directly proportional to the amount of amplicon produced. The TaqMan 
chemistry is the most widely used real-time PCR assay and has been used for multiple 
purposes [Bustin SA et al 2005, Kubista M et al 2006]. The various available chemistries 
using fluorogenic probes for real-time PCR include Taqman (hydrolysis) probes, dual 
hybridization probes, molecular beacons and scorpion probes. 
Figure 2.2: The Taqman real time quantitative PCR assay (hydrolysis probes) 
R Q
5’
3’
3’
5’
5’
3’
3’
Reverse primer
Forward primer
a) Denaturation and annealing
Taqman
Probe
Figure 2.2: The Taqman assay (hydrolysis probes)
Two fluorescent dyes, 
a reporter (R) and a 
quencher (Q), are 
attached to the 5' and 
3' ends of a TaqMan ® 
probe.
When the Taqman probe is intact, the reporter and quencher dyes stay 
close to each other, and fluorescence emission is quenched. The primer 
and Taqman probe anneal to the complementary DNA strand following 
denaturation
cDNA
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b) Cleavage
Probe
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c) Polymerisation completed
Figure 1 contd.
After hybridisation
and during each 
extension cycle, the 
5’ endonuclease
activity of theTaq
DNA polymerase 
cleaves the probe 
and separates the 
reporter and 
quencher dyes.
Once separated 
from the quencher,
the reporter dye 
emits its 
characteristic
fluorescence.
 
In addition to fluorescent probes the other chemistry available for amplicon 
detection are the double-stranded (ds) DNA-intercalating agents (DNA-binding dyes). 
These include SYBR Green 1 or ethidium bromide and this is the simplest and most cost-
effective method as amplicon-specific labelled hybridization probes are not required. 
SYBR Green 1 only fluoresces when intercalated into dsDNA. The intensity of the 
fluorescence signal is therefore dependent on the quantity of dsDNA present in the 
reaction. The main disadvantage of this method is that it is not specific since the dye 
binds to all dsDNAs formed during the PCR reaction (i.e. non-specific PCR products and 
i ure 2.2 continued 
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primer-dimers). With fluorogenic probes, non-specific amplification due to mispriming 
or primer-dimer artifact does not generate signal as specific hybridization between probe 
and template is necessary for fluorescence emission. Also, fluorogenic probes can be 
labelled with different and distinguishable reporter dyes, thus allowing the detection of 
amplicons that may have been produced by one or several primer pairs in a single PCR 
reaction – termed multiplex real-time PCR. 
 It is important to note that because of the enormous amplification possible with 
PCR, contamination of new PCRs with trace amounts of amplification products, i.e. 
carry-over contamination, can yield false positive results. Other sources of contamination 
could be from samples with high DNA levels or from positive control templates. Carry-
over contamination can be controlled by incorporating dUTP in place of dTTP as a dNTP 
substrate in all PCRs of cDNA [Longo MC et al 1990]. All subsequent fully pre-
assembled starting PCR reactions should then be treated with the enzyme uracil DNA 
glycosylase (uracil N-glycosylase or UNG), followed by thermal inactivation of UNG. 
UNG cleaves the uracil base from the phosphodiester backbone of uracil-containing 
DNA, but has no effect on natural (i.e. dTTP or thymine-containing) DNA (also, UNG 
has no effect on RNA). The resulting apyrimidinic sites block replication by DNA 
polymerases, and are very labile to acid/base hydrolysis. Because UNG does not react 
with dUTP, and is also inactivated by heat denaturation prior to the actual PCR, carry-
over contamination of PCRs can be controlled effectively if the contaminants contain 
uracils in place of thymines. 
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Instrumentation 
The ABI PRISM® 7700 Sequence Detection System (Perkin-Elmer–Applied 
Biosystems, Foster City, CA, USA) (figure 2.3) was used in the performance of all real 
time quantitative PCR assays in our experiments.  
Figure 2.3: The ABI PRISM ® 7700 
The ABI PRISM 7700. Amplification is performed in closed, optical tubes of a 96-well 
microplate that is placed in a combined thermal cycler/detector, the ABI 7700. 
Fluorescence is induced by a laser directed to each of the 96 sample wells, and the 
fluorescence emission data for each sample are collected once every few seconds as the 
PCR products are being generated. Simultaneous use of more than one reporter dye or 
fluorescent probe is possible. The starting copy number is determined by monitoring 
when PCR product is first detected – the higher the starting copy number of the target, 
the sooner a significant increase in fluorescence is observed. The data are fed to a 
computer that analyses and displays the results, which eliminates the need for post-PCR 
processing. 
 
 
 
The 7700 system has a built-in thermal cycler and a laser directed via fibre-optic 
cables to each of the 96 sample wells. Fluorescence is induced during the PCR by 
distributing laser light to all 96 samples contained in thin-walled reaction tubes via the 
multiplexed array of optical fibres. This fluorescence emission data for each sample is 
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collected once every few seconds as the PCR products are being generated and travels 
back through the cable fibres to be directed to a spectrograph with a charge-coupled 
device (CCD) camera. The starting copy number is determined by monitoring when PCR 
product is first detected – the higher the starting copy number of the target, the sooner a 
significant increase in fluorescence is observed. The data are fed to a computer, which 
analyses and displays the results, eliminating the need for post-PCR processing. Because 
each well is irradiated sequentially, the dimensions of the CCD array can be used for 
spectral resolution of the fluorescent light. Also, as the 7700 instrument detects an entire 
fluorescence spectrum (500 – 660nm), the system is capable of distinguishing and 
quantitating multiple fluorophores in each sample well.  
The software analyzes the data by first calculating the contribution of each 
component dye to the experimental spectrum. Each reporter signal is then divided by the 
fluorescence of an internal reference dye (ROX) in order to normalize for non-PCR 
related fluorescence fluctuations occurring well-to-well or over time. The use of this 
internal reference dye, enabled by the ability to distinguish fluorophores, increases the 
precision of the data obtained with the 7700 system. The other advantage of 
distinguishing fluorophores is that probes labelled with different reporter dyes can be 
used so that more than one PCR target can be detected in a single tube. By plotting the 
increase in fluorescence versus cycle number, the system produces amplification plots 
that provide a more complete picture of the PCR process than assaying product 
accumulation after a fixed number of cycles. 
This instrument can be used for assays based on DNA-binding dyes, molecular 
beacons and hydrolysis (Taqman) probes. RT-PCR reactions typically take 2 hours to 
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complete. Its description by the manufacturer as a real-time technique is not strictly 
correct as, unlike competing systems, the progress of the PCR reaction can be analysed 
only after termination of the amplification run. Although the ABI Prism® 7700 Sequence 
Detection System from Applied Biosystems was the first commercially available 
thermocycler for real-time PCR, it has now been discontinued. It has recently been 
replaced by the ABI Prism 7900HT, which has similar specifications to the 7700 but is 
completely automated and designed especially for very high throughput applications (384 
samples per run). 
 
Real-Time PCR Quantitation 
a) Definition of terms 
Described here are the definitions of the terms used in quantitation analysis. 
• Amplification plots 
As mentioned earlier, using any of the developed chemistries, the increase in 
fluorescence emission during the PCR reaction can be detected in real time by a modified 
thermocycler. The computer software constructs amplification plots using the 
fluorescence emission data that are collected during the PCR amplification. An 
amplification plot is the plot of fluorescence signal versus PCR cycle number. Figure 2.4 
demonstrates a representative amplification plot. 
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Figure 2.4: Model of a single amplification plot illustrating the nomenclature commonly 
used in real-time quantitative PCR 
 
 
• Baseline 
The baseline is defined as the PCR cycles in which a reporter fluorescent signal is 
accumulating but is beneath the limits of detection of the instrument. By default, the 
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computer software sets the baseline from cycles 3 to 15; however, this often needs to be 
changed manually. 
 
• Rn 
 The reporter signal is normalised to the fluorescence of an internal passive 
reference dye [ROX (Applied Biosystems) – this is composed of a 25µM solution of 5-
carboxy-X- rhodamine in 10mM Tris-HCL (pH 8.6), 0.1mM EDTA and 0.01% Tween® 
20] to allow for well-to-well corrections in fluorescent fluctuations caused by changes in 
concentration or volume (the passive reference dye does not participate in PCR 
amplification). Rn is this normalised reporter signal and is calculated by the computer 
software program.  It represents the fluorescence signal of the reporter dye divided by the 
fluorescence signal of the passive reference dye (ROX™).  
Therefore Rn = fluorescence signal of reporter dye                                  
            fluorescence signal of the passive reference dye (ROX)  
 
During PCR, this number will increase as amplicon copy number increases until the 
reaction reaches a plateau.  
 
• ∆Rn 
A computer software program calculates a ∆Rn using the equation ∆Rn = Rnp – 
Rnb, where Rnp is the  fluorescence emission of the product at each time point 
(normalized to ROX) and Rnb is the fluorescence emission of the baseline (normalized to 
ROX) established in the first few cycles of PCR. 
Similar to Rn, ∆Rn increases during PCR as amplicon copy number increases until the 
reaction approaches a plateau. The ∆Rn values are plotted versus the cycle number in an 
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amplification plot. During the early cycles of PCR amplification, ∆Rn values do not 
exceed the baseline. 
 
• Threshold 
An arbitrary threshold is chosen by the computer, based on the variability of the 
baseline. It is calculated as ten times the standard deviation of the average signal of the 
baseline fluorescent signal between cycles three to 15. A fluorescent signal that is 
detected above the threshold is considered a real signal that can be used to define the 
threshold cycle (Ct) for a sample. If required, the threshold can be manually changed for 
each individual experiment so that it is in the region of exponential amplification across 
all amplification plots (this region is depicted in the log view of the amplification plots as 
the portion of the plot, which is linear). 
 
• Ct 
This is defined as the fractional PCR cycle number at which the reporter 
fluorescence is greater than the minimal detection level (i.e., the threshold). The Ct 
(threshold cycle) is a basic principle of fluorescence based real-time PCR and is an 
essential component in producing accurate and reproducible data. Fluorescence values 
are recorded during every cycle and represent the amount of product amplified to that 
point in the amplification reaction. The presence of more template at the start of the 
reaction leads to a fewer number of cycles reaching the point at which the fluorescent 
signal is recorded as statistically significant above background. This Ct value will always 
occur during the exponential phase of target amplification, which occurs during the early 
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cycles of PCR. As reaction components become limiting, the rate of target amplification 
decreases until the PCR reaction is no longer generating template at an exponential rate 
(plateau phase) and there is little or no increase in PCR product. The quantity of PCR 
product observed at the end of the reaction is very sensitive to slight variations in reaction 
components. This is because endpoint measurements are generally made when the 
reaction is beyond the exponential phase and a slight difference in a limiting component 
can have a major effect on the final amount of product. For example, side reactions, like 
formation of primer dimers, can consume reagents to different extents from tube to tube. 
Thus, it is possible for a sample with a higher starting copy number to end up with less 
accumulated product than a sample with a lower starting copy number. This is the main 
reason why Ct is a more reliable measure of starting copy number than an endpoint 
measurement of the amount of accumulated PCR product. During the exponential phase 
none of the reaction components is limiting and therefore Ct values are very reproducible 
for replicate reactions with the same starting copy number. A Ct value of 40 or higher 
means no amplification (i.e. no detectable fluorescence after 40 cycles of PCR). Thus, the 
essential principle of real-time quantitative PCR is that reactions are characterized by the 
point in time during cycling when amplification of a PCR product is first detected rather 
than the amount of PCR product accumulated after a fixed number of cycles and the 
higher the starting copy number of the nucleic acid target, the sooner a significant 
increase in fluorescence is observed. 
 
 
 
 95 
b) Quantitation methods 
Two methods are available to quantify real-time RT- PCR results: 
i)  Standard-curve or absolute quantitation 
As shown by Higuchi and coworkers, the plot of the log of initial target copy 
number for a set of known standards (five- or tenfold serial dilution) versus Ct is a 
straight line (the standard curve) [Higuchi R et al 1993]. Quantitation of the amount of 
target in the “unknown” samples of interest is accomplished by measuring Ct and using 
the standard curve to determine starting copy number. The most common source of a 
known sample is a plasmid for the gene of interest and the standard curve is generated 
based on a serial dilution of a starting amount. Another option, and easier to generate if a 
plasmid is unavailable, is the use of a synthetic single-stranded sense oligonucleotide for 
the entire amplicon. The advantage of this approach is that it significantly simplifies the 
process of obtaining a standard curve for amplicons up to 100 bp, which encompasses 
most real-time PCR amplicons. Furthermore, it is also less susceptible to bias when 
quantified by a spectrophotometer due to the relative purity of the oligonucleotide. 
Together with the greater precision of measurement of the standard and the possibility of 
calculating the moles of oligonucleotide (hence, number of copies), it is possible to 
approximate the number of copies of a template in an unknown sample, although not in 
terms of absolute copy number. One final option for a standard curve is to use a cell line 
with a known copy number or expression level of the gene of interest. The standard curve 
method is used in circumstances when absolute quantitation is critical for the investigator 
[eg. when measuring a small number of genes in either a few or many samples (Dumur 
CI et al 2002, Jurado J et al 2003)] and in quantitation of viral load [Ngaosuwankul N et 
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al 2010]. The entire process of calculating Cts, preparing a standard curve, and 
determining starting copy number for unknowns is performed by the software of the 7700 
system. 
 
ii)  Relative quantitation 
Relative quantitation is also known as the comparative threshold method (2-∆∆Ct 
method). This method eliminates the need for standard curves and mathematical 
equations are used to calculate the relative expression levels of a target relative to a 
reference control or calibrator such as a non-treated sample, RNA from normal tissue or 
relative to another treated sample. The amount of target, normalized to an endogenous 
housekeeping gene and relative to the calibrator, is then given by 2-∆∆Ct, where ∆∆Ct = 
∆Ct(sample) - ∆Ct(calibrator), and ∆Ct is the Ct of the housekeeping gene subtracted 
from the Ct of the target gene. The equation thus represents the normalized expression of 
the target gene in the unknown sample, relative to the normalized expression of the 
calibrator sample. For this calculation to be valid and in order to obtain reliable results, it 
is imperative that the amplification efficiencies of the housekeeping and target gene are 
approximately equal and at or above 90%. This can be established by looking at how Ct 
(of both target and housekeeping gene) varies with template dilution. If the plot of 
starting RNA/ cDNA quantity versus ∆Ct is close to zero, it implies that the amplification 
efficiencies of the target and housekeeping genes are very similar. If a housekeeping gene 
cannot be found whose amplification efficiency is similar to the target, the standard curve 
method is then preferable. Alternatively, new primers can be designed and/or optimized 
to achieve a similar efficiency for the target and housekeeping gene amplicons. 
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 The solutions to the following equations need to be calculated in a 
sequential manner in order to elucidate relative expression levels. 
 
A)     ∆Ct = Ct target gene (eg. CXCR4) – Ct housekeeping gene (eg. β-actin) 
 In real-time quantitative PCR experiments specific errors will be introduced due 
to minor differences in the starting amount of RNA, quality of RNA or differences in 
efficiency of cDNA synthesis and PCR amplification. In order to minimize these errors 
and correct for sample-to-sample variation, a cellular RNA is simultaneously amplified 
with the target, which serves as an internal reference against which other RNA values can 
be normalized [Karge WH et al 1998].The most common genes used for normalization, 
termed housekeeping genes, are: β-actin, a cytoskeletal protein; glceraldehyde-3-
phosphate dehydrogenase (GAPDH), a glycolytic enzyme; ribosomal RNA (rRNA). 
These genes should theoretically be expressed at a constant level amongst different 
tissues of an organism and at all stages of development, and their expression levels 
should also remain relatively constant in different experimental conditions. However, 
none of these housekeeping genes are ideal. It has been shown that GAPDH expression 
may be variable in different tissues [Barber RD et al 2005] with expression levels also 
being altered by glucose, insulin, heat shock and cellular proliferation and additionally β-
actin levels may be modified by experimental treatments [Bustin SA 2000, Chervoneva I 
et al 2010, Rhoads RP et al 2004, Steele BK et al 2002, Yperman J et al 2004]. rRNA 
production is less likely to vary under conditions affecting mRNA transcription [Dheda K 
et al 2004, Bas A et al 2004]. However, it is not always a good representative of total 
mRNA population in a cell as rRNA is expressed at a much higher level than mRNA. 
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Other alternative housekeeping genes have been proposed but none have been entirely 
satisfactory and no single unequivocal reference gene has yet been identified. Some 
authors have suggested the use of several housekeeping genes in a single experiment and 
that the mean expression of these multiple housekeeping genes can be used for 
normalization [Vandesompele J et al 2002].  
Importantly, selection of the housekeeping gene for each specific experiment 
should be made very carefully as the reliability of the results depends on the choice of the 
most relevant housekeeping gene according to the cells of interest and specific 
experimental treatments. We have used β-Actin mRNA as an internal standard to 
normalise patterns of gene expression when using the Taqman assay.  
 
B)         ∆∆Ct = ∆Ct sample - ∆Ct calibrator (eg. 1542 CPT3X; see chapter 5)  
The normalised amount of target gene (eg. CXCR4) is a unitless number that can 
be used to compare the relative amount of target in different samples. One way to make 
this comparison is to designate one of the samples as a calibrator. This sample with the 
lowest detectable expression level of the target is usually chosen as the calibrator (eg. 
1542 CPT3X CXCR4 mRNA expression in our experiments in chapter 5). This 
calculation can in fact be considered a second normalisation step where all samples are 
normalised to the calibrator sample.  
 
C)         Relative quantitation = 2-∆∆CT 
The final equation thus represents the normalised expression of the target gene in 
the unknown sample, relative to the normalised expression of the calibrator sample.  
 99 
Importantly, as mentioned earlier, the 2-∆∆CT method can only be used if the 
efficiency of PCR amplification for the target gene is approximately equal to that for the 
housekeeping gene. For every target gene this has to be tested by plotting the ∆CT 
against varying RNA dilutions of target and housekeeping genes. If the slope of this line 
is <0.1, this reflects similar efficiencies. The advantage of this system is that no standards 
have to be constructed. A disadvantage is that the efficiencies of amplification of 
housekeeping and target gene have to be similar to obtain reliable results. 
 
Primer, probe & amplicon design 
Great care should go into the design of the assay. Primers, probes and amplicons 
are designed to very exacting specifications and the TaqMan system provides its own 
primer/probe design software from Applied Biosystems known as Primer Express®, 
which is probably the most widely used oligonucleotide design program for developing 
real-time quantitative PCR assays. Primer3, a free program from Massachusetts Institute 
of Technology, USA can also be used to generate good real-time PCR assays. 
 
•    Amplicon Design 
 The amplicon length for the PCR product using real-time RT-PCR should be as 
small as reasonably possible, the optimal being 50 – 150 base pairs in length for designs 
using hybridisation probes (includes the Taqman assay). Shorter amplicons amplify more 
efficiently than longer ones and are more tolerant of reaction conditions. This is because 
they are more likely to be denatured during the 92–950C step of the PCR, allowing the 
probes and primers to compete more effectively for binding to their complementary 
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targets. As the extension rate of Taq polymerase is between 30 and 70 bases/second, it 
also means that polymerisation times as short as 15 seconds are sufficient to replicate the 
amplicon, making amplification of genomic DNA contaminants less likely and reducing 
the time it takes to complete the assay. Higher efficiency also means that the assays are 
more likely to work the first time. In addition, high-efficiency assays enable relative 
quantitation to be performed using the comparative threshold method (2-∆∆CT). This 
method increases sample throughput by eliminating the need for standard curves when 
looking at expression levels of a target relative to a reference control. 
 
• Primer /Probe Design  
A summary of the primer and probe design guidelines using Primer Express 
(the primer/probe design programme for the Taqman system) is shown in table 2.1.    
The optimal length for single-stranded primers is 15–20 bases with a G/C content 
in both primers and probes of 20–80%. Regions with a G/C content in excess of this may 
not denature well during thermal cycling, leading to a less efficient reaction. In addition, 
G/C-rich sequences are susceptible to non-specific interactions that may reduce reaction 
efficiency and produce non-specific signal. For this same reason, primer and probe 
sequences containing runs of four or more G bases should be avoided. A/T-rich 
sequences require longer primer and probe sequences in order to obtain the recommended 
Tm. This is rarely a problem for quantitative assays; however, probes approaching 40 
base pairs can exhibit less efficient quenching and produce lower synthesis yields. 
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Table 2.1.   Shown here is a summary of the primer and probe design guidelines used by the 
primer/probe design program, Primer Express, for real-time quantitative Taqman PCR.  
 
 
Taqman® Probe Guidelines 
 
Sequence Detection Primer Guidelines 
(for Taqman® Assays or SYBR Green Assays) 
Probe selected first and primers designed as close as possible to the probe without overlapping it 
(amplicons of 50 – 150 base pairs strongly recommended) 
G/ C content kept in 20 – 80% range 
 
Runs of identical nucleotide avoided; this is especially true for guanine, where runs of four or more 
Gs should be avoided 
 
When using Primer Express® software 
the Tm should be 68 – 700C  
 
 
When using Primer Express® software the Tm should be 
58 – 600C  
 
No G on the 5’ end 
The strand that gives the probe more C 
than G bases should be selected 
 
The five nucleotides at the 3’ end should have no more 
than two G and/ or C bases 
 
 
Selecting primers and probes with the recommended Tm is one of the factors that 
allows the use of universal thermal cycling parameters. The Tm for TaqMan primers 
should be in the range of 68–70°C. Having the probe Tm 8–10 °C higher than that of the 
primers ensures that the probe is fully hybridized during primer extension. 
Primer Express ®software does not select Taqman probes with a G on the 5´ end. 
The quenching effect of a G base in this position on reporter fluorescence will be present 
even after probe cleavage. This can result in reduced normalized fluorescence values 
(Rn), which can impact the performance of an assay. Having G bases in positions close to 
the 5´ end, but not on it, has not been shown to compromise assay performance. Another 
observation is that probes with more C than G bases will often produce a higher Rn. 
Since Primer Express® software does not automatically screen for this feature, it must be 
checked manually. If a probe is found to contain more G than C bases, the complement of 
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the probe selected by Primer Express® software should be used, ensuring that a G is not 
present on the 5´ end. 
Non-specific priming is minimized by selecting primers that have only one or two 
G/Cs within the last five nucleotides at the 3´ end. Under certain circumstances, however, 
such as a G/C-rich template sequence, this recommendation may have to be relaxed to 
keep the amplicon under 150 base pairs in length. It should, however, be followed as 
often as possible, and even when it is not possible, primer 3´ ends extremely rich in G 
and/or C bases should be avoided. 
 
Universal Thermal Cycling Parameters  
All quantitative assays designed using Primer Express software or their 
guidelines can be run using the same universal thermal cycling parameters. This 
eliminates any optimisation of the thermal cycling parameters and means that multiple 
assays can be run on the same plate without sacrificing performance. Table 2.2 shows the 
universal thermal cycling parameters for quantitative TaqMan® when using DNA or 
cDNA as the substrate. 
Table 2.2: Universal Thermal Cycling Parameters for real-time quantitative TaqMan® PCR 
Times and Temperatures 
                        Each of 40 Cycles  
Initial Steps 
 
Melt Anneal / Extend 
HOLD HOLD CYCLE 
  2 min* 
50 0C 
 
10 min** 
       95 0C 
 
15 sec 
95 0C 
 
1 min 
60 0C 
 
*The 2 min hold at 50 °C is required for optimal AmpErase UNG activity. 
** The 10 min hold at 95 °C is required for AmpliTaq Gold DNA Polymerase activation. 
Also, 10-min incubation at 95 °C is necessary to cleave the dU-containing PCR product generated in the low 
temperature (18 to 50°C) incubation, to substantially reduce AmpErase UNG activity, and to denature the native DNA 
in the experimental sample. Because UNG is not completely deactivated during the 95 °C incubation, it is important to 
keep the reaction temperatures greater than 55 °C, to prevent amplicon degradation. 
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SECTION 2.3 
Flow cytometry 
What is flow cytometry? 
“Cytometry” refers to the measurement of the physical and chemical 
characteristics of cells. “Flow cytometry” refers to the technique where these 
measurements are made individually of single particles (e.g. cells, nuclei, chromosomes) 
suspended within a stream of liquid as they pass through a light source, usually a laser, 
focused at a very small region. All parameters measured can be divided into two main 
groups: 
1) those related to light scattering, which mainly reflects the size of the cell and its 
internal complexity, and  
2) those related to  fluorescence. These are associated with the presence of one or more 
fluorochromes inside the cell or attached to the cell surface membrane, either in a natural 
(autofluorescence) or artificial (i.e. using fluorochrome conjugated monoclonal 
antibodies) way. 
The emitted fluorescence and light scatter of each particle is collected, filtered 
and converted to digital values that are stored on a computer. The important feature of 
flow cytometry is that measurements are made on each individual particle within the 
suspension in contrast to measuring an average property for the entire population. 
Average measurements do not detect subpopulations that have small differences from the 
overall population. In addition to measuring the physical and chemical characteristics of 
single cells, it is possible using this technique to physically separate or sort 
subpopulations from the larger pool of particles. A very large number of particles can be 
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evaluated in a very short time; some systems can run particles at rates approaching 
100,000 particles per second while collecting 10 to 20 parameters from each particle. 
Also, particles of almost any size can be evaluated by flow cytometry. These range from 
particles that are below the resolution limits of visible light, as they can be detected by 
their fluorescent signatures, to those particles as large as several thousand microns. 
 There are numerous applications of flow cytometry in both basic and clinical 
research, with this technology providing rapid and accurate measurements of a relatively 
broad range of cell characteristics that include DNA and/or RNA cell content, enzyme 
activity, the detection and quantitation of cell antigens, the analysis of multidrug cell 
resistance, membrane potential, mitochondria and chromosomes, the measurement of 
intracellular pH or ions such as free Ca2+. [Givan AL 2004, Ibrahim SF and van den 
Engh G 2007, Krishhan VV et al 2009, Preffer F and Dombkowski D 2009]. In addition, 
flow cytometry allows sorting of cells and subcellular components such as the 
chromosomes [Givan AL 2004, Ibrahim SF and van den Engh G 2004, Ibrahim SF and 
van den Engh G 2007]. 
It should be noted that flow cytometery is a generic term, whilst FACS 
(Fluorescence Activated Cell Sorter) is a trademark of the Becton-Dickinson 
Corporation.  
 
Historical aspects of flow cytometry and the flow cytometer 
The beginnings of flow cytometry date back to the synthesis of dyes in the late 
1800s and to the seminal work by Caspersson and Schultz published in “Nature” in 1938 
[Caspersson T and Schultz J 1938]. They demonstrated that DNA content, measured by 
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ultraviolet and visible light absorption in unstained cells, doubled during the cell cycle. In 
the 1940s, Papanicolaou demonstrated that he could identify cells as being cancerous 
from cervical cancer, by observing the staining patterns obtained by staining tissues with 
specifically designed stains [Papanicolaou GN and Traut R 1941]. 
However, it was not until 1950, when Coons and Kaplan reported on the 
improved detection of antigens using fluorescence antibody methods [Coons AH and 
Kaplan MH 1950], that it was realised that fluorescence measurements could offer more 
advantages than absorption. Since then, fluorescein remains the most common label for 
quantitative immunofluorescence analysis, and now for routine flow cytometric 
applications in scientific research. 
The automated flow analysis of single cells had its beginnings when Moldovan 
reported a photoelectric method for counting individual cells flowing through a capillary 
tube mounted on a microscope stage [Moldovan A 1934]. The system had major 
technical difficulties but in 1956 there was a breakthrough in flow cytometry when an 
apparatus was built by WH Coulter in which blood cells, in saline suspensions, passed 
one by one through a small orifice and were detected by changes of electrical impedance 
at the orifice [Coulter WH 1956]. This instrument was the forerunner of the modern flow 
cytometers.  
In the 1960s Louis Kamentsky began the drive to design and build single-cell 
analyzers. Kamentsky was interested in using optical character recognition techniques to 
identify cancer cells. Because of the lack of computation, this became a difficult goal and 
in place of image-based technology, Kamentsky focused on single-cell analysis and the 
design of a cytometer that measured absorption and scatter and used it to measure the 
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nucleic acid content and light scattering of unstained mammalian cells in a flow stream 
[Kamentsky LA et al 1965].  Later the same year, the first flow sorter was described by 
Fulwyler [Fulwyler MJ 1965]. The instrument separated biological cells according to 
their volume, which was determined as they passed through a Coulter aperture. 
Thus, flow cytometry was based mainly on light scattering and fluorescence and 
the first applications were measurement of nuclear DNA (using stoichiometric DNA 
stains) and cell surface antigens (using immunofluorescence). Methodologies and 
applications since then have expanded rapidly. 
 
Fluorescence 
The principles of fluorescence are a key concept in flow cytometry. When a 
compound absorbs light, electrons are raised from the ground state to an excited state. 
The electrons return to the ground state via a variety of routes; some routes such as the 
loss of the energy by heat do not result in fluorescence, but certain molecules lose energy 
by a process of radiative transfer, termed fluorescence. When stimulation of the 
fluorescent compound is stopped by removing the exciting light source, fluorescence 
emissions cease rapidly. Therefore fluorescence is a property of molecules to absorb light 
energy at one wavelength, termed the excitation wavelength, and then rapidly re-radiate 
some of that energy as light of a longer or emission wavelength eg. fluorescein 
isothiocyanate (FITC) excited with pure blue light appears to fluoresce greenish-yellow. 
Fluorescence is always of a lower energy, and hence longer wavelength, than the exciting 
light. 
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Immunofluorescence is a technique that allows visualization of cellular features or 
structures by linking these to a fluorescent molecule i.e. one that emits light when 
stimulated by light at a separate wavelength. These fluorescent molecules may be either 
dyes that bind directly to structures in or on the cell, or they may be fluorochromes 
(figure 2.5) conjugated to a ligand such as monoclonal antibodies. The fluorochromes 
(and dyes) used for flow cytometry must be compatible with the laser in the cytometer. 
This means that the fluorochromes must be excited at the wavelength of the laser light 
source and should fluoresce at a wavelength distinct from the laser light.  
The characteristic distribution of radiated energy for a fluorochrome is called its 
emission spectrum (figure 2.5). The emission spectrum of each fluorochrome has a clear 
peak, significantly different and distinct from the others (and which visually gives the 
fluorochrome a particular color). This allows flow cytometric assays to use multiple 
different fluorochromes in one experiment to simultaneously evaluate different cell 
features without significant overlap or interference from individual emission spectra. 
Figure 2.5: Emission spectra for 3 common fluorochromes.  
X axis – light wavelength; Y axis – intensity of emission. FITC – fluorescein 
isothiocyanate. PE – phycoerythrin. PE–CY5 - a tandem conjugate of two fluorochromes 
(PE and Cyanine-5).  
 
 
 
 
 
      FITC                                   PE                                         PE-CY5                      
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Light scatter 
The flow cytometer is able to detect (and quantitate) immunofluorescence as well 
as light scatter signals. The light scatter signals are the result of the laser light reflecting 
and refracting off the cells. Two types of light scatter are measured. 
1) Light scatter measured in the forward direction i.e. along the same axis that the 
laser light is traveling or near 1800 from the point at which the laser beam intersects the 
cell, is called forward, or low angle, scatter. This forward scatter roughly correlates with 
cell size and surface properties of cells eg. cell ruffling. Therefore it can be used to 
distinguish cell size as well as live from dead cells. 
Note – in the forward direction it is necessary to use a blocker bar to eliminate 
unscatterred laser light.  
2) Light scatter measured at a right angle to the direction of the laser beam is 
termed orthogonal or side light scatter.  This is detected in the side or 900 scatter channel 
and its intensity correlates with the granularity of the cell. 
 
The modern flow cytometer 
• Fluidic system (figure 2.6) 
 
The role of the fluidic system is to focus the cells/ particles in a fine stream and move 
them, one at a time, past a precise point to intersect the laser and the optical path for the 
detectors. Also, the fluidic system is essential in cell sorting by flow cytometry. Initially, 
a suspension of fluorescently labelled single cells is introduced into the flow cytometer. 
Whilst flowing rapidly through a narrow channel in the instrument, a small amount of 
cell suspension joins a larger amount of cell-free buffer, called "sheath fluid". This is 
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termed a coaxial stream i.e. a stream within a stream, and therefore consists of an inner 
sample stream surrounded by an outer sheath stream; the fluids in the two streams do not 
mix (figure 2.6).  
Figure 2.6: The coaxial stream 
Laminar Coaxial Flow
Coaxial Stream
Sheath fluid
Sheath fluid
Sample
Figure 2.6
 
The outer sheath stream focuses the inner stream and minimizes the turbulence arising 
from the resistance of the tubing. The coaxial stream ensures the cells are spaced out 
sequentially and that they pass the laser beam(s) one at a time. Additionally, the coaxial 
stream keeps the cells centered in the flowing stream so that they pass the laser beam 
optimally centered. The flow channel is positioned vertically to the laser beam. 
Positive air pressure acting on the sample reservoir keeps the sample fluid flowing 
continuously. In a similar manner, sheath fluid flow is controlled by a second positive air 
pressure regulator acting on the sheath chamber. A purge line is connected to the sheath 
inlet to allow a vacuum to be applied for clearing blockages and air bubbles. 
Basic Optics of a Flow Cytometer
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• Optical system and analysis (figure 2.7) 
The optical system has two components: 
a) a light source, usually a laser, which is necessary to appropriately excite the 
cells, in addition to the lens and mirrors needed to focus and direct the laser beam to the 
flow chamber containing the cells. Lasers, which emit light at specific peak emission 
wavelengths, need to be matched with the fluorochromes used for immunofluorescent 
staining analyzed on the cytometer. 
b) a variety of mirrors and filters (materials that absorb certain wavelengths whilst 
transmitting others), which are needed for the collection of light emitted from, or 
scattered by, the cells (figure 2.7). These include dichroic mirrors, which reflect light 
above a specific wavelength and only permit light below that wavelength to pass through; 
short pass filters (that permit only light below a specified wavelength to pass through); 
long pass filters (that permit only light above a specified wavelength to pass through); 
bandpass filters (that permit light in a specified range of wavelengths to pass through). 
These mirrors and filters also separate and direct emissions of different 
wavelengths to the corresponding detectors or photomultipliers (PMT). In the PMTs, the 
incident light is converted into electronic signals. Further electronic and computational 
processing results in graphic display and statistical analysis of the measurements being 
made.  
Some modern cytometers are capable of analyzing up to 13 parameters for each 
cell (forward scatter, side scatter, and as many as 11 colours of immunofluorescence) [De 
Rosa SC et al 2001, Wood B 2006] allowing size, protein content, DNA content, lipid 
content, antigenic properties, enzyme activity, etc for each cell to be measured, and 
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therefore permitting a multidimensional representation of a population to be obtained. It 
is almost always possible to analyze at least 1,000 cells per second. With appropriate 
specimens, some cytometers can analyse up to 100,000 cells per second without a 
significant sacrifice in the quality of data [Ashcroft RG and Lopez PA 2000, Ibrahim SF 
and van den Engh G 2007]. 
 
• Colour Assignment  
A signal emitted by a fluorochrome is detected by its associated photo-multiplier 
tube (PMT) and converted to a parameter for acquisition. The series of optical filters and 
mirrors is used to allow only a specific region of the spectrum to reach each of the PMTs 
(figure 2.7). In the flow cytometer the PMT detectors are labeled FL1, FL2, FL3 and 
onwards, with each detecting light of only a specific emission wavelength.  
In the Becton Dickinson FACScan there is an argon laser with a strong emission 
at 488 nm and there are three PMTs each detecting fluorescence (with an additional two 
for detecting forward and side scatter) at specific wavelengths produced by the excitation 
of several commonly used fluorochromes and dyes (table 2.3). 
Table 2.3: Photomultiplier detection of light emission produced by common 
fluorochromes/ dyes in the Becton Dickinson FACScan 
FITC - fluorescein isothiocyanate; PE – phycoerythrin; PI – propidium iodide; 
PE–CY5 - a tandem conjugate of two fluorochromes (PE and Cyanine-5)  
Photomultiplier 
Light emission 
wavelength detected 
(colour) 
Fluorochrome 
FL1 515-545 nm (green) FITC 
FL2 564-606 nm (yellow-
orange) PE / PI 
FL3 650-675 nm (red) PE-CY5 
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A wide variety of fluorochrome conjugated ligands (eg. monoclonal antibodies) 
and dyes are available for directly estimating cellular parameters such as nucleic acid 
content (DNA, mRNA). Analysis of cell cycle position by quantitation of cellular DNA 
was one of the earliest applications of flow cytometry. It is still the method of choice for 
fast, accurate determination of cell cycle distributions. In the simplest method, cellular 
DNA is detected using a fluorescent dye that binds preferentially to DNA. A key feature 
of DNA dyes is that they are stoichiometric i.e. the number of molecules of probe bound 
is equivalent to the number of molecules of DNA. Propidium iodide is the most 
commonly used. Fluorescent molecules in flow cytometry are now also used in 
measuring enzyme activity, calcium flux, membrane potential, pH and the density and 
distribution of cell-surface and cytoplasmic determinants and receptors, as well as 
allowing functional subpopulations of cells to be identified.  
 
Analysis of data 
• Histograms and dot plots.  
As mentioned earlier light from a specific region of the spectrum is detected by a 
PMT. This converts it via an amplifier to a voltage i.e. electrical output that is 
proportional to the original fluorescence intensity and the voltage on the PMT.  These 
electrical pulses are then processed by a series of linear and log amplifiers. The use of a 
logarithmic scale to measure fluorescence is indicated in most biological situations and 
the effect is to normalise the distribution. The use of a logarithmic scale is also required 
when there is a broad range of fluorescence (again true of most biological distributions) 
as this type of amplification expands the scale for weak signals and compresses the scale 
for “strong” or specific fluorescence signals.  
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These voltages, which are a continuous distribution, are converted to a discrete 
distribution by an Analog to Digital converter (ADC) which places each signal into a 
specific channel depending on the level of fluorescence.  These channels correspond to 
the original voltage generated by a specific "light" event detected by the PMT detector. 
Thus the ADC assigns a channel number based on the pulse height for individual events. 
Therefore, brighter specific fluorescence events will yield a higher pulse height and thus 
a higher channel number when displayed as a histogram. The greater the resolution of the 
ADC, the closer this reflects the continuous distribution. The ADCs in the FACScan are 
10-bit, i.e., they divide data into four decades across 1024 channels with 256 channels per 
decade. For the FACScan, the number of decades is fixed. 
 The flow cytometry data is most often represented as histograms or dot plots. 
A histogram is a graph of the fluorescent intensity on x-axis and the number of cells in 
each channel on the y-axis. Using the FACScan, histograms have 1,024 channels (with 
higher channel numbers representing a higher signal intensity of a fluorescent/ scatter 
after amplification) displayed on the ‘x’ axis using a 4-log decade logarithmic scale (256 
channels per decade). Only the intensity of one parameter (scatter or fluorescence) can be 
represented on a histogram.  
 In contrast to histograms, dot plots (also known as bivariate display, two 
parameter histograms, scattergram, bitmap) show the correlated distribution of intensity 
for two parameters (eg. forward scatter versus side scatter) and each cell is represented by 
a dot, positioned on the X and Y scales (often both 1024 channels, 4-log decade 
logarithmic scales) according to the intensities detected for that cell. Dot plots can be 
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divided into quadrants, which divide the light intensity channels into areas of interest. 
The number of particles in each of the defined areas can then be counted. 
 Both histograms and dot plots can reveal whether there are discrete 
subpopulations of cells with different intensities.  
 
• Gating and negative controls.  
Usually data only from single, viable cells is required and data from cell debris 
(particles smaller than cells), dead cells, and clumps of 2 or more cells needs to be 
eliminated. Subcellular debris and clumps can be distinguished from single cells by size 
(estimated by the intensity of low angle forward scatter). Dead cells have lower forward-
scatter and higher side-scatter than living cells. These differences are accurately 
preserved following formaldehyde fixation (despite the fact that after fixation, all the 
cells are dead). The computer can be configured to display the fluorescence signals only 
from those particles with a specified set of scatter properties, namely, living single cells. 
This is called a scatter-gated fluorescence analysis. It is actually possible to "gate" on any 
set of signals in order to analyse the specific data of either the main cell population or a 
subpopulation.  
Quadrant gates can be subjectively set on dot plots using the background levels of 
fluorescence of either the respective unstained negative control (contains only the 
fluorochrome-conjugated secondary antibody without the primary antibody) or 
fluorochrome isotype matched control population of cells (when a fluorochrome-
conjugated primary antibody is used). These negative control samples are needed to 
demonstrate the amount of non-specific binding that one may get with the antigen 
 116 
specific antibody. It should be noted that the fluorochrome isotype matched control 
primary antibody has no specificity to any epitope on the cells being analysed, is the 
same species and isotype, is used at the same concentration and is conjugated with the 
same fluorochrome as the antigen specific primary antibody.  
When quadrant gates are used on the graph, each quadrant then demonstrates the 
following: 
1) Lower-left quadrant represents cells negative for the descriptors on both the x- and y-
axis  
2) Upper-right quadrant represents cells dual-positive for the descriptors on both the x- 
and y-axis                                                                                                                             
3) Upper-left quadrant represents cells positive for the y-axis desciptor, but negative for 
the x-axis descriptor                                                                                                                           
4) Lower-right quadrant represents cells positive for the x-axis descriptor, but negative 
for the y-axis descriptor  
 
 Important aspects of sample preparation for flow cytometry 
The aim of sample preparation is to produce a single cell suspension with minimal 
aggregation, termed a "monodisperse suspension". The sample should contain as little 
debris and as few dead cells and clumps as possible. The latter disrupts the smooth flow 
of fluid or blocks tubes within the flow cytometer. With all preparative methods great 
care needs to be taken to ensure that the technique itself does not bias the results. For 
example, enzymatic preparative techniques can alter cell-surface antigens and affect cell 
viability. 
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The monodisperse cells are labelled, by incubation under appropriate conditions, 
with a fluorescent tag. This can be a fluorescent dye, fluorescent-conjugated antibody or 
ligand. For accurate interpretation of results, it is important that the staining is specific for 
and proportional to the feature to be measured. It is not unusual for fluorescent probes 
and monoclonal antibodies to bind non-specifically and care needs to be taken to block 
cross-reactions. Data can be acquired in the flow cytometer with the cells either alive or 
fixed with formaldehyde/ paraformaldehyde. With fixed cells, the fluorescence and light 
scatter properties are stable, and data acquisition can be postponed for days or weeks.  
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SECTION 2.4 
 
Cell migration assays 
The most common method used to study cell motility in vitro was first described 
by Boyden S in 1962. Transwell® migration assays are one of the modifications of the 
Boyden Chamber system and were used by us to study the chemotaxis of cells in 
response to the ligand for CXCR4 i.e. CXCL12. Increased motility of cells in this assay is 
matched by increased migration and invasion of cells in vivo [Klemke RL et al 1998]. 
The Boyden Chamber system and Transwell® migration assays use a hollow plastic 
chamber (upper compartment), sealed at one end with a porous filter membrane (refer to 
chapter 3, figure 3.2). This chamber is suspended over a larger well (lower compartment) 
which may contain medium and/or chemoattractants. Cells are placed inside the upper 
compartment chamber and allowed to migrate through the pores, to the other side of the 
membrane. Migratory cells are then stained and counted.  
The pore size has to be chosen small enough in relation to the size of the cells 
being investigated so that the cells actively migrate through the pores and cannot 
passively pass across the membrane by just dropping through them. The pore diameter of 
the Transwell® membrane usually ranges from 3-12µm (commercially available), and is 
selected to suit the subject cells. Smaller pore size results in a greater challenge for the 
migrating cells. Most cells range in size from 30-50µm and can migrate efficiently 
through 3-12µm pores. The majority of cell migration assays use an 8µm pore size, as 
this is appropriate for the majority of cell types. This pore size supports optimal 
migration for most epithelial, fibroblast and tumour cells. The assay runs only for a few 
(3 to 6) hours, although this is dependent on cell type. In this assay, the investigator 
 119 
analyzes the migratory activity by counting the transmigrated cells on the lower side of 
the filter (after 3 hours) or the cells in the lower compartment (after 6 hours). The 
“Boyden Chamber” assay is a very common assay and its standardized performance 
allows a high comparability of results. 
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MATERIALS AND METHODS  
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SECTION 3.1 
MATERIALS AND METHODS USED IN CHAPTER 4: 
ELUCIDATION OF CHEMOKINE RECEPTOR EXPRESSION 
(CXCR AND CCR GROUPS) IN PROSTATE CELL LINES 
 
Standard materials  
All chemicals and solvents were purchased from either Sigma-Aldrich Co. Ltd., 
UK or British Drug Houses (BDH) Ltd., UK unless otherwise stated. 
Cell culture reagents 
All materials used in routine cell culture were purchased from GibcoBRL (Life 
Technologies Ltd., UK). Foetal bovine/ calf serum (FBS) was purchased from Sigma-
Aldrich Co. Ltd., UK. All plastic ware for cell culture use was manufactured by Nunc 
Ltd., UK. 
Continuous cell lines 
Details of the origins of human cell lines used and their growth media are shown 
in table 3.1.  
Routine Maintenance   
All cell lines were maintained under identical conditions as monolayers in 25cm2 / 
80cm2 flasks in 5ml / 15ml of their required medium at 370C or 330C in a humidified 
atmosphere of 5% CO2 in air. At least twice per week, the medium from the culture flasks 
was removed and replaced with an equal quantity of fresh medium. Cells were 
subcultured when they reached 70-80% confluency. This was done by first washing the 
monolayers with phosphate buffered saline (PBS) and then incubating with 1x trypsin 
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(1ml and 2mls for a 25cm2 and 80cm2 flask respectively) for 3 minutes at 370C. The cells 
were detached from the culture surface by a gentle tap on each side of the flask, which 
was also sufficient to produce a crude single cell suspension. The detached cells were 
then taken up into 20ml medium and distributed into four 25cm2 flasks or two 80cm2 
flasks. The medium in the flasks was replaced with fresh medium 24 hours after 
passaging to remove unattached cells. 
Preparation of a Single Cell Suspension  
When cells were required for experiments, exponentially growing cells (70-80% 
confluent) were detached from the culture surface by first washing with PBS and 
incubating with 1x trypsin (1ml and 2mls for a 25cm2 and 80cm2 flask respectively) for 3 
minutes at 370C. The detached cells were taken up in 10-15mls medium and a fine single 
cell suspension was produced by passing cells through a 19 gauge needle prior to 
counting. To 100µl of this cell suspension was added the same volume of 0.1% trypan 
blue and viable cell number was assessed using a haemocytometer (Freshney 1983). The 
number of cells per millilitre was calculated as follows: 
Mean number of viable cells (in 4 squares) x 2 (dilution factor) x 104 = number of cells/ml. 
An appropriate dilution of cells was made to produce the final cell number required for 
experiments. 
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* Each new 500ml bottle containing FBS was heated to 560C for 1 hour to inactivate 
complement prior to storage in 25ml aliquots at -200C. 
Cell Line Derivation Primary 
Reference 
Growth Medium (incubation 
temp0C) 
 
DU145 
 
 
 
 
PC3 
 
 
 
 
LNCaP 
 
 
 
 
 
1542 
CPT3X 
 
 
 
 
1542 
NPTX 
 
 
 
Pre 2.8 
 
 
 
 
 
 
S2.13 
 
 
 
MDA-
MB-231 
 
Established from a metastatic 
CNS lesion of prostatic 
adenocarcinoma in 69 years old 
patient 
 
Established from a metastatic 
bone marrow lesion of prostatic 
adenocarcinoma in 62 years old 
patient 
 
Established from a metastatic 
supraclavicular lymph node 
lesion of prostatic 
adenocarcinoma in 50 years old 
patient 
 
Established from a primary 
prostatic adenocarcinoma in a 
radical prostatectomy specimen 
 
 
 
Established from normal 
prostatic epithelium in same 
individual as 1542 CPT3X 
 
 
Established from normal 
prostatic epithelium in a 71 
years old patient 
 
 
 
 
Established from stroma in same 
individual as Pre 2.8 
 
 
Established from epithelial cells 
in pleural effusion of 51years old 
patient with stage IV invasive 
ductal carcinoma 
 
Stone KR et 
al, 1978 
 
 
 
Kaighn ME et 
al, 1979 
 
 
 
Horoszewicz 
JS et al, 1980 
 
 
 
 
Bright RK et 
al, 1997 
 
 
 
 
Bright RK et 
al, 1997 
 
 
 
Alam TN et 
al, 2004 
 
 
 
 
 
Daly-Burns B 
et al 2007  
 
 
Cailleau R et 
al 1974 
 
 
 
RPMI (Roswell Park Memorial Institute 
Medium) 1640 medium supplemented with 
8% *FBS and 2mM L-glutamine (370C) 
 
 
RPMI 1640 medium supplemented with 8% 
*FBS and 2mM L-glutamine (370C) 
 
 
 
RPMI 1640 medium supplemented with 8% 
*FBS and 2mM L-glutamine (370C) 
 
 
 
 
Keratinocyte – SFM (serum free medium) 
supplemented with 4% *FBS, 2mM L-
glutamine, 30µg/ml bovine pituitary extract 
(BPE), 5ng/ml EGF (370C) 
 
 
Keratinocyte – SFM supplemented with 4% 
*FBS, 2mM L-glutamine, 30µg/ml bovine 
pituitary extract, 5ng/ml human 
recombinant EGF (370C) 
 
PrEGM (prostate epithelial-specific growth 
medium) supplemented with BPE 2ml, 
insulin 0.5ml, hydrocortisone 0.5ml, 
GA1000 0.5ml, retinoic acid 0.5ml, 
transferrin 0.5ml, triiodothyronine 0.5ml, 
epinephrine 0.5ml, hEGF 0.5ml (330C)    
 
RPMI 1640 medium supplemented with 8% 
*FBS and 2mM L-glutamine (330C) 
 
 
RPMI 1640 medium supplemented with 8% 
*FBS and 2mM L-glutamine (370C) 
Table 3.1: Details of continuous human cell lines used 
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Primers: designing primers and primer details   
                  
Designing primers 
Primers were designed and their specificity checked using the Basic Local 
Alignment Search Tool (BLAST) database at the National Centre for Biotechnology 
Information (NCBI) website (www.ncbi.nlm.nih.gov). Using the GI numbers (GenInfo 
Identifier sequence identification number) for the genomic and cDNA sequences 
(obtained from Genbank, which is part of the Nucleotide database at NCBI) of specific 
genes the BLAST 2 sequences tool produced the alignment of these two given sequences 
using the BLAST engine for local alignment. Thus intron-spanning primers could be 
designed so that products amplified from cDNA (complementary deoxyribose nucleic 
acid – has no introns) during polymerase chain reaction (PCR) could be differentiated 
from products amplified from genomic DNA (containing introns and therefore much 
larger). Often if the introns were long, the genomic DNA product would not be amplified 
because of the poor PCR efficiency of this longer product. 
The following principles were followed when designing primers: 
• Primers were usually 20-30 base pairs long to allow a reasonably high annealing 
temperature (longer than 30 does not improve primer specificity). 
• Primer annealing was improved by having guanine or cytosine at the 3’ end, as 
the three H+ bonds formed by guanine to cytosine are stronger than the two 
formed between adenine and thymine / uracil . 
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• Primers were designed so that a total of 50 or more hydrogen bonds form when 
the primers anneal and primers contained approximately equal numbers of purines 
(adenine and guanine) and pyrimidines (thymine and cytosine). 
• Repetitive sequences and stretches of more than 3 of the same base were avoided 
to ensure specificity. 
• Complementary sequences either within a primer or between a primer pair were 
minimised to prevent the formation of primer dimers - an artifact where the 
primer itself acts as a template resulting in a short length product.  
• The distance between the sense and the antisense primer i.e. the length of desired 
product did not exceed 10 kilobases (the polymerase enzyme is less effective at 
amplifying the cDNA after 3kb). 
• When performing reverse transcriptase-PCR (RT-PCR) there is a risk of cDNA 
contamination by genomic DNA. This was overcome by designing intron 
spanning primers in adjacent exons. The genomic DNA segment including the 
intron is too large to amplify. However, the intron is spliced out in the formation 
of mRNA so the cDNA can be amplified.   
 
Primer details 
Primer sequences, annealing temperatures used and product size details are shown 
in table 3.2. 
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Table 3.2: Details of chemokine receptor primers used in PCR.  
The expression of the receptor CXCR6 was not elucidated as it was not formally named 
until 2002 [Murphy PM 2002]. Similarly, CXCR7 was not named until 2005 [Balabanian 
K et al 2005]. Additionally, there is no information publicly available at this time to 
confirm whether this designation for CXCR7 has been accepted by the International 
Union of Immunological Societies (IUIS) / World Health Organisation (WHO) 
Subcommittee on Chemokine Nomenclature (also, the function of the CXCR7 receptor is 
currently controversial with some studies suggesting it is a non-signalling scavenger 
receptor for CXCL11 and CXCL12 [Naumann U et al 2010].  
The CCR11 receptor has been disqualified as a chemokine receptor [Murphy PM 2002]. 
We did not elucidate the expression of the CCR4 and CCR10 receptors. 
Receptor Sense 
(5’ to 3’) 
Antisense 
(5’ to 3’) 
Annealing 
temperature 
(0C) 
Product size 
(base pairs) 
CXCR1 TCT GAC TGC AGC 
TCC TAC TG  
GAA TTG TTT GGA 
TGG TAA GC  
60 627 
CXCR2 CTC CAC CTT CAG 
ACT GGT AG  
CAA AGC TGT CAC 
TCT CCA TG  
60 411 
CXCR3 GCC CAG CCA TGG 
TCC TTG AG  
CGT AGA AGT TGA 
TGT TGA AG 
60 417 
CXCR4 AAC CAG CGG TTA 
CCA TGG AG  
CAT CTG CCT CAC 
TGA CGT TG 
60 558 
CXCR5 AGC CTC TCA ACA 
TAA GAC AG  
GGC AAG ATG AAG 
ACC AGC AG  60 367 
CCR1 AGA CTT CAC GGA CAA AGT CC 
TAC CTG TCA ATC 
GTC AGC AG  60 438 
CCR2 GAC TGC CTG AGA 
CAA GCC AC  
CAA TAG CCA GGT 
ATC TAT CG 
60 505 
CCR3 TCT TCC ACA GGC 
ACT TGC TC  
ACT ATC TAA CAT 
TCA GGT GC 
60 414 
CCR5 CTG TGT AGT GGG 
ATG AGC AG 
GAG GAT GAC CAG 
CAT GTT GC 
63 455 
CCR6 GTC ATC ACA TTG 
GTG AGC TG 
GGA TGT CTG CAA 
TGG CCA TG 
63 458 
CCR7 TTT ACC GCC CAG 
AGA GCG TC  
CGT AGC GGT CAA 
TGC TGA TG 63 485 
CCR8 CAT TGA GCT GCA CTC ACA TG 
GTA CCT GTC CAC 
ACT CAT GA 63 496 
CCR9 CCA GAC ACT GAG 
AGC TGG TG 
ACG CTG ATG CAC 
ATG ATC AG 63 462 
CXCL12 ACA GAT GCC CAT 
GCC GAT TC 
CCT GCA CAG CTC 
AGA GAA TC 
60 630 
GAPDH TCC TGC ACC ACC 
AAC TG 
GCC TGC TTC ACC 
ACC TT 
60 450 
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Cell line RNA: RNA extraction from cell lines 
RNA was extracted using the silica-gel-based RNeasy Mini kit (Qiagen Ltd., 
UK) using the manufacturer’s instructions. With the RNeasy procedure, all RNA 
molecules longer than 200 nucleotides are isolated. The procedure provides enrichment 
of mRNA since most RNAs <200 nucleotides (such as 5.8S rRNA, 5S rRNA, and 
tRNAs, which together comprise 15–20% of total RNA) are selectively excluded. 
Cells grown to 70-80% confluence in a 80cm2 flask were harvested by 
trypsinisation and subsequently lysed with a mixture of β -mercaptoethanol (Sigma-
Aldrich Co. Ltd., UK) and RLT buffer [guanidine isothiocynate (GITC)-containing lysis 
buffer]. The latter is highly denaturing and immediately inactivates RNases to ensure 
isolation of intact RNA. Complete lysis or disruption, with GITC-containing buffer, of 
plasma membranes of cells and organelles was required to release all the RNA contained 
in the sample (incomplete disruption results in significantly reduced yields). The cell 
lysate was homogenized using a QIA shredder spin column. Homogenization was 
necessary to reduce the viscosity of the cell lysates produced by disruption. 
Homogenization shears the high-molecular-weight genomic DNA and other high-
molecular-weight cellular components to create a homogeneous lysate. Incomplete 
homogenization results in inefficient binding of RNA to the RNeasy membrane and 
therefore significantly reduced yields. An equal volume of 70% ethanol was then added 
to the homogenized lysate to ensure selective binding of RNA onto the silica based 
RNeasy spin column, and the sample was loaded onto the RNeasy column. A wash with 
RW1 buffer (composition not released) followed by two washes with RPE buffer 
(composition not released) removed sheared genomic DNA, and protein contaminants. 
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RNA was eluted from the RNeasy spin column with 30µl DEPC-treated water and 
recovered by centrifugation. It was stored at –700C. 
 
 
Leucocyte RNA: isolation of RNA from leucocytes 
 
Whole blood (5mls) was collected into a commercially available tube containing 
ethylenediaminetetraacetic acid (EDTA). The blood (5mls) was carefully pipetted into a 
tube containing Ficoll-Hypaque (5mls) (Sigma-Aldrich Co. Ltd., UK) and the solution 
centrifuged (2000rpm for 20 minutes). With great care the buffy coat was pipetted off 
and subsequently washed twice in phosphate buffered saline (PBS) (500µl), the latter 
being removed each time after separation of the leucocytes by centrifuging (2000rpm for 
1 minute). RNA could then be extracted from the isolated leucocytes by using the the 
Nucleospin Nucleic Acid Purification Kit (CLONTECH) (the RNeasy Mini kit 
(Qiagen Ltd., UK) was not suitable for extraction of RNA from body fluids according to 
the manufacturer’s instructions). Similar principles were involved as to RNA extraction 
from cell lines but an extra step involving incubation of the sample with DNase 1 enzyme 
at room temperature for 15 minutes was included. 
 
Measurement of RNA concentration 
 
RNA concentrations were measured by UV spectophometry using a DU650 series 
spectrophotometer (Beckman Ltd., UK). 4µl of eluted RNA was diluted with sterile water 
to 400µl (1/100) and added to a microcuvette. The spectrophotometer was blanked with 
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water following which the absorbance, or optical density (OD), of the sample was 
measured at 260nm and at 280nm and the RNA concentration was calculated as follows: 
OD260 x 40µg/ml x dilution factor = RNA concentration µg/ml 
An absorbance of 1 unit at 260nm corresponds to 40µg/ml of RNA. This relation is valid 
only for measurements in water. The ratio of the readings at 260 nm and 280 nm provides 
an estimate of the purity of RNA with respect to contaminants that absorb in the UV 
spectrum, such as protein. The 260nm/280nm ratio of pure RNA in water is 
approximately 2.0.  
 
Performance of RT-PCR 
 
mRNA was derived from cell lines using one of the commercially available kits 
(refer to earlier section). Table 3.3 demonstrates the protocol followed for the RT 
reaction. After reverse transcription the cDNA can be amplified by PCR immediately or 
stored for several months at -20ºC. 
PCR was carried out in a Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin 
Elmer Ltd., UK). All primers were synthesized by Invitrogen (GibcoBRL, UK) and 
supplied as lyophilised stock. For each primer an equal volume of sterile water (in µl) as 
the amount of nmoles supplied was added to provide a stock of 1000µM. For experiments 
2µl aliquots of this stock solution were made up with sterile water to 200µl i.e. a 10µM 
solution. 
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Table 3.3: Constituents of a 20µl reverse transcriptase reaction 
 
1µg mRNA is diluted to 11µl in RNAase free [diethylpyrocarbonate (DEPC) treated)] 
water 
 
*Add 1µl of OligodT 12-18 (0.5µg/µl) primer (to make 12 µl solution)   
The 12µl solution is heated to 700C for 10 minutes 
Centrifuge for few seconds and put solution on ice 
Add 4µl of 5x first strand buffer, 2µl of 0.1M DTT (dithiothreitol) and 1µl of 10mM 
dNTPs (the single nucleotides or deoxynucleoside triphosphates dATP, dTTP, dGTP, 
dCTP) 
 
**Heat at 42ºC for 50 minutes, but after two minutes 1µl (200units) SUPERSCRIPT II 
(reverse transcriptase) is added to each tube  
 
***Heat at 70ºC for 10 minutes 
*mRNA has several adenosine (A) nucleotides at its 3’ end – the polyA tail. A primer, 
made up of several thymidine (T) nucleotides - oligo-deoxythymidine (oligodT), is 
complementary and will bind to this polyA tail. The heat removes the secondary structure 
of the mRNA and allows the oligodT to anneal to the polyA tail. 
** reverse transcriptase hybridises the single deoxynucleoside triphosphates (dNTPs) to 
their complementary base sequentially from the oligodT primer, to make cDNA. 
***this step inactivates the reverse transcriptase enzyme 
 
 
To perform PCR a master mix was made, using multiples of the ingredients 
shown in table 3.4, depending on the number of samples to be used. The master mix was 
added to 3µl of cDNA in PCR tubes on ice. A drop of mineral oil was also added to 
prevent evaporation during the PCR process.  
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1. 5 µl 10x buffer 
2. 5 µl dNTP (2mM) 
3. 3 µl MgCl2  (25mM) 
4. 2 µl sense primer (10µM=10pmol/µl) 
5. 2 µl antisense primer (10µM =10pmol/µl) 
6. 29.5 µl H2O  
 
The samples were then placed in a pre-programmed PCR machine and heated at 
950C for 3 minutes before 0.5µl (2.5Units) of Red Hot DNA polymerse (Advanced 
Biotechnologies Ltd., UK) was added and the programme started. This “hot start” 
minimizes non-specific annealing of primers to non-target DNA sequences and reduces 
the incidence of primer oligomerisation therefore resulting in a more specific and 
efficient PCR reaction. The PCR cycle that was used is shown here but described in more 
detail in chapter 2, figure 2.1. 
950C –2 minutes 
950C – 45 seconds 
600C – 45seconds 
720C – 45seconds 
740C – 7 minutes 
  
 
Controls 
To confirm the presence of amplifiable DNA in samples PCR is simultaneously 
performed with primers for an alternative target eg. glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Also, if PCR is to be used for quantitative applications 
Table 3.4: PCR master mix for 1x 50µl 
reaction 
containing 3 µl cDNA (made up on ice) 
35 cycles 
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GAPDH amplification is performed as a standard in order to confirm similar starting 
concentrations of cDNA (and therefore indirectly RNA) template between samples. To 
do this GAPDH PCR should be performed at a number of cycles during which 
amplification is linear (i.e. before the plateau phase is reached for the reaction; for more 
details of this refer to Taqman real time quantitative PCR in chapter 2). We amplified 
GAPDH at several different numbers of cycles and elucidated that amplification is still in 
the linear range at 26 cycles (figure 3.1). 
Figure 3.1: Optimisation of GAPDH PCR cycles. This shows an agarose gel viewed on 
an ultraviolet transilluminator and captured using the Gel doc system (Quantity One 
Software, Biorad Ltd, UK). 
GAPDH was amplified at several different numbers of cycles and it can be seen that 
amplification was still in the linear range at 26 cycles. 
Optimisation of GAPDH PCR cycles
22              26              30              35 Number of cycles
Figure 2
  
 
To avoid PCR amplification of contaminating genomic RNA/ DNA a mRNA 
negative control (therefore cDNA negative) was also included in each reverse 
Figure 3.1 
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transcriptase reaction (12µl DEPC water used in this control reverse transcriptase 
reaction). 
Due to the enormous amplification possible with PCR, special laboratory 
practices are necessary in order to avoid false positive amplifications. Sources of sample 
contamination may be from carryover from previous PCR reactions or from samples with 
high DNA levels or from positive control templates. In order to minimize this we 
followed the following procedures:  
a) Clean laboratory coat was worn (not previously worn while handling amplified PCR 
products or used during sample preparation) and also clean gloves when preparing 
samples for PCR amplification. 
b) Separate areas and dedicated equipment and supplies were maintained for: 
– Sample preparation 
– PCR setup 
– PCR amplification 
– Analysis of PCR products 
c) Amplified PCR products were never brought into the PCR setup area. 
d) Reactions and components were capped as much as possible to avoid splashing PCR 
samples. 
e) Laboratory benches and equipment were periodically cleaned with 10% bleach 
solution. 
It should be noted the presence of multiple products does not necessarily imply 
contamination. It may be due to lack of primer specificity. By reducing the number of 
cycles or increasing the annealing temperature the specificity improves. A small product 
[20-30 base pairs (bp)] may represent primer dimers (see primer design). 
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Agarose Gel Electrophoresis 
Once PCR was complete agarose gel electrophoresis was used to visualize the 
amplified products. A 1-3% gel was used depending on product size - higher 
concentrations allow better discrimination of smaller products. The desired amount of 
agarose was dissolved in 1x TAE (tris acetate EDTA) buffer for 5-10 minutes at full 
power in a conventional microwave oven. The gel was then cooled to 500C, 
supplemented with 1µg/ml ethidium bromide and poured onto a clean plastic gel plate to 
set at room temperature. Prior to loading, an appropriate volume of 5x DNA loading 
buffer was added to each sample. In addition, a product size-marking DNA ladder [1 
kilobase (kb)] was loaded onto the agarose gel and an electric current (125V) was passed 
across the gel in a horizontal gel tank (Hybaid, UK). Gels were viewed on an UV 
transilluminator (ethidium bromide binds to DNA and fluoresces in ultra-violet light), 
images captured using Gel Doc system (Quantity One software, Biorad Ltd., UK) and 
printed on thermal paper (Mitsubishi P91 thermal printer). 
 
DNA extraction from agarose gel 
DNA (for later sequencing) was purified from agarose gel using the silica based 
QIAquick Gel Extraction Kit (Qiagen Ltd., UK). This protocol was designed to extract 
and purify DNA of 70 bp to 10 kb from agarose gels in TAE. Initially, amplified PCR 
product (40µl) was run on a 1x TAE agarose gel. Using a clean scalpel blade the 
fragment of interest was cut out from the gel as quickly as possible to minimize UV-
mediated DNA damage. DNA was then extracted and purified according to the 
manufacturer’s instructions. Briefly, buffer QG (3 volumes) (solubilisation buffer; exact 
composition not released), containing guanidine thiocyanate, solubilized the agarose gel 
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slice at 500C for 10 minutes and provided the appropriate conditions for binding of DNA 
to the silica membrane in the QIAquick spin column. The adsorption of DNA to the 
membrane was efficient only at pH 7.5. Buffer QG contained a pH indicator, which was 
yellow at pH 7.5 and orange or violet at higher pH. If the color of the mixture was orange 
or violet, 10 µl of 3 M sodium acetate, pH 5.0, was added until the color of the mixture 
turned to yellow. Isopropanolol (1 volume) was then added to the sample to increase the 
yield of DNA fragments <500bp and >4kb. The mixture was then centrifuged in the 
QIAquick spin column with DNA adsorbing to the silica-gel membrane whilst 
contaminants (eg. salts, enzymes, unincorporated nucleotides, agarose, dyes, ethidium 
bromide) passed through the column. Salts were quantitatively washed away by 
centrifuging with ethanol-containing buffer PE (0.75ml) (wash buffer; exact composition 
not released). DNA was eluted with 30 µl of the buffer EB (elution buffer; 10 mM 
Tris·Cl, pH 8.5). Buffer EB provided the basic (pH 7.0 and 8.5) conditions necessary for 
maximum elution efficiency. DNA was stored at –20°C. 
 
DNA sequencing 
The chain terminator method for DNA sequencing was employed using the ABI 
PRISM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit. The principles 
of the chain terminator method for DNA sequencing were first described by Sanger et al 
1977.  2µl of the agarose gel extracted DNA was mixed with an equal amount of 5x 
loading buffer and run on a 1.5% agarose gel in order to visually check the concentration 
and quality of the purified DNA. An appropriate volume of gel-extracted DNA 
(depending on its concentration judged visually by running on 1.5% agarose gel, as 
mentioned earlier) was diluted in sterile water to a total volume of 14.5µl. Sense primer, 
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0.5µl of a 4µM solution (4pmol/µl), was added followed by sequencing reaction mix (5µl 
of Terminator Ready Reaction Mix from the ABI PRISM dRhodamine Terminator 
Cycle Sequencing Ready Reaction Kit) containing AmpliTaq DNA Polymerase FS 
(fluorescent sequencing), dNTPs, ddNTPs (di-deoxynucleosides ddATPs, ddTTPs, 
ddCTPs, ddGTPs - in relatively low concentration compared to dNTPs), magnesium 
chloride and Tris-HCl buffer (Ph 9.0). Each ddNTP was fluorescently tagged with 1 of 4 
different fluorescent dyes [either rhodamine 6G (R6G), tetramethyl-6-carboxyrhodamine 
(TAMRA), rhodamine 110 (R110) or ROX] that emitted a specific wavelength of light 
when excited by a laser. Also ddNTPs were chain terminators because they lack the 
3’OH residue of the deoxyribose backbone and when incorporated into the growing DNA 
strand, they prevent phosphodiester bond formation with the next dNTP. The solution 
was then placed in a Perkin Elmer-Gene Amp 2400 thermal cycler (Perkin Elmer Ltd., 
UK) and PCR performed under the following conditions:  
 
960C –1minute, 
960C – 30seconds 
500C – 15seconds 
600C – 4 minutes 
40C – hold 
 
DNA replication in the presence of both dNTPs and ddNTPs terminated the 
growing DNA strand at each base and resulted in many copies of different sized DNA 
fragments being produced. Moreover each new DNA fragment was labelled with a 
fluorescent dye, which was specific for the terminal base. Precipitation of PCR products 
was subsequently performed by incubating with a mixture of 95% ethanol and 3M 
sodium acetate (50µl and 2µl respectively) for 15 minutes on ice followed by 
centrifugation (25minutes at maximum speed) and pipetting of the supernatant. The 
25 cycles 
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remaining DNA pellet was washed with 70% ethanol (100µl) and the alcohol left to 
evaporate. The pellet was stored in the dark until automated sequencing was performed 
by running the fluorescently labelled DNA fragments on the ABI PRISM 377 DNA 
Sequencer (this automated sequencing was performed at the Ludwig Institute, UCL by a 
colleague scientist). Basically these fragments were loaded into the top of a 
polyacrylamide gel with fragments separating into distinct bands according to size. Near 
the base of the gel the bands passed through the beam of a constantly scanning laser, 
which excited the fluorophores or fluorescent dyes attached to DNA bands (i.e. ddNTP). 
The wavelengths of the resulting light emissions were then identified and the signal 
quantitated. Thus the emitted wavelength or colour identified the terminal base 
characteristic of each band, and the quantitation of each band’s fluorescent signal gave 
the relative number of fragments within each band. In addition to nucleotide sequence 
text files the automated sequencer also provided trace diagrams termed 
electropherograms. 
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SECTION 3.2 
MATERIALS AND METHODS USED IN CHAPTER 5: 
QUANTITATION OF CXCR4 mRNA EXPRESSION IN CELL LINES 
AND PATIENT PROSTATE TISSUE SAMPLES  
Quantitation of CXCR4 mRNA was performed using the TaqMan® real time 
quantitative PCR assay (principles of this technique are described in chapter 2).  
All reactions were conducted in the ABI PRISM® 7700 Sequence Detection 
System (Perkin-Elmer–Applied Biosystems, Foster City, CA, USA) (chapter 2, figure 
2.3) using the universal thermal cycling parameters detailed in chapter 2, table 2.2. Also, 
all reactions were run in triplicate on a MicroAmp Optical 96-well reaction plate 
(Applied Biosystems) and each reaction mixture was made up to a total of 25µl with 
RNAse free water. Every reaction additionally contained Taqman Universal PCR 
Master Mix (Applied Biosystems). This mix is optimized for the Taqman reactions and 
contains AmpliTaq Gold DNA polymerase, AmpErase  Uracil N-Glycosylase 
(UNG), dNTPs with dUTP, Passive Reference dye (ROX) and optimized buffer 
components. The following components were added when necessary to this reaction 
mixture:  
 
a) CXCR4 primers and probe  
The reverse complement (i.e. the sequence reversed and then its complementary 
base pairs) of the CXCR4 mRNA target sequence was used to generate the primer and 
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probe sequences (using Primer Express® software) as it was not possible to devise these 
with the original sequence and fulfill the strict criteria for their design (table 3.5). 
 
Table 3.5: CXCR4 Primers, Probe and Amplicon Details (designed using Primer 
Express® software and supplied by Applied Biosystems)  
*Labelled with 6-FAM fluorescent dye covalently linked to the 5’ end and TAMRA 
quencher dye at the 3’ end  
 
 
 
Sequence (5’ to 3’) 
Length 
(no of 
bases) 
Tm 
(0C) 
Concentration 
(pmol/µl) 
Forward 
primer 
(junction 
spanning) 
 
AGGGCCTGAGTGCTCCAGTAG 
 
21 
 
59.5 
 
9.60 
Reverse 
primer 
 
CGGTGTAGTTATCTGAAGTGTATATACTGATC 
 
32 
 
58.3 
 
9.60 
*Probe  
CTCCATGGTAACCGCTGGTTCTCCAGA 
 
27 
 
69.5 
 
5 
Amplicon   
- 
 
90 
 
- 
 
- 
 
 
b) Housekeeping gene (β-actin) primers and probe 
Pre-developed Taqman assay reagents control kit (Applied Biosystems) 
containing control (i.e. housekeeping gene) primers and probe reagent. This product 
contained a pre-mixed solution of β-actin primers and probe. The probe was labelled with 
a VIC fluorescent dye (VIC is an acronym – Applied Biosystems have not released 
the chemical composition of this dye). The sequence of the β-actin primers and probe 
was not provided by Applied Biosystems. The volume of the mixture necessary for a 
50µl reaction was advised.  
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c) cDNA from cell lines 
Cell line extracted RNA was reverse transcribed into cDNA as described earlier in 
this chapter. In several optimisation experiments, a mixture of cDNA derived from 
DU145/ LNCaP/ PRE 2.8 cell lines was used. 
 
d) Patient prostate RNA samples  
Table 3.6 summarises available information on the patient samples. These RNA 
samples were provided by H. Klocker at the University of Innsbruck in Austria: nine 
fresh primary prostate tumours (radical prostatectomy specimens) were initially frozen 
and later cut into 50µm sections. Tumour cells were laser microdissected and RNA 
extracted using the Stratagene RNA isolation kit and following the manufacturer’s 
instructions. Tumour stage in these RNA samples ranged from pT2c to pT3a with no 
evidence of local lymph node spread on histological examination and no evidence of 
distant metastasis on radiological staging. Combined Gleason grade varied from 5 to 9. 
Benign epithelial prostatic tissue was also obtained from 6 of these patients with primary 
prostate cancer (again using using laser capture microscopy) and RNA extracted using 
the Stratagene RNA isolation kit (one patient had benign tissue isolated from two 
different areas). Another 2 samples were from benign areas in patients with prostatic 
carcinoma, but no sample was taken from the neoplasm. 
The patient samples were labelled from number 1 to 18 (during experiments we 
were not aware as to the derivation of each sample). In our laboratory, from each sample, 
20µl cDNA was made from 200ng of RNA using the SUPERSCRIPT™ II reverse 
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transcriptase kit (Invitrogen - GibcoBRL, UK) - thus 10ng RNA was equivalent to 1µl 
cDNA in these patient samples. 
 
Table 3.6: Clinically localized patient primary prostate tumour and benign prostate 
samples - summary of available information (all tissue derived from frozen fresh radical 
prostatectomy specimens). Samples were randomly labelled from numbers 1 to 18 
(during experiments we were not aware as to the derivation of each sample)  
Sample 
No. 
Carcinoma/ 
Benign 
Prostate 
weight - 
grams 
(without 
SV) 
pT N M Gleason 
grade 
Combined 
Gleason 
grade 
1 
2 
13 
Carcinoma 
Benign 
Benign TS Zone 
37 3a 0 0 3+2 5 
3 
4 
Carcinoma 
Benign 
40 2c 0 0 3+3 6 
5 
6 
Carcinoma 
Benign 
47 2c 0 0 3+3 6 
7 
8 
Carcinoma 
Benign TS Zone 
34 3a 0 0 3+3 6 
9 
10 
Carcinoma TS Zone 
Benign 
20 2c 0 0 3+2 5 
11 
12 
Carcinoma 
Benign TS Zone 
45 2c 0 0 3+4 7 
14 Carcinoma 31 3a 0 0 4+5 9 
15 Benign 19 2c 0 0 3+4 7 
16 Carcinoma 24 2c 0 0 3+3 6 
17 Carcinoma 15 2c 0 0 3+3 6 
18 Benign 40 2a 0 0 3+3 6 
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Reactions for optimisation of CXCR4 primer concentrations 
This experiment was done in order to elucidate the concentration of reverse and 
forward primers necessary for optimal assay performance and determine the minimum 
primer concentrations giving the maximum ∆Rn.  
These reactions contained a constant concentration of fluorogenic probe (5pmol - 
equivalent to1µl), DU145/LNCaP/PRE cDNA mixture (equivalent to a total of 100ng 
starting RNA) and 12.5µl of Taqman Universal PCR Master Mix (Applied 
Biosystems). However, varying concentrations of CXCR4 forward and reverse primers 
were added, resulting in 50 nM to 900 nM solutions of forward or reverse primer.  
 
Reactions for optimization of starting RNA quantity  
Optimisation of starting RNA quantity was necessary in order to elucidate the 
minimal amount of RNA necessary for the reaction to proceed.  
These reactions contained a constant concentration of fluorogenic probe (5pmol - 
equivalent to1µl), forward/ reverse primers (500nM solution) and Taqman Universal 
PCR Master Mix (Applied Biosystems) (12.5µl). Also, varying dilutions of cDNA (again 
derived from a mixture of DU145/LNCaP/PRE RNA) equivalent to a range of starting 
RNA quantities (0.001ng – 100ng) was added to each reaction mixture.  
 
Reactions used in calculating the relative efficiency plot 
This was necessary to check that the amplification efficiencies of the target 
(CXCR4) and endogenous control (β-actin) were approximately equal.  
CXCR4 reactions - these reactions contained a constant concentration of CXCR4 
specific fluorogenic probe (2.5pmol equivalent to 0.5µl), forward/ reverse primers 
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(300nM solution - elucidated from previous experiment) and Taqman Universal PCR 
Master Mix (Applied Biosystems) (12.5µl). Variable dilutions of DU145/LNCaP/PRE 
2.8 cDNA mixture, equivalent to a range of starting RNA amounts (9.375ng - 120ng), 
were included.  
β-actin reactions - these reactions contained a constant concentration of β-actin 
specific fluorogenic probe – primers mix (1.25µl – as advised by Applied Biosystems for 
a 25µl reaction) and Taqman Universal PCR Master Mix (Applied Biosystems) 
(12.5µl). Variable dilutions of DU145/LNCaP/PRE 2.8 cDNA mixture, equivalent to a 
range of starting RNA amounts (9.375ng - 120ng), were included.  
 
Final reactions used in determining CXCR4 mRNA levels in cell lines and patient 
samples (using real time quantitative PCR)  
 
Final results for real time quantitation of CXCR4 mRNA in all cell lines and 
patient samples were obtained. Therefore the wells contained either cell lines or patient 
tissue and within these CXCR4 or β-actin cDNA was amplified.  
Cell line wells containing CXCR4 reactions - these reactions contained the 
equivalent of 10ng cell line RNA which had been reverse transcribed into  cDNA (0.2µl), 
2.5pmol fluorogenic probe (0.5µl), forward/ reverse primers 300nM solution, and 
Taqman Universal PCR Master Mix (Applied Biosystems) (12.5µl).  
Cell line wells containing β-actin reactions - these reactions contained the 
equivalent of 10ng cell line RNA which had been reverse transcribed into  cDNA (0.2µl), 
constant volume of fluorogenic probe – primers mix (1.25µl) and Taqman Universal 
PCR Master Mix (Applied Biosystems) (12.5µl).  
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Patient samples wells - volumes as above but 10ng of RNA (which had been 
reverse transcribed into cDNA) was contained in 1µl of sample. 
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SECTION 3.3  
MATERIALS AND METHODS USED IN CHAPTER 6: 
ELUCIDATION OF CELL MEMBRANE CXCR4 CHEMOKINE 
RECEPTOR (PROTEIN) EXPRESSION IN PROSTATE CELL 
LINES 
 
The principles of sample preparation using the protocols described below were 
that using individual cell lines, a monodisperse cell suspension was prepared and 
incubated initially with primary anti-CXCR4 antibody and then subsequently with a 
fluorochrome conjugated secondary antibody (note that one of the primary anti-CXCR4 
antibodies was also fluorochrome conjugated; all antibodies used are shown in table 3.7a 
and b). The control reaction contained only fluorescent secondary and no primary anti-
CXCR4 antibody (note that when using the fluorochrome conjugated primary antibody 
no secondary antibody was needed and the control contained a fluorochrome isotype 
matched primary control antibody, which did not bind to cellular antigens). The specimen 
was finally fixed in formaldehyde prior to determining cell surface CXCR4 receptor 
expression by using the Becton Dickinson FACScan.   
The Becton Dickinson FACScan uses an air-cooled argon gas laser with fixed 
wavelength emission of 488 nm. The FACScan  can measure up to five parameters 
including forward light scatter, side light scatter and three fluorescence parameters:  
 - Green fluorescence signal received by the PMT, FL1, which measures emitted light in 
the green range of the spectrum (515 to 545 nm) eg. FITC.                                              
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- Yellow-orange fluorescence signal received by the PMT, FL2, which measures emitted 
light in the yellow-orange range of the spectrum (564-606 nm) eg. PE and PI.                          
- Red  Fluorescence signal received by the PMT, FL3, which measures emitted light in 
the red range of the spectrum (above 650-675nm) eg. PE-CY5.                                                   
The FACScan can analyze cell suspensions at the rate of several hundred cells per 
second. Typically, approximately 10,000 cells per sample are acquired (or anywhere in 
the range 5,000 – 15,000). In the FACScan, fluorescence/ scatter is represented on a 
logarithmic scale with the data divided into four decades across 1024 channels with 256 
channels per decade.  
Data was analysed using CellQuest™ software. 
In our experiments a total of 10,000 events were analysed in each sample using 
the Becton Dickinson FACScan, with data due to dead cells/cell debris and non-specific 
binding of the secondary antibody being gated out of the final results when appropriate. 
All experiments were repeated in triplicate in order to confirm the results and 
representative histograms and dot plots are shown in the results (chapter 6). 
 
 
Primary and secondary antibodies 
 
Antibodies - all primary and secondary antibodies used are shown in tables 3.7a and 3.7b. 
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Table 3.7: Details of primary and secondary antibodies used 
 
Table 3.7a) i) Primary anti-CXCR4 antibodies 
 
Host/ 
Isotype 
Mono/ 
polyclonal 
Epitope 
in 
CXCR4 
Clone Source Concentration/ 
Dilution used 
Fluoro
chrome 
Rabbit/ 
IgG 
polyclonal ECL2 
(partly 
transmenbrane 
region - amino 
acids 176-293) 
H-118 
(Fusin) 
Santa Cruz 
Biotechnology, 
Inc. 
 
200µg/ml 
1/1 
- 
*Mouse/ 
IgG2a, κ 
monoclonal on ECL2 
and ECL1 
12G5 BD PharMingen 12.5µg/ml 
1/1 
PE 
Mouse/ 
IgG2a  
monoclonal on ECL2 44708.1
11 
R&D Systems 100µg/ml 
1/1 
- 
Mouse/ 
IgG2b 
monoclonal on ECL2 44716.1
11  
 
R&D Systems 100µg/ml 
1/1 
- 
Mouse/ 
IgG2b 
monoclonal on ECL2 44717.1
11  
 
R&D Systems 100µg/ml 
1/1 
- 
*Fluorochrome isotype matched primary antibody is necessary for use in the control 
population of cells. Details of this are given in table 3.7a) ii).   
 
 
 
Table 3.7a) ii) Fluorochrome isotype matched control primary antibody (for use in 
control experiment for primary anti-CXCR4, PE conjugated mouse IgG2a, κ shown in 
table 3.7a)i)) 
 
 
 
 
 
 
 
 
 
 
 
*Mouse/ 
IgG2a, κ 
monoclonal does not 
bind to 
CXCR4  
MOPC-
173 
 
BD PharMingen 12.5µg/ml 
1/1 
PE 
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Table 3.7b) Secondary antibodies 
 
 
Reaction protocols 
All procedures were performed in a hood to keep all solutions and antibodies 
sterile. The protocols followed are described.  
 
a) Protocol using non-fluorescent primary anti-CXCR4 antibody and FITC-conjugated 
secondary antibody 
The protocol described here was the same for all experiments involving non-
fluorescent primary antibodies and FITC-conjugated secondary antibodies. The dilutions 
of the antibodies given are for primary mouse IgG2b clone 44717.111 (R&D Systems) 
and secondary anti-mouse IgG2b, γ2b chain specific (SouthernBiotech). The dilutions 
used for the other antibodies are given in tables 3.7a and 3.7b. 
Host 
species 
Antigen Source Concentration/ 
Dilution Fluorochrome 
Goat anti-rabbit 
IgG 
Sigma 1mg/ml 
1/50 
FITC 
Goat anti-mouse 
IgG2a (γ2a 
chain 
specific) 
SouthernBiotech 
 
1mg/ml 
1/50 
FITC 
Goat anti-mouse 
IgG2b (γ2b 
chain 
specific) 
SouthernBiotech 
 
1mg/ml 
1/50 
 
FITC 
Goat Anti-mouse 
IgG F(ab’)2 
(γ2b chain 
specific) 
SouthernBiotech 1mg/ml 
1/50 
FITC 
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Cells in a 80cm2/ 25cm2 flask were dissociated with undiluted non-enzymatic Cell 
Dissociation Solution (Sigma) and resuspended in the appropriate culture medium. The 
cells were counted with a haemocytometer, centrifuged and resuspended in 1% bovine 
serum albumin in phosphate buffered saline (BSA-PBS) at 2.5 x 106 cells/ml. 200µl of 
this cell suspension (500,000 cells) was then distributed in a well within a round 96 well 
plate (two wells for each cell line) prior to being incubated on ice for 20-30 minutes. 
Following centrifugation at 1500 rpm for 3-5 minutes, supernatant was removed with a 
pipette. The cells were subsequently resuspended in 20µl of the primary anti-CXCR4 
antibody diluted at 100µg/ml in sterile PBS (the dilution for mouse IgG2b clone 
44717.111 - R&D Systems) or in 20µl sterile PBS only (control). Following this, 
incubation for 1 hour on ice was necessary. After this, two washes with 1% BSA-PBS 
were performed by first centrifuging the incubated cells at 1500rpm for 3 minutes, 
removing supernatant, resuspending the cells in 200µl 1% BSA-PBS and then repeating 
the procedure. Once again the supernatant was removed before the addition to the cells of 
1/50 concentration of secondary FITC antibody (anti-mouse IgG2b, γ2b chain specific - 
SouthernBiotech) (1µl of secondary FITC antibody in 49µl 1% BSA-PBS). Incubation 
for 30 minutes in the dark was then essential, and this was followed by another 2 washes 
in 1% BSA-PBS. The cells were then fixed by resuspending in 200µl of 3.7% 
formaldehyde and incubation on ice for 15 minutes in the dark. 300µl PBS was then 
added and the cells stored at 40C in the dark in a 5mls FACS tube. FACS analysis was 
performed within 24 hrs. 
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b) Protocol using PE conjugated primary anti – CXCR4 antibody 
 
The method was exactly the same as that described for non-PE conjugated 
primary antibodies described above except that there was no need for incubation with a 
secondary antibody. The reactive anti-CXCR4 antibody used was PE conjugated mouse 
IgG2a, κ chain specific clone 12G5 (BD PharMingen), and the non-reactive isotype 
control antibody was PE conjugated mouse IgG2a, κ chain specific clone MOPC-173 
(BD PharMingen). Dilutions of the antibodies used are given in tables 3.7a and 3.7b.  
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SECTION 3.4 
MATERIALS AND METHODS USED IN CHAPTER 7: 
ESTABLISHING THAT THE CXCR4 RECEPTOR IS FUNCTIONAL 
IN CELL LINES DERIVED FROM PROSTATE CANCER 
METASTASES 
In cell migration assays the cell lines DU145, PC3 and 1542 NPTX were used 
(the latter was used as a control because 1542 NPTX had been shown in the results from 
chapter 6 to have extremely low or absent CXCR4 protein expression). The protocol was 
based on that described by Muller A et al 2001.  
Figure 3.2: Costar Transwell culture chamber 
 
 
Cell Migration Assays 
0.1ml 
cell suspension 
in  RPMI/1% 
BSA +/- anti-
CXCR4 
antibody 
0.6ml 
RPMI/1% 
BSA 
Solution +/- 
CXCL12α 
Microporous 
polycarbonate 
membrane with 
8µm pores  
Fibronectin 
Transwell 
Costar Transwell® culture chamber 
Upper compartment 
Lower compartment 1mm 
Figure 3.2 
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Cell migration assays were conducted using Transwell 24 well cell culture 
chambers (Costar) (figure 3.2). Each Transwell was 6.5mm in diameter with a 
translucent polycarbonate membrane attached to the bottom of the well. The 
polycarbonate membrane was 10µm thick with 8µm pores. Stock 0.1% (1mg/ml) 
fibronectin from bovine plasma (Sigma-Aldrich) was diluted 1/100 with PBS to create a 
10µg/ml solution. 50µl of this diluted solution was coated onto the lower surface of the 
polycarbonate membrane of each Transwell and left to dry at room temperature for 2 
hours. 
Serum free RPMI 1640 with 1% BSA and L-glutamine was filter sterilized by 
syringing through a 0.2µm syringe filter (Nalgene). Recombinant human SDF1α/ 
CXCL12 was made up with 1ml 0.1% BSA to form a 10µg/ml stock solution. This 
CXCL12 stock solution was diluted in serum free RPMI / 1% BSA to 150ng/ml (30µl 
stock solution made up to 2000µl). 600µl of this solution was added to the lower chamber 
(cluster plate well). In the control experiments 600µl serum free RPMI / 1% BSA alone 
(without SDF1α) was added to the lower chamber. 
Appropriate cell lines were resuspended in serum free RPMI / 1% BSA at a 
concentration of 4 x 105 cells/ ml. 100µl of this cell suspension was added to the upper 
compartment of the Transwell. When necessary, IgG2b anti-CXCR4 monoclonal 
antibody (clone 44717.111) (R & D Systems) was added to the cells (100µg in 1ml PBS 
stock antibody solution). To do this, the cells were spun down and serum free RPMI / 1% 
BSA aspirated. The cells were then resuspended in the antibody solution at room 
temperature for 5 minutes (20µl, equivalent to 2µg, of stock antibody solution per 500µl 
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of centrifuged cell suspension) before the aspirated serum free RPMI / 1% BSA was 
again added (thus IgG2b antibody concentration 4µg/ml). 100µl of this cell suspension 
and antibody solution was then added to the upper compartment of the Transwell. 
Simultaneously in other wells without antibody, cells were spun down and resuspended 
for 5 minutes in serum free RPMI / 1% BSA alone (without antibody). 
All wells were incubated for 3 hours at 370C in a humid atmosphere of 5% CO2 / 
95% air. After incubation the Transwell was removed from the cluster plate and the 
upper surface of the polycarbonate membrane was wiped gently with a cotton wool bud 
to remove cells from the upper surface. The Transwell was then suspended in PBS (1 
minute) followed by fixation of cells in the fibronectin layer with 3.7% formaldehyde 
(BDH Laboratories) (15 minutes). The Transwell was again washed in PBS (1 minute) 
and then the cells were stained by leaving the well in haematoxylin (Gill’s formula; 
Vector Laboratories) (10-12 minutes). This was followed by one final wash in PBS. 
Stained cells were then counted using a microscope. This was done under x200 
magnification and the mean number of cells per three high power fields (the central and 
the two vertically adjacent fields) for each well was calculated.     
All experiments were repeated on three separate occasions using four Transwell  
wells each time for each CXCL12 ligand concentration. 
The results of the migration assays were assessed with the “Student’s t test”. The 
level of significance was defined as p < 0.05. 
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SECTION 4.1 
INTRODUCTION AND AIMS 
The hypothesis stated that prostate cancer may use chemokine receptor – ligand 
interactions in the process of metastasis to preferred sites. In order to pursue this 
hypothesis the first aim was to determine the expression, at mRNA level (messenger 
ribonucleic acid), of the chemokine receptors in the CXCR and CCR groups in prostate 
cell lines (the expression of thirteen receptors in total was demonstrated).  
Several cell lines were used which were derived from normal prostate epithelium 
and stroma, primary prostate cancer and metastatic prostate cancers. As all CXCR and 
CCR receptors and the CXCL12 ligand are expressed by various subsets of human 
leucocytes, RNA extracted from leucocytes was thus used as a positive control in all 
experiments involving chemokine receptor (or ligand) expression.   
mRNA expression was assessed in the cells using standard reverse transcriptase 
polymerase chain reaction (RT-PCR). By analysing these initial results and the pattern of 
expression of the chemokine receptors being screened we would be able to elucidate 
whether any specific receptor may be important in the metastasis of prostate cancer (eg. 
over-expression in metastatic cells). Any receptor of interest could then be studied in 
more detail in further experiments in an attempt to verify the hypothesis.  
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SECTION 4.2 
RESULTS 
1) Chemokine receptors and ligand expression - the expression of the known 
chemokine CXCR and the majority of the CCR receptors was demonstrated. This was 
done to investigate whether there was differential expression of any of these receptors 
between the benign, primary and metastatic prostate cancer cell lines, which would 
indicate whether they may have a role in the organ specific metastatic process. In 
addition, the expression of the CXCL12 ligand was elucidated in the prostate cell lines. 
The positive controls were leucocytes obtained from human whole blood, which are 
known to express the chemokine receptors and ligands (refer to chapter 1). A negative 
control was routinely used for all assays to confirm the absence of contamination. For 
these negative controls, RNA was omitted from the RT reaction mixture and the reverse 
transcription was carried out as described in chapter 3. 
As Muller A et al 2001 had shown (using real-time quantitative PCR techniques) 
there were high levels of CXCR4 RNA in the MDA-MB-231 breast cancer cell line, we 
performed standard RT-PCR to confirm these results with a view to using these cells as a 
positive control in experiments related to CXCR4 expression.  
Therefore following agarose gel electrophoresis of amplified PCR products, 
starting mRNA quantitation of chemokine receptors was estimated initially by visual 
comparison of band intensities (real-time quantitative PCR would later be performed for 
any receptors of interest). Several different patterns of receptor expression were 
observed, which are shown in figures 4.1a - n and summarized in table 4.1:  
• receptor mRNA undetectable in all cell lines (CXCR5, CCR3, CCR7, CCR8)  
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• receptor detected at low/ very low levels in only one metastatic cell line (CXCR1, 
CXCR3, CCR2, CCR9) 
• expression at low/ very low concentrations in one or more malignant and benign cell 
lines (CXCR2, CCR1, CCR5, CCR6)  
• upregulation of receptor expression with high/ moderate levels in metastatic cells (in 
addition to the stromal cell cultures S2.13) and  very low or no detectable mRNA in the 
primary prostate and benign epithelial cell lines (CXCR4). 
 
Importantly, it was noted that there was no detectable CXCR4 expression in the 
breast ductal carcinoma cell line MDA-MB-231. 
CXCL12 ligand mRNA was not detected in any of the prostate cell lines. 
 
 
 
 
 
 
 
Figures 4.1a – n: 
All the images in this figure are of agarose gels viewed on an ultraviolet transilluminator 
and captured using the Gel doc system (Quantity One Software, Biorad Ltd, UK). 
The images demonstrate the expression of CXCR and CCR chemokine receptors and 
CXCL12 ligand in cell lines using standard RT-PCR performed at 35 cycles. A 1kb DNA 
ladder was used. 
Lane 1 – no RNA control, 2 – DU145, 3 – LNCaP, 4 – PC3, 5 – 1542 CPT3X, 6 – 1542 
NPTX, 7 – Pre 2.8, 8 – S2.13, 9 – leucocytes, 10 – MDA-MB-231   
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Figure 4.1a 
Figure 4.1b 
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CXCR3 and GAPDH Expression
1           2          3          4             5            6  7            8            9
Figure 2.3c
 
 
 
 
 
 
 
 
Figure 4.1c 
Figure 4.1d 
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1           2          3          4          5           6      7           8            9
CXCR5 and GAPDH ExpressionFigure 2.3e
 
 
 
 
 
 
 
 
 
Figure 4.1e 
Figure 4.1f 
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CCR3 and GAPDH Expression
1          2         3           4             5             6  7            8              9
Figure 2.3h
 
 
 
 
 
 
Figure 4.1g 
Figure 4.1h 
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Figure 4.1i 
Figure 4.1j 
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CCR7 and GAPDH Expression
1            2          3          4          5          6      7           8          9
Figure 2.3k
 
 
 
 
1          2          3          4          5          6        7          8          9
CCR8 and GAPDH ExpressionFigure 2.3l
 
 
 
 
Figure 4.1k 
Figure 4.1L 
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CCR9 and GAPDH Expression 
1           2          3          4          5          6       7          8          9
Figure 2.3m
 
 
 
 
CXCL12 and GAPDH Expression
1            2            3           4            5            6           7             8             9
Figure 2.3n
 
 
 
 
 
Figure 4.1m 
Figure 4.1n 
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Table 4.1: Summary of CXCR and CCR receptor and CXCL12 ligand expression 
observed in cell lines.  
This was estimated by visual comparison of band intensities on agarose gel 
electrophoresis of amplified PCR products shown in figure 4.1a - n.  
VL - very low expression, L – low expression, M – moderate expression, H – high 
expression, empty box  - no detectable expression, nt – not tested.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DU145 LNCaP PC3 1542  
CPT3X 
1542 
NPTX 
PRE 
2.8 
S2.13 MDA-
MBA-231 
CXCR1 VL        nt 
CXCR2  VL  VL VL L  nt 
CXCR3 L       nt 
CXCR4 H H M VL VL  M  
CXCR5        nt 
CCR1     VL  VL nt 
CCR2  VL      na 
CCR3        nt 
CCR5 L VL    L  nt 
CCR6 VL VL VL  VL VL VL nt 
CCR7        nt 
CCR8        nt 
CCR9  L      nt 
CXCL12        nt 
Receptor / 
ligand  
Cell lines 
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2) Sequencing of CXCR4 receptor – for the leucocyte positive control and the 
cell line DU145, we extracted and purified the CXCR4 PCR product from the agarose gel 
and subsequently used it in sequencing reactions. This sequencing was done to ensure the 
correct product was being amplified. A representative electropherogram is shown in 
figure 4.2.  
Using the NCBI BLASTN programme, which compares a nucleotide “query” 
sequence against a nucleotide sequence database, we confirmed that this sequence in 
figure 4.2 (using a region of 416 nucleotide bases) corresponded to that of human 
CXCR4 mRNA transcript variant 2 (this only differs from transcript variant 1 by 
encoding a CXCR4 isoform with a shorter N-terminus, Gupta SK and Pillarisetti K 
1999). This gene is located on chromosome 2q21. The bit score and expectation (e) -
value were 793 and 0 respectively (derived from BLASTN search), suggesting that it is 
extremely improbable that this exact alignment occurred by chance alone. There was no 
evidence of any mutations in this section of the DU145 CXCR4 cDNA sequence.  
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Figure 4.2: Nucleotide sequence electropherogram obtained by extracting the CXCR4 
PCR product from an agarose gel using the DU145 cell line. A similar electropherogram 
was obtained using the CXCR4 PCR product from leucocytes. Using the NCBI BLASTN 
programme, we confirmed that this sequence corresponded to that of human CXCR4 
mRNA (transcript variant 2). 
Note that the automated sequencing and production of this nucleotide sequence 
electropherogram was performed by a colleague scientist at the Ludwig Institute, UCL. 
 
Figure 2.4 CXCR4 Nucleotide Sequence Electropherogram
 
 
 
 
 
 
Figure 4.2 
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SECTION 4.3  
DISCUSSION  
These results demonstrated that the CXCR4 receptor is upregulated particularly in 
metastatic prostate cancer cell lines (DU145, LNCaP, PC3) as compared with prostate 
cancer cell lines derived from a primary tumour (1542 CPT3X) and those originating 
from normal prostate epithelium (1542 NPTX, Pre 2.8) (figure 4.1d). It appeared from 
the results that presence of the androgen receptor was not related to CXCR4 mRNA 
expression as on the agarose gels DU145 and LNCaP were observed to have high 
CXCR4 mRNA levels whereas PC3 expressed moderate levels (DU145 and PC3 do not 
express androgen receptor in contrast to LNCaP cells which do). Of note is that it has 
been recently demonstrated that androgens increased the levels of both CXCR4 mRNA 
and functional protein in LNCaP prostate cancer cells [Frigo DE et al 2009]. 
The cell line S2.13 established from stroma derived from a non-malignant 
prostate also expressed CXCR4 mRNA at moderate levels (figure 4.1d) – this is in 
accordance with fibroblast chemokine receptor expression in other tissues [Bourcier T et 
al 2003, Eck SM et al 2009, Franco OE et al 2010, Mishra P et al 2010] where chemokine 
receptors and their ligands are thought to be associated in the control of stromal cell 
proliferation, viability or differentiation.  
It was surmised that the CXCR4 receptor, in a similar manner to breast cancer as 
observed by Muller A et al 2001, may play a significant role in the directional migration 
of metastatic prostate cancer cells to specific organs and further experiments were 
performed to clarify this (chapters 4, 5 and 6). Also, by extracting and sequencing the 
CXCR4 PCR product from the agarose gel for the leucocyte positive control and the cell 
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line DU145, we ensured that the correct product was being amplified with no evidence of 
any mutations in this section of the DU145 CXCR4 cDNA sequence.   
In our results, the pattern of expression of the remaining CXCR and CCR 
receptors did not suggest a very significant role for their involvement in the metastasis of 
prostate cancer. However, the results did demonstrate that mRNA of CXCR3 and CCR9 
was observed at low levels in only the metastatic cell lines DU145 and LNCaP 
respectively (figures 4.1c and 4.1m). The CXCR3 receptor has not previously been 
shown to be involved in prostate cancer progression but has been noted to be involved in 
the organ specific metastasis of human melanoma [Singh S et al 2009b], colon cancer 
[Cambien B et al 2009] and osteosarcoma [Pradelli E et al 2009]. However, Singh S et al 
2004b have established that functional CCR9 is expressed by LNCaP and is associated 
with increased chemotaxis of these cells via its ligand CCL25.     
After it was noted that CXCR4 receptor mRNA levels were elevated particularly 
in DU145, LNCaP and PC3 cells, expression of its ligand, CXCL12, was demonstrated. 
However, CXCL12 mRNA was not expressed in any of the cell lines (figure 4.1n), 
signifying that this ligand does not have an autocrine or paracrine effect on the regulation 
of growth and progression in these cells. This is in contrast to a variety of tumour cell 
lines (already discussed in the introduction) where chemokines have been shown to be 
involved in stimulating cell proliferation in vitro and in vivo via an autocrine or paracrine 
pathway [Araki K et al 2009, Hussain F et al 2010, Lo BK et al 2010, Raychaudhuri B 
and Vogelbaum MA 2010, Sauvé K et al 2009]. Also of interest is that autocrine 
production of CXCL12 by primary tumours has been shown by some investigators to be 
deleterious to the formation of metastasis [Gilbert DC et al 2009, Mirisola V et al 2009]. 
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It is proposed that this is due to a combination of the loss of CXCL12 gradients that 
might otherwise attract cells away from the primary tumour and also saturation of the 
CXCR4 receptor through autocrine CXCL12 production, which may reduce chemotaxis 
towards CXCL12-releasing metastasis target tissues thus decreasing the number of 
metastases formed. As mentioned in chapter 1, CXCL12 ligand has, in fact, been 
observed in several studies to be constitutively expressed by stromal cells in tissues 
which are the preferred site of prostate cancer metastasis, with highest expression in bone 
marrow (fibroblasts, osteoblasts, endothelial cells), lymph nodes, lung, and liver and 
markedly lower expression levels in the small intestine, skin and skeletal muscle 
[Bradstock KF et al 2000, Imai K et al 1999, Muller A et al 2001, Ponomaryov T et al 
2000, Sun YX et al 2005, Taichman RS et al 2002, Zou YR et al 1998].  
As Muller A et al 2001 had established, using real time quantitative PCR, that 
CXCR4 mRNA was expressed at significant levels in the breast ductal carcinoma cell 
line MDA-MB-231, we had intended to use these cells as a positive control in this and 
further experiments related to CXCR4 expression and functionality. However, using RT-
PCR we were not able to confirm the expression of CXCR4 mRNA in the MDA-MB-231 
cell line (obtained from Michael O’Hare at University College London) (figure 4.1d). An 
email was sent by Professor J. Masters to the authors of the paper and Dr A. Zlotnik, the 
senior author, replied that their MDA-MB-231 cells had been obtained from a colleague 
at Schering-Plough who had selected them on the basis of their potent metastatic 
potential in vivo. Importantly, Dr Zlotnik agreed that other sources of these breast cancer 
cells, eg. The American Type Culture Collection (ATCC), were cells with low to no 
CXCR4 expression. Therefore, in these and further experiments, RNA extracted from 
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leucocytes was used as a positive control as all CXCR and CCR receptors and the 
CXCL12 ligand are expressed by various subsets of human leucocytes (the evidence for 
this has been reviewed in chapter 1).  
Prostate cell lines had been used in the experiments in this chapter as in vitro 
models of human prostate cancer or benign tissue and on the assumption that cell lines 
reflect the genotypic and phenotypic characteristics of in vivo prostate malignancy/ 
benign tissue in humans. There are several advantages to using cell lines including the 
fact that they are easy to handle and represent an unlimited self-replicating source that 
can be grown in almost infinite quantities. In addition, they exhibit a relatively high 
degree of homogeneity and are easily replaced from frozen stocks if lost through 
contamination. Importantly, cancer cell lines are free of contaminating stromal cells or 
other non-malignant cells. Additionally, cell lines are generally good models of the 
characteristics of in vivo human neoplasms retaining the properties of the cancer of origin 
with limitations mainly occurring if they are handled incorrectly. One problem that can 
arise is that cell lines evolve as they are grown continuously over a large number of 
passages. In fact, genotypic and phenotypic variants constantly appear in the cancer cell 
line populations, and selection occurs of those with superior growth properties. This may 
change the characteristics of a cell line drastically.  Also this genetic instability can occur 
due to the uncontrolled passing of cells between laboratories and their exposure to 
different environments (eg. media, sera, trypsin, carbon dioxide levels, humidity 
temperature). The solution to this is that the cells should not be grown indefinitely and 
passed in an uncontrolled manner between laboratories. Adequate frozen stocks of each 
cell line should be produced, and users should return to frozen stocks at regular intervals. 
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If this is done the cell lines retain most of the features of the cancers from which they 
were derived [Masters JR 2000]. 
Also cross-contamination between cell lines is a persistent problem and often 
results in scientific misrepresentation. It has been estimated that 17 - 36% of cell lines are 
of a different origin or species to that claimed [Stacey GN 2000]. Cross-contamination 
can result from poor culture technique when two cell lines accidentally get into the same 
culture. After a few passages, there is no trace of the slower-growing cell line, and it has 
been completely displaced by the faster-growing cell line. Also, cross-contamination can 
occur due to clerical error - mislabelling of growing cells or frozen stocks. It is suggested 
that as an essential quality control, all cell lines should be short tandem repeat (STR) 
profiled [Barallon R et al 2010, Masters JR et al 2001].  
Mycoplasmal infection of cell lines can also occur but this can be prevented by 
regular checking of laboratory cell stock with simple tests. 
However, in our laboratory, cells in culture underwent a maximum of ten 
passages before a return to frozen stock and regular quality control measures were 
implemented. Thus we infer that the cell lines used in our experiments were 
representative models of in vivo human neoplasms or benign tissue. Consequently results 
obtained from the prostate cell lines could be correlated to human tissue in vivo. 
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SECTION 5.1  
 
INTRODUCTION and AIMS 
 
Conventional RT-PCR had demonstrated that levels of CXCR4 receptor mRNA 
were relatively high in the metastatic prostate cell lines DU145, PC3 and LNCaP, in 
comparison to those cell lines derived from primary prostate tumour (1542 CPT3X) and 
normal prostate epithelium (1542 NPTX and Pre 2.8). The first aim in this chapter was to 
accurately quantitate and compare CXCR4 mRNA expression between the individual cell 
lines. Additionally, patient prostate RNA samples, acquired by extracting RNA from 
laser microdissected benign and malignant areas within radical prostatectomy specimens, 
had  been provided by H. Klocker at the University of Innsbruck, Austria. Thus, our aim 
was also to quantitate CXCR4 mRNA levels in these primary prostate cancer specimens 
and benign human prostate tissue samples. 
In the cell line mRNA studies, using conventional RT-PCR in Chapter 4, each 
chemokine receptor RT-PCR reaction was performed in conjunction with a GAPDH 
control. This was done not just to confirm the presence of amplifiable DNA in samples, 
but also to confirm similar starting concentrations of cDNA (and therefore indirectly 
RNA) template between samples as GAPDH PCR was performed at a number of cycles 
during which amplification was linear (i.e. before the plateau phase was reached for the 
reaction; for more details of this refer to chapter 2 and chapter 3). Therefore, following 
agarose gel electrophoresis of amplified PCR products, relative starting mRNA 
quantitation of chemokine receptors was estimated by visual comparison of band 
intensities. However, this visual quantitation is not accurate. More precise agarose gel 
quantitation can be achieved by densitometric measurement of band intensity. 
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Unfortunately, this technique can also be prone to error (eg. variability in ethidium 
bromide staining with gel concentration and thickness and DNA quantities ≤ 10ng). 
Subsequently, in order to quantitate CXCR4 mRNA levels in cell lines, and also in 
patient samples, we used a real-time quantitative PCR assay (TaqMan).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 176 
SECTION 5.2  
RESULTS 
a) Optimisation 
i) Optimisation of CXCR4 primer concentrations  
By independently varying CXCR4 forward and reverse primer concentrations, the 
concentrations that provide optimal assay performance can be identified. Primers are 
always in large molar excess during the exponential phase of PCR amplification and the 
purpose of this procedure is to determine the minimum primer concentrations giving the 
maximum ∆Rn. By spanning a concentration range of 50nM – 900nM solutions for each 
primer, the most favourable primer concentrations were identified. The primer 
concentrations used in the primer optimisation matrix are shown in table 5.1. 
 
 
Table 5.1: Combinations of CXCR4 forward and reverse primer concentrations for 
optimisation (all primer concentrations are nM solutions) 
50 forward 
50 reverse 
 
50 forward 
300 reverse 
50 forward 
900 reverse 
300 forward 
50 reverse 
 
 
300 forward 
300 reverse 
300 forward 
900 reverse 
900 forward 
50 reverse 
 
 
900 forward 
300 reverse 
 
900 forward 
900 reverse 
 
 
 
The mean Ct value for each triplicate reaction was calculated and is presented 
graphically in figure 5.1.  
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Figure 5.1: Optimisation of CXCR4 primer concentrations. By spanning a range of 
concentrations for forward and reverse primers the most favourable primer concentrations 
were identified. The mean Ct +/- SD is shown for each reaction. The 300 nM reaction 
solution of both forward and reverse primers provided an economical as well as an 
acceptably efficient reaction (mean Ct 28.01 +/- 0. 21).  
FIGURE 4: OPTIMISATION OF CXCR4 PRIMER CONCENTRATIONS
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The reaction with the lowest Ct value was the most efficient i.e. that containing 
900nM of both forward and reverse primers (mean Ct - 27.46). However, as this 
constituted a relatively large volume of each primer solution we decided to use the 
300nM concentrations of both primers as this was both economical and provided an 
acceptably efficient reaction (mean Ct 28.01). 
It was not necessary to optimize probe concentrations. 
Figure 5.1 
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ii) Optimisation of starting RNA quantity 
The mean Ct value for each triplicate reaction, using varying quantities of starting 
RNA, was calculated and is presented graphically in figure 5.2. The reaction did not 
progress with a starting RNA quantity of 0.001ng, as its mean Ct value of 39.38, was 
similar to that of the two no template controls (NTC), which contained no cDNA (39.56 
and 39.53). At 0.1, 10 and 100ng of RNA the reaction did proceed with the latter having 
the lowest mean Ct (27.88). However, in order to conserve the scarce patient mRNA, we 
decided that 10ng of starting RNA (mean Ct 30.72) was sufficient for use in future 
experiments as the reaction proceeded efficiently with this starting quantity. 
Figure 5.2: Optimisation of starting RNA quantity. The mean Ct +/- SD is shown for 
each reaction. The target gene does not amplify with a starting RNA quantity of 0.001ng, 
as its mean Ct of 39.38 is similar to that of the two no template controls (NTC – Cts 
39.56 and 39.53). At a starting RNA concentration of 10ng, the reaction proceeds 
satisfactorily (mean Ct 30.72). 
FIGURE 5: OPTIMISATION OF RNA CONCENTRATION
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Figure 5.2 
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iii) Relative efficiency plot 
As mentioned earlier (in chapter 2) the comparative Ct method (2-∆∆Ct) can only 
be used if the amplification efficiencies of the target (CXCR4) and endogenous control 
(β-actin) are approximately equal. Therefore ∆Ct (where ∆Ct = Ct CXCR4 – Ct β-actin) 
must be plotted against varying total RNA levels of both genes to ensure that it stays 
constant across this range. If the ∆Ct remains constant, the slope of the graph, ∆Ct vs log 
total RNA, will be <0.1 (i.e. close to zero) and thus reflect similar amplification 
efficiencies. Figure 5.3 demonstrates that the slope of the line was -0.0976 (close to zero) 
and this consequently suggested similar amplification efficiencies of both genes (CXCR4 
and β-actin) between total RNA quantities of 9.375ng and 120ng and therefore the 
comparative Ct method could be used. 
 
 
 
 
 
 
 
 
Figure 5.3: 
Relative amplification efficiency scatter plot.  
The ∆Ct (where ∆Ct = Ct CXCR4 – Ct β-actin) is plotted against log total RNA (ng) in 
the reaction. The mean ∆Ct is shown for each reaction. The best fit straight line is shown 
(as calculated by the Excel programme). As the slope of the line is close to zero  
(-0.0976), it suggests similar amplification efficiencies of both genes (CXCR4 and β-
actin) between total RNA quantities of 9.375ng and 120ng and thus the comparative Ct 
method can be used. 
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FIGURE 6: CXCR4 / b-ACTIN RELATIVE EFFICIENCY PLOT
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b) Background to analysis of final results 
For CXCR4 mRNA expression analysis, the baseline was manually adjusted on 
the amplification plots between 3 – 22, when analysing all results. The threshold was 
manually adjusted to 0.02. 
For β-actin mRNA expression analysis the baseline was manually adjusted on the 
amplification plots between 3 – 16. The threshold was manually adjusted to 0.03. 
Figure 5.3 
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It should be noted that patient samples were randomly numbered 1-18 and we 
were blinded as to which samples were benign/ malignant until analysis of relative gene 
expression was completed.  
CXCR4 mRNA expression was normalised in each cell line and patient sample to 
β-actin expression (i.e. ∆Ct calculated, where ∆Ct = mean sample Ct CXCR4 minus 
mean sample Ct β-actin). Following this 1542 CPT3X was used as the calibrator and 
∆∆Ct calculated where ∆∆Ct = ∆Ct sample minus ∆Ct 1542 CPT3X. Finally ∆∆Ct 
values were used in the equation 2-∆∆Ct to give expression levels of normalised CXCR4 
for each sample relative to 1542 CPT3X (see tables 5.2a – c in final results section). 
PRE 2.8 and MDA-MB-231 cell lines were not used as the calibrator samples as 
they showed no detectable CXCR4 mRNA expression as the mean CXCR4 Ct for both 
was 40, or more, which suggested no (CXCR4) cDNA amplification (it should be noted 
that cDNA was present in each of these two cell lines as there was satisfactory β-actin 
amplification – see table 5.2a in results section).   
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c) Final results 
Table 5.2a demonstrates the results and calculation of relative quantitation, using 
the comparative threshold (2-∆∆Ct) method, for one experiment consisting of three samples 
for each cell line. 
The final results, for three separate experiments, are tabulated in tables 5.2b and 
5.2c and presented in graphical form in figures 5.4a and b. 
 
Table 5.2a 
This demonstrates calculation of relative quantitation, using the comparative threshold  
(2-∆∆Ct) method, for one experiment consisting of three samples for each cell line. 
CXCR4 mRNA expression for each individual cell line, relative to CXCR4 mRNA 
expression in the cell line 1542 CPT3X, is shown with standard deviation. 1542 CPT3X 
was used as the calibrator as it had the lowest detectable expression of CXCR4 mRNA. 
Pre 2.8 and MDA-MB-231 had no detectable CXCR4 expression as the mean CXCR4 Ct 
for each was 40 cycles (or more), which suggests no cDNA amplification (it should be 
noted that cDNA was present in each of these two cell lines as there was satisfactory β-
actin amplification) Human leucocytes were used as a positive control. Each experiment 
was repeated in triplicate (i.e. twice more – table 5.2b). The second decimal place of all 
results is shown. 
 
*∆Ct = mean Ct CXCR4 (target gene) – mean Ct β-actin (housekeeping gene). The 
standard deviation of the difference is calculated using  
 
the formula:     s =       (s1)2 + (s2)2      
where s is the new standard deviation,  
s1 is the standard deviation of β-actin expression,  
s2 is the standard deviation of CXCR4 expression. 
 
**∆∆Ct = ∆Ct sample – ∆Ct calibrator (i.e. 1542CPT3X). The normalised amount of 
target gene, CXCR4, is a unitless number that can be used to compare the relative amount 
of target in different samples. This sample with the lowest detectable expression of 
CXCR4 was chosen as the calibrator; 1542 CPT3X in our experiments. As this is 
subtraction of an arbitrary constant, the standard deviation of ∆∆Ct is the same as the 
standard deviation of the ∆Ct value. 
 
***2-∆∆Ct This final equation represents the normalised expression of CXCR4 (target 
gene) in the unknown sample, relative to the normalised expression of the calibrator 
sample (1542 CPT3X). 
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Table 5.2a 
 
 
β-actin Ct 
 
 
CXCR4 Ct 
 
 
Cell line 
 
Sample 
1 
Sample 
2 
Sample 
3 
Mean  
β-
actin 
Ct 
Sample 
1 
Sample 
2 
Sample 
3 
Mean   
CXCR4 
Ct 
 
*∆Ct 
 
 
**∆∆Ct 
 
 
***2-∆∆Ct 
LNCaP 
 
20.87 21.13 21.18 21.06 
+/-0.16 
31.28 31.34 31.36 31.32 
+/- 0.04 
10.26 
+/-0.17 
 
-8.25 
+/-0.17 
 
305.14 
(270.92-343.67) 
DU145 
 
19.61 19.69 19.54 19.61 
+/-0.07 
28.22 28.19 28.06 28.15 
+/-0.08 
8.54 
+/-0.11 
 
-9.97 
+/-0.11 
 
1007.57 
(931.38-
1089.98) 
PC3 19.1 19.02 18.81 18.97 
+/-0.14 
 
32.92 33.42 33.11 33.15 
+/-0.25 
14.17 
+/-0.29 
 
-4.34 
+/-0.29 
 
20.34 
(16.60-24.93) 
1542 
CPT3X 
 
19.28 19.17 19.31 19.25 
+/- 0.07 
37.1 37.89 38.33 37.77 
+/-0.62 
18.52 
 
0 1 
1542 NPTX 
 
19.14 19.37 19.42 19.31 
+/- 0.14 
36.77 36.19 37.02 36.66 
+/-0.42 
17.35 
+/-0.45 
 
-1.17 
+/-0.45 
 
2.25 
(1.64-3.07) 
Pre 2.8 20.02 20.17 20.12 20.10 
+/- 0.07 
40 40 40 40 
+/-0 
N/A N/A 0 
S2.13 
 
17.87 18.06 17.99 17.97 
+/-0.09 
31.7 31.87 31.91 31.82 
+/-0.11 
13.85 
+/-0.14 
 
-4.66 
+/-0.14 
 
25.39 
(22.93-28.12) 
Blood 
leucocytes 
18.44 18.4 18.18 18.34 
+/-0.14 
23.52 23.48 23.88 23.62 
+/-0.22 
5.28 
+/-0.26 
 
-13.23 
+/-0.26 
 
9630.08 
(8036.26-
11540.01) 
MDA-MB-
231 
 
18.33 18.62 18.4 18.45 
+/-0.15 
40 40 40 40 
+/-0 
N/A N/A 0 
1
8
3
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Table 5.2b: 
This shows mean relative CXCR4 mRNA expression in cell lines (with standard 
deviation) for the three samples run in experiments 1, 2 and 3. The overall mean relative 
CXCR4 expression and standard deviation were calculated. This same data is also 
presented graphically in figure 5.4a. 
 
 
Cell line 
 
First  
experiment:  
relative CXCR4  
expression 
Second  
experiment:  
relative CXCR4  
expression 
Third  
experiment:  
relative CXCR4  
expression 
Overall  
mean  
relative CXCR4  
expression 
 
LNCaP 
 
408.25 
(385.20-432.69) 
 
507.28 
(387.80-663.58) 
 
305.14 
(270.92-343.67) 
 
406.89 
(347.97- 499.98) 
 
DU145 1165.44 
(1008.35-1347.01) 
1686.71 
(1427.66-1992.76) 
1007.57 
(931.38-1089.98) 
1286.57 
(1122.46 – 1476.58) 
PC3 15.56 
(11.69-20.71) 
26.84 
(22.53-31.97) 
20.34 
(16.60-24.93) 
20.91 
(16.94 – 25.87) 
1542 CPT3X 1 1 1 1 
1542 NPTX 1.67 
(1.28-2.17) 
2.13 
(1.46-3.11) 
2.25 
(1.64-3.07) 
2.01 
(1.46 – 2.78) 
Pre 2.8 
 
not 
detected 
not  
detected 
not 
detected 
not 
detected 
S2.13 32.97 
(28.24-38.49) 
37.44 
(30.29-46.27) 
25.39 
(22.93-28.12) 
31.93 
(27.15 – 37.63) 
Blood leucocytes 11558.5 
(10483.52-12743.71) 
14868.79 
(12891.1-17149.9) 
9630.08 
(8036.26-11540.01) 
12019.13 
(10470.29 – 
13811.21) 
MDA-MB-231 not 
detected 
not  
detected 
not  
detected 
not  
detected 
 
 
 
 
 
 
 
Table 5.2c 
Represented here are the results of the mean relative CXCR4 mRNA expression for the 
laser microdissected patient samples, numbered 1 to 18 (refer to chapter 3, table 3.6). 
*Samples derived from primary prostate tumour cells (clinically localized neoplasms); 
the remaining were from benign prostatic tissue (samples were provided by H. Klocker at 
the University of Innsbruck, Austria). Histological details of these prostate specimens and 
patient staging are shown in chapter 3, table 3.6. Calculations were performed in the same 
way as for table 5.2a. In order to conserve patient RNA for further experiments, only 3 
reactions were run in only one experiment for each of the 18 prostate samples. We were 
not aware as to the derivation of each sample during experiments (i.e. as to which sample 
was derived from benign or malignant prostate tissue). This same data is also presented 
graphically in figure 5.4
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Table 5.2c 
 
β-actin Ct 
 
 
CXCR4 Ct 
 
 
Patient 
sample 
 
Sample 1 Sample 
2 
Sample 
3 
Mean  
β-actin 
Ct Sample 
1 
Sample 
2 
Sample 3 
Mean   
CXCR4 
Ct 
 
∆Ct 
 
 
∆∆Ct 
 
 
2-∆∆Ct 
*1 
22.9 22.78 23.41 
23.03+/-
0.33 29.87 29.44 29.81 29.70+/-0.23 
6.67+/-
0.40 
-11.84+/-
0.40 
3674.50  
(2770.13-4874.12) 
2 
21.24 21.2 21.27 
21.23+/-
0.03 29.66 29.4 29.87 29.64+/-0.23 
8.40+/-
0.23 
-10.11+/-
0.23 
1107.68 
(939.19-1306.4) 
*3 
24.02 24.06 24.02 
24.03+/-
0.02 32.69 33.31 32.86 32.95+/-0.32 
8.92+/-
0.32 
-9.6+/- 
0.32 
776.04 
(621.15-969.56) 
4 
24.61 24.57 24.49 
24.55+/-
0.06 33.1 33.2 32.86 33.05+/-0.17 
8.49+/-
0.18 
-10.02+/-
0.18 
1040.69 
(915.37-1183.17) 
*5 
24.08 23.8 23.94 
23.94+/-
0.14 31.03 31.01 30.16 30.73+/-0.49 
6.79+/-
0.51 
-11.72+/-
0.51 
3389.05 
(2370.028-4846.22) 
6 
24.14 24.08 24.01 
24.07+/-
0.06 30.12 30.29 30.42 30.27+/-0.15 
6.2+/-
0.16 
-12.32+/-
0.16 
5113.16 
(4564.02-5728.37) 
*7 
21.9 22.09 21.76 
21.91+/- 
0.16 28.89 29.03 29.33 29.08+/-0.22 
7.16+/-
0.27 
-11.35+/-
0.27 
2616.33 
(2155.95-3175.03) 
8 
22.37 22.36 22.45 
22.39+/-
0.04 29.54 29.43 29.67 29.54+/-0.12 
7.15+/-
0.12 
-11.36+/-
0.12 
2640.63 
(2413.30-2889.36) 
*9 
24.2 24.43 24.36 
24.33+/-
0.11 29.61 29.43 29.51 29.51+/-0.90 
5.18+/-
0.14 
-13.33+/-
0.14 
10321.27 
(9312.14-11439.76) 
10 26.08 25.93 25.89 
25.96+/-
0.10 33.08 32.75 33.14 32.99+/-0.21 
7.02+/-
0.23 
-11.49+/-
0.23 
2889.62 
(2459.24-3395.32) 
*11 23.65 23.68 23.52 
23.61+/-
0.08 29.75 29.45 29.51 29.57+/-0.15 
5.95+/-
0.18 
-12.56+/-
0.18 
6066.57 
(5354.64-6873.16) 
12 22.57 22.75 22.35 
22.55+/-
0.20 28.09 28.26 28.17 28.17+/-0.08 
5.61+/-
0.21 
-12.90+/-
0.21 
7661.08 
(6588.3-8908.53) 
13 26.47 26.58 26.47 
26.50+/-
0.06 34.45 34.05 34.46 34.32+/-0.23 
7.81+/-
0.24 
-10.70+/-
0.24 
1671.19 
(1412.77-1976.88) 
*14 21.85 22 21.62 
21.82+/-
0.19 27.8 27.89 27.64 27.77+/-0.12 
5.95+/-
0.22 
-12.56+/-
0.22 
6066.57 
(5174.39-7112.58) 
15 23.21 22.93 23.29 
23.14+/-
0.18 29.47 29.5 29.68 29.55+/-0.11 
6.40+/-
0.22 
-12.11+/-
0.22 
4430.74 
(3802.68-5162.53) 
*16  
 24.03 24.03 24.1 
24.05+/-
0.04 31.19 31.18 31.13 31.16+/-0.03 
7.11+/-
0.05 
-11.40+/-
0.05 
2714.86 
(2619.41-2813.80) 
*17 22.87 22.76 22.76 
22.79+/-
0.63 30.03 29.9 30.68 30.20+/-0.41 
7.40+/-
0.42 
-11.11+/-
0.42 
2215.37 
(1652.73-2969.53) 
18 21.13 21.3 21.26 
21.23+/-
0.08 27.72 27.53 27.58 27.61+/-0.09 
6.38+/-
0.13 
-12.14+/-
0.13 
4513.40 
(4116.87-4948.12) 
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Figure 5.4a and b: 
The graphs show relative CXCR4 mRNA expression in prostate cell lines and patient 
samples using real-time (Taqman) quantitative RT-PCR. These figures are the graphical 
representation of the data from table 5.2b and table 5.2c. CXCR4 mRNA expression for 
each sample, including patient samples, are shown relative to 1542 CPT3X (as this cell 
line had the lowest detectable expression of CXCR4 mRNA). Human leucocytes were 
used as a positive control. DU145, LNCaP and PC3 had 1287, 407 and 21 times CXCR4 
mRNA levels respectively, relative to 1542 CPT3X. The cell line 1542 NPTX, derived 
from normal prostate epithelial cells, had similar CXCR4 mRNA expression to that of 
1542 CPT3X (the former having only twice the quantity) and results for Pre 2.8 are not 
shown as these cells had undetectable levels of receptor mRNA (similar to MDA-MB-
231). 
 
In the laser microdissected patient clinically localized primary tumour samples and 
patient benign tissue specimens mean relative CXCR4 mRNA expression for tumours 
was 4205 (range 776 – 10,321); mean relative expression for benign samples was 3542 
(range 1040 – 7661). Thus expression in both these two groups was significantly greater 
than that of the primary prostate cancer cell line 1542 CPT3X. 
 
FIGURE 7a: Real time quantitative (Taqman) PCR for prostate cell lines 
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FIGURE 7b: Real time quantitative (Taqman) PCR for laser microdissected  patient samples 
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 It can be seen from figure 5.4a that highest relative mRNA CXCR4 expression is 
seen in the positive control sample derived from blood leucocytes (12,019 times that of 
1542 CPT3X). Also from figure 5.4a (and table 5.2b) it is obvious that there is great 
variation in CXCR4 mRNA expression with the metastatic cell lines DU145, LNCaP and 
PC3 having approximately 1287, 407 and 21 times CXCR4 mRNA respectively, relative 
to the primary prostate tumour cell line 1542 CPT3X. Additionally, Pre 2.8 had no 
Figure 5.4b 
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detectable CXCR4 expression and 1542 NPTX had a mean relative expression 
approximately twice that of the 1542 CPT3X. Thus these two cell lines derived from 
normal prostate epithelial cells, have very little CXCR4 mRNA expression in comparison 
to all 3 metastatic cell lines but particularly in comparison to DU145 and LNCaP.  
In the laser microdissected clinically localized patient primary tumour samples, 
CXCR4 mRNA expression (mean relative expression for primary tumours was 4205) was 
higher than that of the metastatic cell lines, DU145, LNCaP and PC3 (mean relative 
expression 1287, 407 and 21 respectively), and thus significantly greater than that of the 
primary prostate cancer derived cell line 1542 CPT3X (figure 5.4b).  
Benign patient prostate epithelial tissue samples demonstrated similar CXCR4 
mRNA levels to the primary tumour samples (mean relative expression 3542 in benign 
samples). Using the unpaired Student’s t test there was no significant difference in 
CXCR4 gene expression between patient primary prostate tumour samples and benign 
prostate tissue. 
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SECTION 5.3 
DISCUSSION 
Real time quantitative PCR had been used to quantitate CXCR4 mRNA 
expression in cell lines and patient samples. The results were calculated for all samples 
(cell lines and human tissue) relative to 1542 CPT3X (the calibrator) as this had the 
lowest detectable level of CXCR4 mRNA expression. It was demonstrated that the 3 
metastatic cell lines had significantly greater CXCR4 mRNA expression in comparison to 
the cells derived from primary tumour (1542 CPT3X) and those of normal prostate 
epithelial origin. DU145 cells particularly had relatively high levels in comparison even 
to LNCaP and PC3 (1287, 407 and 21 times respectively that of the calibrator). This large 
difference in expression between DU145 and LNCaP had not been apparent on visual 
inspection when using conventional PCR, as both appeared to have comparable band 
densities on the agarose gel (refer to chapter 4). However, other results from conventional 
PCR were confirmed as Pre 2.8 and MDA-MB-231 had no detectable CXCR4 mRNA 
expression and 1542 NPTX and 1542 CPT3X had similar levels (the former only twice 
that of the latter; both were described as having very low levels on agarose gel 
electrophoresis). From these cell line results, which confirmed our previous observations 
using conventional RT-PCR, we could hypothesise that CXCR4 mRNA expression may 
be related to metastasis of prostate cancer.  
Interestingly, laser microdissected clinically localised primary prostate tumour 
samples (mean relative CXCR4 mRNA expression 4205) and benign prostate epithelial 
tissue (mean relative CXCR4 mRNA expression 3542) from patients both had CXCR4 
mRNA levels much higher than that of DU145 (the cell line expressing the highest levels 
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of CXCR4 mRNA). Certainly, 1542 CPT3X cells (derived from a primary prostate 
malignancy) were not representative of primary prostate tumours in vivo as regards 
quantity of CXCR4 receptor mRNA.  Statistically (using the unpaired Student’s t test) 
there was no significant difference in CXCR4 gene expression between patient primary 
prostate tumour samples and benign prostate tissue.  However, Sun YX et al 2003, have 
suggested that post-transcriptional modification of the CXCR4 receptor plays a major 
role in regulating protein expression; in fact this group observed that CXCR4 mRNA 
levels were highest in human BPH tissue but actual protein levels were highest in 
metastatic prostate tissue (see chapter 8). Therefore in our patient samples, although 
CXCR4 mRNA levels are high in primary tumour samples and in patient benign tissue 
specimens, protein expression may be much lower. 
Alternatively, if high CXCR4 mRNA levels are translated into high protein 
expression in clinically localized patient primary tumours, this may be the result of a 
survival benefit in primary cancer cells expressing this receptor in vivo, and these 
tumours may be more aggressive and likely to metastasise. Mochizuki H et al 2004 have 
noted in human prostate tissue that positive expression of CXCR4 protein was an 
independent and superior predictor for bone metastasis to Gleason sum and Darash-
Yahana M et al 2004 demonstrated that high levels of CXCR4 induced a more aggressive 
phenotype in prostate cancer cells in vivo. Additionally, in vivo CXCR4 expression may 
promote proliferation and neoangiogenesis in primary tumours leading to rapid local 
growth. Related to this is the finding that subcutaneously injected prostate cancer cells 
transfected with CXCR4 grew larger tumours with increased muscle invasion compared 
with parental cells [Darash-Yahana M et al 2004]. Unfortunately, we were unable to 
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obtain follow-up details (from Austria) of these patients with primary tumours to 
investigate whether they relapsed locally or systemically. It is possible that in vivo 
metastatic cells may express CXCR4 mRNA at even higher levels than primary tumour 
but we were not able to obtain fresh prostate metastatic tissue from patients, which could 
be laser microdissected and analysed. 
It should, however, be noted that although mRNA levels are high and 
subsequently the majority of this translated into protein, actual protein levels may still be 
low due to regulation of cellular protein. As regards CXCR4, it has been demonstrated 
that this receptor undergoes significant spontaneous endocytosis and that recycling of 
internalized receptors is not efficient [Tarasova NI et al 1998]. Therefore in the patient 
samples, or the cell lines derived from metastases, levels of functional protein may be 
depleted.  
It is also possible, although less likely, that primary prostate cancer and/ or benign 
prostate tissue samples had high CXCR4 mRNA expression because these samples may 
have contained stromal or other non-cancerous contaminating tissue. Stromal cells are 
known both in vitro (S2.13 mean relative CXCR4 mRNA expression was 31.93) and in 
vivo to express high levels of this chemokine receptor [Bourcier T et al 2003, Hosokawa 
Y et al 2005, Puxeddu I et al 2006].   
Consequently, having established CXCR4 mRNA levels, our next goal was to 
elucidate protein expression of this chemokine receptor.  
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CHAPTER 6 
 
 
 
 
ELUCIDATION OF CELL 
MEMBRANE CXCR4 CHEMOKINE 
RECEPTOR (PROTEIN) EXPRESSION 
IN PROSTATE CELL LINES  
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SECTION 6.1 
INTRODUCTION AND AIMS 
Using conventional RT – PCR followed by real time quantitative PCR, we had 
established that CXCR4 mRNA expression was particularly high in metastatic prostate 
cell lines DU145, LNCaP and PC3 and significantly lower in those cell lines derived 
from primary prostate tumour (1542 CPT3X) and normal prostate epithelium (1542 
NPTX and Pre 2.8).  
However, mRNA expression is a useful but not a consistently reliable predictor of 
cellular protein levels. For example, transcript and protein concordance in LNCaP has 
been reported to vary from 32% [Waghray A et al 2001] to 83% [Lin B et al 2005]. There 
can be several reasons for the poor correlation between the level of mRNA and the level 
of protein, and these may not be mutually exclusive. First, there are many complicated 
and varied post-transcriptional mechanisms involved in turning mRNA into protein that 
are not yet sufficiently well defined to be able to compute protein concentrations from 
mRNA; second, regulation may actually occur at the protein level eg. short in vivo 
protein half life or endocytosis of cell surface proteins with inefficient recycling of 
internalized receptors [latter has been reported in relation to the CXCR4 receptor by 
Tarasova NI et al 1998]; and/or third, there may be a significant amount of error and 
noise in both protein and mRNA experiments that limit our ability to get a clear picture. 
Levels of protein expression in cells may be established by using various methods 
including immunohistochemistry, Western blotting or flow cytometry. However, using 
flow cytometry, one can obtain accurate data for individual cells. Also, the technique has 
the ability to identify distinct cell populations as defined by their size and granularity, the 
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capacity to gate out dead cells and additionally one can definitively localize the position 
of a protein to the cell surface. 
Therefore our aim in this section was to quantitate CXCR4 protein expression in 
each individual cell line and simultaneously confirm that the CXCR4 receptor was 
expressed on the cell membrane. We achieved these aims by using flow cytometry. 
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SECTION 6.2 
RESULTS 
Note that in all experiments a total of 10,000 events were analysed in each sample 
with data due to dead cells/cell debris and non-specific binding being gated out of the 
results only when appropriate. All experiments were repeated in triplicate in order to 
confirm the results and representative histograms and dot plots are shown. 
 
 
a) Optimisation of conditions 
 
1) Optimisation of cell dissociation  
On performing flow cytometry analysis, enzymatic digestion of adherent cells in 
culture with trypsin presumably resulted in damage to the epitope on the CXCR4 receptor 
as no binding of primary antibody occurred when trypsin based cell dissociation solution 
was used. Therefore non-enzymatic cell dissociation solution (Sigma) was used for cell 
preparation in all experiments. 
 
2) Optimisation of primary antibody isotype 
Anti-CXCR4 primary antibodies initially used for flow cytometry analysis, using 
the DU145 cell line, were poorly reactive for cell membrane CXCR4 receptor detection. 
In total five primary antibodies were used (see chapter 3, table 3.7a). The results of 
differential antibody binding (using DU145 cells), using each of these five different 
primary anti-CXCR4 antibodies, are summarized in table 6.1 with graphical 
representation, via histograms and dot plots, in figures 6.1a - e.  
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The increase in the geometric mean fluorescent intensity (GMFI - also known as 
the geometric mean channel fluorescence), demonstrated on the histograms, is given for 
each primary antibody in table 6.1. This was derived by: 
GMFI with primary anti-CXCR4 antibody minus GMFI in negative control (latter 
without primary anti-CXCR4 antibody i.e. experiment contains only secondary antibody). 
(It should be noted that with log-amplified data the geometric mean is better suited for 
use, rather than the arithmetic mean, as it takes into account the weighting of the data 
distribution and is a good indicator of the central tendency of the population). 
Additionally the percentage of DU145 cells showing CXCR4 receptor positivity, 
detected by each antibody, was calculated using the dot plots by:  
% of cells in right upper quadrant using primary anti-CXCR4 antibody minus % of cells 
in right upper quadrant in negative control (latter without primary anti-CXCR4 antibody 
i.e. experiment contains only secondary antibody; these are cells remaining in the right 
upper quadrant after subjective insertion of the quadrant gates). 
Both of the above calculations are each individually derived from either the 
histogram or dot plots. The increase in GMFI was a more accurate method of analysing 
our data (dot plots are a better method for visualizing subpopulations within a specimen).  
It can be seen that mouse IgG2b monoclonal antibody clone 44717.111 (R&D 
Systems) recognized a much greater proportion of cell surface CXCR4 (figures 6.1a - e 
and table 6.1) than any of the other primary antibodies used, and thus demonstrated 
greater specificity for binding the CXCR4 receptor. This monoclonal antibody was 
therefore used in all further experiments for CXCR4 receptor detection in prostate cell 
lines.  
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Table 6.1: The results of differential primary antibody binding to the cell membrane 
CXCR4 receptor in the DU145 cell line using each of five different primary anti-CXCR4 
antibodies. The results are derived from figures 6.1a - e. The increase in geometric mean 
fluorescent intensity (geometric mean channel fluorescence) is relative to the negative 
control. It can be seen that mouse IgG2b monoclonal antibody clone 44717.111 (R&D 
Systems) bound to a much greater proportion of cell surface CXCR4. 
 
Antibody 
Increase in geometric mean 
fluorescent intensity 
(channels) 
% of cells demonstrating 
CXCR4 receptor positivity 
Rabbit IgG clone H-118 
(Fusin) 
15.48 13.16 
Mouse IgG2a, κ, clone 
12G5 
5.87 20.09 
Mouse IgG2a clone 
44708.111 
59.29 60.15 
Mouse IgG2b clone 
44716.111  
32.47 50.44 
Mouse IgG2b clone 
44717.111  
204.56 77.61 
 
 
Figures 6.1a – e 
The data from this figure is summarized in table 6.1. 
This figure shows representative flow cytometry histograms and dot plots for the results 
of differential primary anti-CXCR4 antibody binding to DU145 cells using five different 
primary antibodies. A total of 10,000 cells were analysed in each sample and no cells 
were gated out of these results.  
On both the histograms and dot plots the x-axis shows fluorescence intensity (channel 
number) on 1024 channels encompassing 4-log decades (i.e. logarithmic scale).  
On the histograms the y-axis shows cell counts in each channel, whereas on the dot plots, 
the y-axis shows side scatter intensity - SSC (channel number) on a linear scale.  
Quadrant gates were set on the dot plots using the background levels of fluorescence of 
either the respective unstained negative control (contains only the fluorochrome-
conjugated secondary antibody without the primary antibody – figures 6.1a, c, d, e) or 
fluorochrome isotype matched control population of cells (when a fluorochrome-
conjugated primary antibody is used – figure 6.1b). Cells in the right upper quadrant were 
taken as positive for CXCR4 receptor expression (the percentage of cells in the right 
upper quadrant in the negative control samples was subtracted out of the final results). 
GMFI refers to geometric mean fluorescent intensity (geometric mean channel 
fluorescence). 
 
 
Figure 6.1a: Results of flow cytometry using primary anti-CXCR4 antibody IgG clone H-118 (Fusin)
Negative Control – contains secondary antibody only
Contains primary and secondary antibody
Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
15.48
% of cells demonstrating CXCR4 receptor positivity
13.16
1
9
8
Figure 6.1b: Results of flow cytometry using primary anti-CXCR4 antibody IgG2a, κ, clone 12G5
Negative Control – contains non-reactive 
PE-conjugated isotype control antibody 
Contains PE conjugated primary anti-CXCR4 antibody
Histogram Dot plot - contains non-reactive
PE-conjugated isotype control antibody
Dot plot - contains PE-conjugated 
primary anti-CXCR4 antibody
Increase in GMFI (channels)
5.87
% of cells demonstrating CXCR4 receptor positivity
20.09
1
9
9
Figure 6.1c: Results of flow cytometry using primary anti-CXCR4 antibody IgG2a clone 44708.111
Negative Control – contains secondary antibody only
Contains primary and secondary antibody
Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
59.29
% of cells demonstrating CXCR4 receptor positivity
60.15
2
0
0
Figure 6.1d: Results of flow cytometry using primary anti-CXCR4 antibody IgG2b clone 44716.111
Negative Control – contains secondary antibody only
Contains primary and secondary antibody
Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
32.47
% of cells demonstrating CXCR4 receptor positivity
50.44
2
0
1
Figure 6.1e: Results of flow cytometry using primary anti-CXCR4 antibody IgG2b clone 44717.111
Negative Control – contains secondary antibody only
Contains primary and secondary antibody
Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
204.56
% of cells demonstrating CXCR4 receptor positivity
77.61
20
2
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3) Non–specific binding of secondary antibody   
As the primary antibody of choice in obtaining the final results was mouse IgG2b 
monoclonal antibody clone 44717.111 (R&D Systems) the appropriate secondary 
antibody for use was FITC-conjugated anti-mouse IgG2b (γ2b chain specific) 
(SouthernBiotech) (see chapter 3, table 3.7b). However, non-specific binding of this 
secondary antibody needed to be eliminated or optimised.  
Figure 6.2a shows DU145 cell autofluorescence when no fluorescent tag is added 
to the cells. This autofluorescence comes from normal cell components which fluoresce, 
such as riboflavin and flavoproteins.  In the negative control sample (figure 6.2b), when 
only FITC-conjugated secondary antibody, anti-mouse IgG2b γ2b chain specific, 
SouthernBiotech (see chapter 3, table 3.7b), 1/50 dilution is added to the cells, non-
specific binding of the secondary antibody is seen which is maintained when the primary 
anti-CXCR4 antibody (IgG2b clone 44717.111 - R&D Systems) is present (figure 6.2c). 
We attempted to decrease this non-specific cell binding by dilution of the secondary 
antibody to 1/100. Unfortunately this was unsuccessful and non-specific binding still 
persisted (figure 6.2d). Non-specific binding can also be due to Fc mediated binding, but 
it was established that FITC-labelled secondary F(ab’)2 anti-mouse IgG2b fragments (γ2b 
chain specific) (SouthernBiotech) did not bind to the primary antibody  as shown in 
figure 6.2e (also refer to discussion at the end of this chapter).  Thus on final analysis of 
the data this non-specific cell binding of the secondary antibody was gated out of the 
results (and 1/50 dilution of anti-mouse IgG2b (γ2b chain specific) secondary antibody 
was used in further experiments).  
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4) Optimisation of primary antibody dilution  
Dilution of primary antibody resulted in markedly decreased binding to its 
epitope. Thus it was necessary to incubate cells in 20µl of the undiluted primary anti-
CXCR4 antibody (mouse IgG2b monoclonal antibody clone 44717.111) stock solution. 
This, in combination with using non-enzymatic cell dissociation solution for cell 
preparation, did lead to some clumping of cells, which had to be accepted in order to 
achieve optimal primary antibody binding.  
 
 
 
 
 
 
 
 
 
 
 
 
Figures 6.2a - e 
Dot plots demonstrating autofluorescence and non-specific binding of secondary 
antibody.  
The x-axis shows fluorescence intensity (channel number) on 1024 channels 
encompassing 4-log decades (i.e. logarithmic scale). The y-axis shows side scatter 
intensity (channel number) on a linear scale.  
The primary antibody used was mouse IgG2b clone 44717.111 and the secondary 
antibodies used were FITC-conjugated anti-mouse IgG2b (γ2b chain specific) 
(SouthernBiotech) or FITC-conjugated anti-mouse IgG F(ab’)2 (γ2b chain specific) 
(SouthernBiotech). 
Areas bound by red border represent non-specific secondary antibody binding. 
 
 
 
 
 
Figure 6.2: a) Autofluorescence – no 
primary or secondary antibody
c) anti-CXCR4 primary antibody and 
1/100 dilution secondary antibody
b) No primary and 1/50 dilution of 
secondary antibody
c) anti-CXCR4 primary antibody and 
1/50 dilution secondary antibody
e) Anti-CXCR4 primary antibody and 
F(ab’)2 fragments secondary antibody
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b) Final results 
 
Representative flow cytometry results for CXCR4 receptor expression in cell lines 
are shown in figure 6.3 and summarized in table 6.2 [using undiluted anti-CXCR4 
primary mouse IgG2b monoclonal antibody clone 44717.111 (R&D Systems) together 
with 1/50 dilution of FITC labeled anti-mouse IgG2b (γ2b chain specific) 
(SouthernBiotech) secondary antibody].  
 
Table 6.2: This summarises the results data from figure 6.3 and shows the results from 
one experiment elucidating cell membrane CXCR4 receptor expression in cell lines. 
 
 
DU145 LNCaP 
Cell Population 
      1                   2 
PC3 1542-
CPT3X 
1542-
NPTX 
Pre 
2.8 
S2.13 MDA-
MB-231 
Increase in 
GMFI (channels) 
166.48 11.66 214.98 99.27 8.07 10.1 3.71 51.7 11.58 
% of cells 
demonstrating 
CXCR4 receptor 
positivity 
87.44 34.28 64.83 71.99 26.47 32.52 21.68 88.52 26.17 
 
 
 
 
Figures 6.3a – h: 
Representative flow cytometry histograms and dot plots are shown for cell membrane 
CXCR4 receptor expression in each cell line. A total of 10,000 events were analysed in 
each sample, with data due to dead cells/cell debris and non-specific binding of the 
secondary antibody being gated out of the final results when appropriate (note that it is 
not possible to completely gate out this data). The histogram and dot plot axes are 
labelled in the same manner as described in the legend to figure 6.1a - e. 
The results, from this figure, for all cell lines are summarized in table 6.2. 
Note that undiluted anti-CXCR4 primary mouse IgG2b monoclonal antibody clone 
44717.111 (R & D Systems) together with 1/50 dilution of FITC labelled anti-mouse 
IgG2b (γ2b chain specific) (SouthernBiotech) secondary antibody was used in all 
experiments. 
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Figure 6.3a: Results of flow cytometry for DU145
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Figure 6.3b: Results of flow cytometry for LNCaP
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Figure 6.3c: Results of flow cytometry for PC3
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Dot plot -
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% of cells demonstrating CXCR4 receptor positivity
26.47
Figure 6.3d: Results of flow cytometry for 1542 CPT3X
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Figure 6.3e: Results of flow cytometry for 1542 NPTX
2
1
1
Negative Control – contains secondary antibody only
Contains primary and secondary antibody
Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
3.71
% of cells demonstrating CXCR4 receptor positivity
21.68
Figure 6.3f: Results of flow cytometry for Pre 2.8
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Histogram Dot plot - negative control 
– contains secondary
antibody only
Dot plot -
contains primary and 
secondary antibody
Increase in GMFI (channels)
51.7
% of cells demonstrating CXCR4 receptor positivity
88.52
Figure 6.3g: Results of flow cytometry for S2.13
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Figure 6.3h: Results of flow cytometry for MDA-MB-231
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In scrutinizing the results, the increase in GMFI detailed in the histograms was a 
more accurate method of analyzing our data as compared to calculating the percentage of 
cells exhibiting CXCR4 positivity from the dot plots. This is well demonstrated on 
reviewing the data for the LNCaP cell line (figure 6.3b). There are clearly two 
subpopulations of cells, which exhibit different concentrations of CXCR4 expression,  
and despite the fact that the first subpopulation has a small increase in the GMFI (11.66 
channels), a significant number of cells (34.28%) are, however, considered positive for 
the CXCR4 receptor as they appear in the right upper quadrant of the dot plot. 
Theoretically, a situation could arise using the dot plots where all of the cells of both 
subpopulations appear in the right upper quadrant and are therefore considered totally 
positive for CXCR4 expression (i.e. 100% of cells demonstrate receptor positivity in both 
subgroups), with the two cell clusters being distinguished in their concentration of plasma 
membrane CXCR4 receptor, only by calculating a mean GMFI for each subpopulation. 
Therefore the advantage of the histogram data is that it enables weak and strong CXCR4 
expression to be easily distinguished numerically by the increase in the mean GMFI. 
 
Three separate experiments were performed for each cell line and the overall 
mean increase in GMFI +/ - standard deviation was calculated (table 6.3). 
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Table 6.3: The overall mean GMFI +/ - standard deviation (SD) has been calculated from 
3 separate flow cytometry experiments investigating CXCR4 receptor expression in each 
cell line.   
 
 
Increase in GMFI (3 separate experiments) 
 
           1                            2                             3 
Overall mean 
increase in GMFI 
+/- SD 
DU145 166.48 176.51 190.90 177.93 +/ - 12.27 
LNCaP i)11.66 
ii) 214.98 
i) 15.04 
ii) 180.70 
i) 20.67 
ii) 190.02 
i) 15.79 +/ - 4.55 
ii) 195.23 +/ - 17.72 
PC3 99.27 93.94 97.17 96.79 +/ - 2.68 
1542 CPT3X 8.07 5.36 7.43 6.95 +/ - 1.42 
1542 NPTX 10.1 7.88 4.91 7.63 +/ - 2.60 
Pre 2.8 3.71 2.61 4.47 3.60 +/ - 0.94 
S2.13 51.7 49.61 45.30 48.87 +/ - 3.26 
MDA-MB-231 11.58 5.37 2.87 6.61 +/- 4.84 
 
 
DU145 expressed quantities of CXCR4 receptor second to that only of a subset of 
LNCaP cells (mean increase in GMFI for DU145 was 177.93 +/ - 12.27 channels). 
LNCaP cells exhibited one subpopulation with a relatively low CXCR4 concentration 
(mean increase in GMFI 15.79 +/ - 4.55 channels), and the other manifested a much 
higher quantity of the receptor (mean increase in GMFI 195.23 +/ - 17.72 channels). 
Additionally, PC3 cells demonstrated comparatively high CXCR4 protein levels (mean 
increase in GMFI 96.79 +/ - 2.68). The remaining cell lines, except the stromal derived 
cells S2.13 (mean increase in GMFI 48.87 +/ - 3.26 channels), displayed relatively low 
quantities of cell surface CXCR4 receptor (mean increase in GMFI 1542 CPT3X = 6.95 
+/ - 1.42; 1542 NPTX = 7.63 +/ - 2.60; Pre 2.8 = 3.60 +/ - 0.94; MDA-MB-231 = 6.61 +/- 
4.84). 
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SECTION 6.3 
DISCUSSION 
a) Optimisation - the results of optimisation of primary antibody isotype 
demonstrated that mouse IgG2b monoclonal antibody clone 44717.111 (R&D Systems) 
recognised a much greater proportion of cell surface CXCR4 (figures 6.1a - e and table 
6.1) in comparison to the other primary antibodies used, and thus demonstrated greater 
specificity for binding the CXCR4 receptor. CXCR4 possesses four extracellular domains 
(chapter 1 figure 1.3): an N-terminal region and three extracellular loops (ECL1, ECL2, 
and ECL3). Using a panel of monoclonal antibodies to CXCR4, Baribaud F et al 2001 
demonstrated that CXCR4 on both primary and transformed T cells as well as on primary 
B cells exhibited considerable antigeneic heterogeneity. This antigeneic heterogeneity in 
CXCR4 was the result of conformational differences most likely in CXCR4 ECL 
domains, and in particular in ECL2. The conformational antigeneic heterogeneity is 
responsible for differential antibody binding in most cell types. It is thought that the 
epitope recognized by the poorly reactive monoclonal antibodies is occluded on a 
variable portion of cell surface CXCR4 receptors. Several explanations for 
conformational differences in CXCR4 have been proposed and investigated. The CXCR4 
receptor (similar to other seven-transmembrane receptors) is subject to a number of 
factors that could alter receptor conformation. The CXCR4 receptor is glycosylated 
(contains two N-linked glycosylation sites, only one of which is used) (Berson JF et al 
1996, Chabot DJ 2000) and sulfated (Farzan M et al, 1999) and can be phosphorylated as 
well (Orsini MJ et al 1999). Heterogeneity in any of these post-translational events would 
result in structurally distinct forms of CXCR4. However, several researchers have shown 
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that these post-translational modifications have little or no effect on antibody reactivity 
(Baribaud F et al 2001, Berson JF et al 1996, Chabot DJ 20003, Farzan M et al 1999). 
Additionally, the CXCR4 receptor associates with other membrane proteins, such as CD4 
in T lymphocytes and cytosolic pertussis toxin-sensitive G proteins (Lapham CK 1996). 
Heterogeneity in CXCR4 interactions with these proteins would not be unexpected 
between cell types, resulting in conformational heterogeneity. However, Baribaud F et al 
2001 demonstrated that this may not be the case.  
Other potential possibilities for CXCR4 conformational differences include 
changes in cell membrane lipid composition (in which the receptor resides), growth 
conditions, receptor oligomerisation, or interactions with as yet unidentified molecules. 
These associations are currently being investigated.  
In our experiments, the epitopes recognized by the primary monoclonal antibodies 
in figures 6.1b, c, d, e, were composed of residues on ECL2. As discussed, it is probable 
that the determinant bound by the poorly reactive monoclonal antibodies in figures 6.1b, 
c, d, is occluded on a variable portion of the CXCR4 receptors. These monoclonal 
antibodies therefore detect only a fraction of available cell surface CXCR4 molecules 
with resultant gross underestimation of receptor density.   
The monospecificity of monoclonal antibodies can sometimes limit their 
usefulness. This is apparent particularly when changes in the structure of an epitope, eg. 
as a consequence of conformational antigeneic heterogeneity in CXCR4, markedly 
affects the binding of the monoclonal antibody. In this situation polyclonal antibodies 
may have better antigen specificity because they are heterogeneous and recognize a host 
 219 
of antigenic epitopes. Therefore, when using a polyclonal antibody, the effect of change 
on a single or small number of epitopes is less likely to be significant. 
We used a polyclonal anti-CXCR4 antibody, Fusin (H-118), but this in fact did 
not bind successfully during cell preparation for flow cytometry (figure 6.1a, table 6.1). 
The increase of GMFI when using this antibody was only 15.48. The unsuccessful 
binding of Fusin (H-118) may be explained by the fact that this polyclonal antibody is 
raised against a recombinant protein corresponding to amino acids 176 - 293 of the 
CXCR4 receptor, which actually maps partly within a transmembrane region of the 
receptor (chapter 1 figure 1.3).  
 Non specific binding of the secondary FITC-conjugated anti-mouse IgG2b (γ2b 
chain specific) antibody (SouthernBiotech) (figure 6.2), could have been due to Fc 
mediated binding.  The Fab fragment of the antibody forms the specific antigen-binding 
site, whereas the non-specific Fc domain allows the antibodies to recruit cells of the 
immune system, such as monocytes, macrophages and dendritic cells, by engaging the Fc 
receptors on these cells. However, tumour cells are also known to possess Fc receptors 
which by various mechanisms can actually result in a growth and survival advantage to 
the neoplasm (Cassard L et al 2002, Nitta T et al 1992, Ran M et al 1988, Ran M et al 
1992). This can therefore result in problematic non-specific binding of the fluorescent 
secdondary antibody during sample preparation for flow cytometry. The use of Fab or 
F(ab’)2 fragments, i.e. antibodies without their Fc ends, can sometimes help to 
significantly decrease or alleviate this difficulty. In our experiments the use of FITC-
labelled secondary F(ab’)2 anti-mouse IgG2b fragments (SouthernBiotech) was 
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unsuccessful as this antibody did not in fact did not bind successfully to the primary 
antibody (figure 6.2e).  
 
b) Final results - the final results obtained via flow cytometry regarding cell 
membrane CXCR4 protein concentrations confirmed our results from previous mRNA 
expression studies. These results additionally confirmed that CXCR4 receptor was 
present on the cell surface/ membrane.  
The metastatic cell lines DU145, LNCaP and PC3 manifested the highest CXCR4 
cell surface receptor levels (figure 6.3, table 6.3). However, LNCaP demonstrated two 
subpopulations of cells – approximately 34% had relatively low CXCR4 protein levels 
(mean increase in GMFI 15.79 channels) and approximately 65% were observed to have 
the highest CXCR4 levels amongst all the cell lines (increase in mean GMFI 195.23 
channels) (figure 6.3b, table 6.3). The presence of these two LNCaP subpopulations is 
most likely explained by the finding that LNCaP cells display phenotypic and genotypic 
heterogeneity in culture [Horoszewicz JS et al 1983, Wan XS et al 2003]. This suggests 
that it would not have been surprising to find even more than two subpopulations of 
LNCaP exhibiting heterogeneity in levels of CXCR4 expression. As it has been recently 
demonstrated that androgens increased the levels of both CXCR4 mRNA and functional 
protein in LNCaP prostate cancer cells [Frigo DE et al 2009], it is possible that 
subpopulations of LNCaP cells with higher androgen receptor levels also manifested an 
increased quantity CXCR4 protein. Another explanation that was considered for the two 
different subpopulations within LNCaP, was that the LNCaP cells may have been 
exposed to hypoxic conditions during cell culture promoting the appearance of a subset of 
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cells with upregulated CXCR4 protein, as investigators have shown that hypoxia induces 
CXCR4 expression in tumour cells via increased levels of HIF-1α (discussed in detail in 
chapter 8) [Dunn LK et al 2009, Schioppa T et al 2003, Staller P et al 2003, Zagzag D et 
al 2005]. However, as cell culture conditions were strictly controlled for all cell lines (see 
chapter 3) and the same results was obtained on at least three different occasions, this was 
regarded as an implausible explanation.  
Although DUI45 had the highest CXCR4 mRNA levels (see chapter 5), these 
cells were second to the subpopulation of LNCaP as regards cell surface CXCR4 protein 
expression (change in mean GMFI 177.93 and 195.23 respectively – table 6.3). This lack 
of correlation between CXCR4 mRNA and protein in DU145 cells may occur due to 
either post-transcriptional mechanisms or regulation of CXCR4 at the protein level. 
Tarasova NI et al 1998 have reported that CXCR4 undergoes endocytosis on binding of 
CXCL12 ligand but recycling of the internalized receptor is inefficient. Recently, Wagner 
PL et al 2009 established that CXCR4 receptor was present on the cell membrane as well 
as in the cytoplasm and nucleus of adenocarcinoma lung cells (the authors suggested only 
cytomembranous CXCR4 was functional). Therefore in DU145, using the protocol for 
flow cytometry described in chapter 3, we may have detected only cell membrane 
CXCR4 receptor. Cytoplasmic and nuclear CXCR4 could have been detected using flow 
cytometry by permeabilising the DU145 cells. Alternatively, total CXCR4 protein levels 
could have been measured and compared between cell lines using Western blotting.  
The cell lines cultured and immortalized from normal prostate epithelium (Pre 
2.8, 1542 NPTX) and primary prostate cancer (1542 CPT3X), exhibited relatively small 
increases in the mean GMFI, signifying extremely low or absent CXCR4 protein 
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expression (table 6.3). A similar result was obtained with the MDA-MB-231 breast 
cancer cells. Particularly for the cell lines in which no CXCR4 mRNA was detected in 
earlier experiments, such as Pre 2.8 and MDA-MB-231, the small changes in GMFI 
could be attributed to non-specific binding of the secondary antibody to dead cell 
remnants and cell clumps, which could not be eliminated.  
Thus, our flow cytometry results, which confirmed over-expression of the cell 
surface CXCR4 chemokine protein in the cell lines derived from prostate cancer 
metastases, augmented our findings from prior experiments and provided further 
evidence that this seven-transmembrane receptor may be involved in the metastatic 
process of prostate cancer.  
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CHAPTER 7 
 
      
       
ESTABLISHING THAT THE CXCR4 
RECEPTOR IS FUNCTIONAL IN 
CELL LINES DERIVED FROM 
PROSTATE CANCER METASTASES 
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SECTION 7.1 
INTRODUCTION AND AIMS 
 
Up to this point we had determined that the cell lines derived from prostate cancer 
metastases (DU145, LNCaP, PC3) expressed relatively high levels of both CXCR4 
mRNA and CXCR4 cell membrane protein in comparison to prostate cell lines that 
originated from benign prostate tissue (1542 NPTX, Pre 2.8, S2.13) and primary prostate 
cancer (1542 CPT3X). The next aim was to establish that the CXCR4 receptor in the 
metastatic cell lines was functional. We aimed to do this by studying the motility or 
chemotaxis of the cells in response to the CXCR4 ligand i.e. CXCL12 (SDF-1). In these 
experiments the cell lines DU145 and PC3 were used in addition to 1542 NPTX. The 
latter was used as a type of control experiment as 1542 NPTX cells had been previously 
shown to have little or no CXCR4 protein expression.  
Cell migration is an essential characteristic of both physiological and pathological 
processes and tumour cell motility plays a critical role in the process of neoplastic 
invasion and metastasis. In 1863, Rudolf Virchow described his observation of motile 
cells, which he had isolated from the lymph fluid and from cartilage tissue [Virchow R 
1863]. However, it is now recognised that, within an organism, only several groups of 
highly specialized cells are able to actively and autonomously migrate. These cells 
include stem cells, leucocytes, fibroblasts, and tumour cells. Neutrophils, which have a 
maximum speed of 15 to 20 µm/min, are the fastest cells of all [Entschladen F et al 2000, 
Werr J et al 1998] whereas, in comparison to these cells, fibroblasts are relatively 
sluggish (0.2 to 1 µm/min) [Park S et al 2005] and, surprisingly, tumour cells are one of  
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the slowest migrating cells (0.1 to 0.3 µm /min) [Entschladen F et al 2004, Irimia D and 
Toner M 2009, Niggemann B et al 2004, Niggemann B et al 1997].  
It should be noted that there are two distinct cell motile behaviours: chemotaxis is 
defined as directional cell movement towards concentration gradients of solubilized 
attractants, whereas chemokinesis is defined as random cell movement in the absence of 
chemoattractant gradients. However, no substance has been described which influences 
only directional migration without an increase of migratory activity. Therefore, 
chemotaxis does not occur independently from chemokinesis.  
Cell motility/migration/chemotaxis can be studied via several different methods, 
the most widely accepted of which is the “Boyden Chamber assay”, initially described by 
Boyden S in 1962. Variations of this chemotactic assay, eg. the Transwell® migration 
assay (which was used in our experiments), have been effectively used to study the 
motility of a variety of cell populations. It has been reported that increased cell migration 
in a Boyden Chamber system correlates with increased invasive properties in vivo 
[Klemke RL et al 1998].  
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SECTION 7.2 
 
RESULTS 
 
It should be noted that all experiments were repeated on three separate occasions 
using four Transwell  wells each time for each CXCL12 ligand concentration. 
Stained cells were counted using a microscope. This was done under x200 
magnification and the mean number of cells per three high power fields (the central and 
the two vertically adjacent fields) for each well was calculated (photographs of migrating 
cells at high power are shown in figure 7.1).     
The results of the migration assays were assessed with the “Student’s t test”. The 
level of significance was defined as p < 0.05. 
The results are presented in table 7.1 and summarized in graphical form in figures 
7.2a - c.  
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Figure 7.1: Photograph of migrating cells in one high power field in a Transwell well  
at x200 magnification 
 
 
 
 
 
DU145 Cells 
PC3 cells 
1542 NPTX 
Cells 
 228 
 
Table 7.1. Results of cell migration assays (all results rounded up or down to the nearest 
whole number). All experiments were repeated on three separate occasions using four 
Transwell  wells each time. After 3 hours of incubation, the mean number of cells per 
three high power fields (the central and the two vertically adjacent fields under x200 
magnification using light microscopy) for each well was calculated and is tabulated. The 
overall mean for all experiments on each cell line was then established in addition to the 
standard error of the mean (SE). 
CXCL12α ligand concentrations are in ng/ml and the anti-CXCR4 antibody (Ab) 
concentration is 4µg/ml.  
 
 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Well 
1 
Well 
2 
Well 
3 
Well 
4 
Mean (rounded 
to nearest whole 
number) +/- SE 
DUI45 with 
no ligand 
29 21 25 27 22 31 23 26 21 30 20 24 25 +/- 1.08 
DU145 with  
50ng/ml ligand 
38 37 44 41 48 47 38 44 47 36 37 50 42 +/- 1.45 
DU145 with  
150ng/ml ligand 
66 82 79 65 81 64 73 63 82 65 69 77 72 +/- 2.21 
DU145 with  
300ng/ml ligand 
78 82 100 98 73 87 76 85 94 76 82 93 85 +/- 2.63 
DU145 with  
450ng/ml ligand 
72 75 92 96 86 76 78 92 86 78 76 80 82 +/- 2.28 
DU145 with  
150ng/ml ligand  
+ Ab 
56 42 48 39 51 50 39 39 36 49 54 40 45 +/- 1.97 
PC3 with  
no ligand 
11 18 12 16 14 18 15 16 18 12 12 18 15 +/- 0.79 
PC3 with  
150ng/ml ligand 
11 12 18 12 9 13 10 12 15 14 12 14 13 +/- 0.69 
PC3 with  
300ng/ml ligand 
25 25 20 19 18 24 22 19 24 18 21 27 22 +/- 0.89 
PC3 with  
300ng/ml ligand 
+ Ab 
16 10 13 11 13 17 12 12 16 12 9 15 13 +/- 0.72 
1542 NPTX  
with no  
ligand 
8 6 7 6 8 7 7 8 4 8 7 3 7 +/- 0.47 
1542 NPTX  
with 150ng/ml 
 ligand 
7 3 6 8 6 5 6 4 5 6 5 3 5 +/- 0.43 
1542 NPTX  
with 450ng/ml 
 ligand 
6 8 7 5 2 7 6 6 6 5 3 9 6 +/- 0.56 
1542 NPTX  
with 150ng/ml 
 ligand 
+ Ab 
4 9 9 6 7 2 5 8 8 5 8 7 7 +/- 0.62 
Transwell wells 1-4 for each of three separate experiments. The mean number of 
cells per three high power fields (the central and the two vertically adjacent fields 
under x200 magnification ) for each well was calculated and is tabulated. 
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Figure 7.2a-c. Effect of CXCL12α on chemotaxis of prostate cell lines (all results 
rounded up or down to the nearest whole number). Cells were placed in upper chamber 
with varying concentrations of CXCL12α ligand in lower chamber of Transwell 
(incubation period was 3 hours). When necessary, 4µg/ml of anti-CXCR4 IgG2b 
monoclonal antibody clone 44717.111 (Ab) was added to the upper compartment. 
* Significant increase versus no ligand control (p<0.05, t test). 
** Significant inhibition by anti-CXCR4 IgG2b monoclonal antibody (Ab) (p<0.05, t 
test). 
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In DU145 cells it was seen that the presence of the CXCR4 ligand, CXCL12α, in 
the lower chamber promoted chemotaxis and increased cell migration into the lower 
chamber from a mean of 25 cells/HPF in the no ligand control to 42 cells/HPF (p<0.05) 
and 72cells/HPF (p<0.05) with a ligand concentration of 50ng/ml and 150ng/ml 
respectively (table 7.1 and figure 7.2a). Increasing the concentration of ligand to 
300ng/ml increased the rate of cell migration to a mean of 85cells/HPF but further 
increases did not affect the rate of cell movement. The addition of anti-CXCR4 IgG2b 
antibody clone 44717.111(R & D Systems) (4µg/ml) into the upper chamber (with 
150ng/ml CXCL12α in the lower) decreased cell migration to 45cells/HPF (p<0.05 in 
comparison with no antibody in upper chamber and 150ng/ml CXCL12α in the lower 
chamber). 
With PC3 there was no significant increase in chemotaxis with a ligand 
concentration of 150ng/ml as compared to the control experiment with no ligand (figure 
7.2b). With CXCL12α at 300ng/ml, cell migration increased from a mean of 15cells/HPF 
(no ligand control) to 22 cells/HPF (p<0.05). The addition of antibody to the latter 
decreased migration to 13 cells/HPF (p<0.05). 
In contrast to DU145 and PC3, using 1542 NPTX cells, there was no significant 
increase in cell migration even when using a ligand concentration of 450ng/ml (7 
cells/HPF with no ligand and 6 cells/HPF with 450ng/ml CXCL12α) (figure 7.2c). 
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SECTION 7.3 
 
DISCUSSION 
 
In order to investigate the functionality of the CXCR4 receptor, we used the cell 
lines derived from metastases, DU145 and PC3, which we had shown had relatively high 
expression of CXCR4 on their cell membranes (chapter 6). 1542 NPTX was used as a 
control experiment as this cell line was derived from benign prostate epithelium and had 
been shown to have extremely low or absent CXCR4 protein expression (chapter 6). The 
main disadvantage of the Boyden Chamber / Transwell® migration assays is that a very 
large number of cells is applied, but only a small fraction of the cells are analysed i.e. the 
migratory active population of cells. Therefore, interpretations on the population as a 
whole can only be made when the cells behave as a homogeneous population. Therefore 
we did not use LNCaP cells in these experiments as it had been demonstrated in chapter 
6, that there were two subpopulations of LNCaP cells, one with relatively low CXCR4 
protein levels and the other expressing CXCR4 receptor at very much higher levels.   
The results suggested that in the metastatic cell lines DU145 and PC3, the 
expressed CXCR4 receptor is functional as the ligand CXCL12α promoted chemotaxis. 
This effect was concentration dependent as increasing the concentration of ligand in 
DU145 cells promoted increased cell migration until saturation was reached (at a ligand 
concentration of 300ng/ml). Also, this increased cell motility was specifically the result 
of CXCR4/ CXCL12α interaction as the addition of anti-CXCR4 antibody decreased cell 
movement. PC3 cells did migrate in the presence of CXCL12α but at a much slower rate 
than DU145 cells and also a much higher concentration of ligand was needed to promote 
cell migration (in the presence of 50ng/ml of CXCL12α DU145 cells migrated, but in the 
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PC3 cell line no significant increase in movement was noted until a ligand concentration 
of 300ng/ml). This slower rate of PC3 chemotaxis may be explained by the finding from 
chapter 6 that PC3 cells had a much lower expression of CXCR4 protein as compared to 
DU145 cells. Additionally of note was that in the 1542 NPTX cell line there was no 
significant increase in cell migration in the presence of the ligand thus suggesting that 
cell movement was due only to chemokinesis (as opposed to chemotaxis). This result was 
not unexpected as Taqman real-time PCR and flow cytometry had established that 1542 
NPTX cells had absent or very low levels of CXCR4 receptor expression. 
Our results had determined that in the cell lines derived from metastases, DU145 
and PC3, CXCR4 receptor was functional and its ligand CXCL12 promoted the 
chemotaxis of these cells. Of particular significance is the observation that in vivo, 
CXCL12 ligand is expressed and secreted at high levels by tissues which are the 
preferred site of prostate cancer metastasis, with highest expression in bone marrow 
(fibroblasts, osteoblasts, endothelial cells), lymph nodes, lung, and liver and markedly 
lower expression levels in the small intestine, skin and skeletal muscle [Bradstock KF et 
al 2000, Imai K et al 1999, Muller A et al 2001, Ponomaryov T et al 2000, Sun YX et al 
2005, Taichman RS et al 2002, Zou YR et al 1998]. Therefore our in vitro experimental 
results suggested that the in vivo preferential metastasis of prostate cancer to specific 
sites, for example lymph nodes and bone, may be due to CXCL12 promoted chemotaxis. 
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SECTION 8.1 
 
RESULTS SUMMARY AND EVALUATION 
 
We hypothesized that prostate cancer may use chemokine ligand – receptor 
interactions in the process of metastasis to preferred sites. 
In order to pursue this hypothesis we initially determined, using conventional RT-
PCR, mRNA levels of the chemokine receptors in the CXCR and CCR groups in prostate 
cell lines derived from metastases (DU145, PC3, LNCaP), primary prostate cancer (1542 
CPT3X) and benign epithelium or stroma (Pre 2.8, 1542 NPTX, S2.13). The expression 
of thirteen receptors in total was demonstrated. The results established that the expression 
of one chemokine receptor, CXCR4 (Fusin), was of particular interest because it was 
noted that CXCR4 mRNA was upregulated in DU145, LNCaP and PC3 cell lines i.e. cell 
lines developed from prostate malignancies that had spread to brain, lymph node and 
bone respectively. However, the RT-PCR results indicated that the cell lines derived from 
primary prostate tumour (1542 CPT3X) and normal prostate epithelium (1542 NPTX and 
Pre 2.8) manifested CXCR4 receptor mRNA at much lower or undetectable levels. The 
presence of the androgen receptor in the metastatic cells was not related to CXCR4 
mRNA expression as DU145 and LNCaP were observed, using RT-PCR, to have high 
CXCR4 mRNA levels whereas PC3 expressed moderate levels (DU145 and PC3 do not 
express androgen receptor in contrast to LNCaP cells which do). However, at this stage, 
although high levels of CXCR4 mRNA had been elucidated in the metastatic cell lines, 
this may have been related to any process in the metastatic cascade including cell 
proliferation, neoangiogenesis, local invasion or chemotaxis. 
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The expression of the ligand for the CXCR4 receptor, CXCL12, was also 
investigated. However, CXCL12 mRNA was not observed in any of the prostate cell lines 
suggesting that it did not have an autocrine or paracrine effect on the regulation of growth 
and progression in these cells, which is in contrast to other malignancies where 
chemokines are involved in promoting cell proliferation in vitro and in vivo via an 
autocrine or paracrine pathway [Araki K et al 2009, Hussain F et al 2010, Lo BK et al 
2010, Raychaudhuri B and Vogelbaum MA 2010, Sauvé K et al 2009]. Interestingly, a 
few researchers have proposed that the autocrine production of CXCL12 by primary 
neoplasms may actually decrease the incidence of metastases, firstly by saturating the 
CXCR4 receptor on primary malignant cells and secondly because CXCL12 chemotactic 
gradients are lost [Gilbert DC et al 2009, Mirisola V et al 2009]. Certainly, in vivo, 
chemotaxis towards CXCL12-releasing metastasis target tissues would be reduced. Sites 
which have been shown to secrete high levels of CXCL12 include bone marrow, where 
CXCL12 is constitutively produced by osteoblasts, fibroblasts and endothelial cells [Imai 
K et al 1999, Muller A et al 2001, Ponomaryov T et al 2000, Sun YX et al 2005, Zou YR 
et al 1998] and also lymph nodes [Muller A et al 2001]. Both bone and lymph nodes are 
favoured sites of metastasis of prostate cancer. It is important to point out that stromal 
and vascular endothelial cells in other tissues eg. skeletal muscle, cardiac muscle, skin 
and kidney do not secrete high levels of CXCL12 [Muller A et al 2001, Phillips RJ et al 
2003, Sun YX et al 2005].  
From the results obtained using conventional RT-PCR we concluded that the 
CXCR4 receptor warranted further investigation, and quantitation of CXCR4 mRNA was 
performed in all prostate cell lines using real-time quantitative PCR (TaqMan). This 
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technique confirmed previous RT-PCR results with DU145, LNCaP and PC3 having 
approximately 1287, 407 and 21 times CXCR4 mRNA levels respectively, relative to 
1542 CPT3X (1542 NPTX had similar expression to 1542 CPT3X and expression in Pre 
2.8 was undetectable by TaqMan PCR). This large difference in expression between 
DU145 and LNCaP had not been apparent on visual inspection when using conventional 
PCR, as both appeared to have comparable band densities on the agarose gel (refer to 
chapter 4). 
CXCR4 cell membrane protein expression was subsequently elucidated in 
prostate cell lines using flow cytometry. This demonstrated that in accordance with high 
CXCR4 mRNA levels, the metastatic cell lines also had high cell surface receptor 
expression. In the remaining cell lines low CXCR4 mRNA correlated with low CXCR4 
protein expression. However, it was observed that there were two subpopulations of 
LNCaP cells - one had relatively low CXCR4 protein levels and the other had the highest 
CXCR4 levels amongst all the cell lines. The occurrence of these two subpopulations is 
most likely explained by the finding that LNCaP cells display phenotypic and genotypic 
heterogeneity in culture [Horoszewicz JS et al 1983, Wan XS et al 2003]. It is possible 
that a subpopulation of LNCaP cells with increased androgen receptor levels also 
expressed an increased concentration of CXCR4 cell surface protein as it has been noted 
that androgens raised the levels of both CXCR4 mRNA and functional protein in LNCaP 
prostate cancer cells [Frigo DE et al 2009]. In our experiments, it would have been 
interesting to simultaneously quantitate androgen and CXCR4 receptor levels within the 
LNCaP subpopulations. Additionally, of note, is that the protocol that we used for flow 
cytometry only established cell membrane CXCR4 protein levels, whereas it is now 
 239 
known that CXCR4 receptor is present on the cell membrane in addition to the cytoplasm 
and nucleus, with nuclear CXCR4 thought to be non-functional [Wagner PL et al 2009]. 
We could have demonstrated total CXCR4 protein levels within cells using Western 
blotting, or alternatively, cytoplasmic and nuclear CXCR4 receptor could have been 
detected using flow cytometry by permeabilising the cell membrane. 
Cell migration assays were used to confirm the functionality of the CXCR4 
receptor in response to its ligand, CXCL12. These studies of cell motility suggested that 
in the metastatic cell lines DU145 and PC3, the expressed CXCR4 receptor was 
functional as the ligand CXCL12α promoted chemotaxis presumably by actin 
polymerization and subsequent pseudopodial invasion. This effect was concentration 
dependent as increasing the concentration of ligand in DU145 cells promoted increased 
cell migration until saturation was reached. Also, this increased cell motility was 
specifically the result of CXCR4/ CXCL12α interaction as the addition of anti-CXCR4 
antibody decreased cell movement. PC3 cells, which had been shown to have lower cell 
surface CXCR4 protein levels, did migrate in the presence of CXCL12α but at a much 
slower rate than DU145 cells and a much higher concentration of ligand was needed to 
promote cell migration (at 50ng/ml of CXCL12α DU145 cells migrated but in the PC3 
cell line no significant increase in chemotaxis was noted until a ligand concentration of 
300ng/ml). However, as demonstrated by Taqman real-time PCR and flow cytometry 
results, 1542 NPTX expressed CXCR4 at very low or absent levels and thus there was no 
significant increase in cell migration in the presence of the ligand. The main disadvantage 
of the Boyden Chamber / Transwell® migration assays is that a very large number of 
cells is applied, but only a small fraction of the cells are analysed i.e. the migratory active 
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population of cells. Therefore, interpretations on the population as a whole can only be 
made when the cells behave as a homogeneous population. It is possible that in the 
DU145 and PC3 cell lines that only a subpopulation of cells with functional 
cytomembranous CXCR4 receptor (as compared to those with non-functional nuclear 
localisation of CXCR4) were able to migrate in response to the CXCL12 ligand. 
However, the in vitro cell migration results suggested that prostate cancer cells 
expressing CXCR4 receptor may migrate to preferred sites of metastasis, such as bone 
and lymph nodes, down a CXCL12 concentration gradient. The next step would have 
been to demonstrate that CXCL12 – CXCR4 mediated chemotaxis is important in vivo in 
the localization of prostate cancer cells to favoured sites of metastasis.  This has since 
been verified by Sun YX et al 2005, who used a murine model to provide critical support 
for the CXCL12 – CXCR4 axis in prostate cancer skeletal metastasis. 
Interestingly, laser microdissected primary tumour samples and benign prostate 
tissue from patients had CXCR4 mRNA levels higher than that of DU145. Sun YX et al 
2003 have, however, suggested that post-transcriptional modification of the CXCR4 
receptor plays a major role in regulating protein expression and therefore, although 
CXCR4 mRNA levels are high in primary tumour samples and in patient benign tissue 
specimens, protein expression may be low, particularly in the benign samples [Sun YX et 
al 2003]. Another explanation would be that high mRNA levels in vivo may not 
necessarily translate into high in vivo CXCR4 protein levels because it has been observed 
that CXCR4 undergoes significant spontaneous endocytosis and that recycling of 
internalized receptors is not efficient [Tarasova NI et al 1998]. Alternatively, high 
CXCR4 expression by patient primary tumours may be the result of a survival benefit in 
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primary cancer cells expressing this receptor in vivo, and these tumours may be more 
aggressive and likely to metastasise. In support of this theory is the discovery by 
investigators that hypoxia induces CXCR4 expression in malignant cells via increased 
levels of HIF-1α [Dunn LK et al 2009, Schioppa T et al 2003, Staller P et al 2003, 
Zagzag D et al 2005]. Therefore CXCR4 may become expressed during primary tumour 
growth when partial pressures of oxygen diminish within the expanding tumour, thereby 
promoting the chemotaxis of cancer cells away from hypoxic areas into sites secreting 
high levels of CXCL12 (which are presumably also well oxygenated). Several 
researchers have confirmed that primary tumours expressing high levels of CXCR4 
protein are likely to behave more aggressively. These include Mochizuki H et al 2004, 
who showed that, in a sample of 35 human primary prostate malignancies, positive 
expression of CXCR4 protein was an independent predictor of bone metastasis. Also, in 
neoplasms other than prostate, high CXCR4 expression in primary cancer of the breast 
[Chu QD et al 2010] and thyroid is associated with a poorer prognosis [Wagner PL et al 
2008].  
It is a possibility that in vivo metastatic prostate cells may, in fact, express 
CXCR4 mRNA at even higher levels than primary tumour but unfortunately we were 
unable to obtain fresh prostate metastatic tissue from patients, which could be laser 
microdissected. An alternative would have been to construct a tissue microarray of 
normal/benign prostate tissue, primary and metastatic prostate tumours [as achieved by 
Sun YX et al 2003] and compare CXCR4 protein expression using 
immunohistochemistry. This tissue microarray has now been constructed by subsequent 
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researchers in the department, although it contains only benign and malignant tissue from 
radical prostatectomy specimens (i.e. it does not contain tissue derived from metastases). 
It should be noted that although the results had specifically suggested that 
CXCL12-CXCR4 interaction promotes the chemotaxis of prostate cancer cells to 
preferred metastatic sites, this pathway may also be involved in additional steps of the 
metastatic cascade such as neoplastic cell proliferation, neoangiogenesis and/ or local 
invasion. Also, the CXCL12-CXCR4 axis is only one of several pathways implicated in 
organ specific metastasis. Other factors include vascular flow patterns, adhesion with the 
endothelium in distant organs and interaction between tumour cells and their 
microenvironment at the secondary site. Establishment of successful cancer metastasis 
may fail as a result of a deficiency in any one of these processes. Additionallly, 
chemotaxis of prostate cancer cells may occur in vivo in the absence of CXCL12-CXCR4 
interaction as alternative (although less potent) chemoattractant molecules have been 
identified including osteonectin, TGFβ1, EGF and IGF1/ 2. 
 
 
SECTION 8.2  
CONFIRMATORY STUDIES OF CXCL12 – CXCR4 INTERACTION 
IN THE MIGRATION AND DISSEMINATION OF PROSTATE 
CANCER 
Not surprisingly, following the paper relating the important role of CXCL12 – 
CXCR4 interaction in breast cancer metastasis by Muller A et al in 2001, many 
investigators throughout the world had the similar idea of demonstrating the significance 
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of this axis in a variety of human neoplasms. We and other researchers simultaneously 
investigated this pathway in prostate cancer. However, Taichman RS et al 2002 were the 
first to publish their research and provide evidence for the involvement of this chemokine 
ligand – receptor axis in prostate cancer metastasis to bone using in vitro studies with 
prostate cell lines. The same group followed up this publication with an important article 
approximately 1 year later with in vivo evidence for the hypothesis [Sun YX et al 2003]. 
They constructed a high-density tissue microarray from clinical prostate samples obtained 
from a cohort of over 600 patients. Immunostaining of the microarrays using CXCR4 
monoclonal antibody revealed weak CXCR4 expression in normal/ benign prostate 
epithelium, moderate-to-strong CXCR4 protein expression in clinically localized prostate 
cancer samples and highest CXCR4 expression in metastatic lesions. However, on 
determining CXCR4 mRNA from a series of patient samples, they discovered that the 
CXCR4 mRNA levels in BPH, localized and metastatic cancers were elevated relative to 
normal adjacent tissues. In fact mean peak CXCR4 mRNA expression occurred in BPH 
tissue, followed by localised prostate cancer and lowest levels in metastatic prostate 
epithelium (but overall there was no statistical difference between the three). It was 
suggested that post-transcriptional regulation of the receptor plays a major role in 
regulating CXCR4 protein expression. More recently, the group have provided support 
for the CXCL12 – CXCR4 axis participating specifically in the localisation of metastatic 
prostate tumours to the bone marrow using a murine model [Sun YX et al 2005] and also 
demonstrated the activation of various signalling mechanisms on CXCL12 binding to 
CXCR4 [Wang J et al 2005]. Additional signalling pathways activated on CXCL12 – 
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CXCR4 interaction have been elucidated by Bendall LJ et al 2005, Goldsmith ZG and 
Dhanasekaran DN 2007, Kukreja P et al 2005, Mellado M et al 2001, Ward SG 2006.  
The findings of Taichman’s group have been both confirmed and extended by 
Xing Y et al 2008, who showed that the stable down-regulation of CXCR4 inhibited 
CXCL12α-promoted prostate cancer cell adhesion to osteosarcoma and endothelial cells, 
inhibited migration plus invasion through Matrigel, and reduced the incidence of prostate 
cancer establishment and growth when the tumour cells were injected into the tibial bone 
of mice. Also, it has been observed that subcutaneously injected prostate cancer cells 
transfected with CXCR4 grew larger tumours with increased muscle invasion compared 
with parental cells [Darash-Yahana M et al 2004]. 
Vaday GG et al 2004 established that single chain Fv anti-CXCR4 antibodies 
inhibited prostate cancer cell migration and invasion in vitro and also reduced CXCL12 
induced calcium mobilisation in PC3 and LNCaP cells. Invasion through ECM 
components by malignant prostate cell lines (LNCaP and/ or PC3) in response to 
CXCL12 was shown to be a result of increased MMP expression (specifically MMP-1, 
MMP-2, MMP-3, MMP-9, MMP-14) [Chinni SR et al 2006, Hu W et al 2008, Singh S et 
al 2004a]. CXCL12 – CXCR4 interaction, resulting in increased MMP-9 and MMP-2 
expression, has been implicated in perineural invasion of prostate cancer using human 
tissue and cell lines [Zhang S et al 2008]. This increased expression of proteases on 
CXCL12 stimulation most likely creates a pathway for cell movement/ invasion.  
Interestingly, Miwa S et al 2005, observed that in a mouse model the 
bisphosphonate, minodoronate, may inhibit prostate cancer cell invasion into the bone 
matrix by repressing the expression of CXCR4 in bone metastasis lesions and Engl T et al 
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2006 have established that CXCL12 – CXCR4 interaction resulted in enhanced 
expression of alpha5 and bets3 integrins in LNCaP and DU145 cell lines, which enabled 
increased adhesion of these cells to human endothelium or to ECM proteins (laminin, 
collagen, fibronectin). These latter findings provide a link between chemokine receptor 
expression and integrin-triggered tumour dissemination.  
Recently, it has been demonstrated that androgens increased the levels of both 
CXCR4 mRNA and functional protein in LNCaP prostate cancer cells [Frigo DE et al 
2009]. Importantly, androgens enhanced the migration of LNCaP cells toward a CXCL12 
gradient, an effect that could be blocked by a specific CXCR4 receptor antagonist [Frigo 
DE et al 2009]. This suggests that androgens may be involved in the regulation of 
pathways that are responsible for the homing of prostate cancer cells to select 
microenvironments. 
Other investigators demonstrated, in a small clinical sample, that positive 
expression of CXCR4 protein was an independent and superior predictor for bone 
metastasis to Gleason sum [Mochizuki H et al 2004] and also that high levels of CXCR4 
induced a more aggressive phenotype in prostate cancer cells in vivo [Darash-Yahana M 
et al 2004]. Additionally, in a series of prostate cancer samples obtained from 52 men 
with metastatic prostate cancer, Akashi T et al 2008, demonstrated that patients with a 
high expression of CXCR4 in tumours had poorer cancer-specific survival than those 
with low expression of CXCR4, thus suggesting that CXCR4 expression was a useful 
prognostic factor for patients with metastatic prostate cancer treated with androgen-
withdrawal therapy.  
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Of particular note and of current interest is that immunostaining of clinical 
prostate specimens has shown that a subpopulation of tumour cells with a stem cell-like 
phenotype (i.e. possible prostate cancer stem cells which were CD133+) also expressed 
CXCR4 [Miki J et al 2007]. The authors suggested that the CXCL12 - CXCR4 pathway 
may be important in the chemotaxis of these possible cancer stem cells. 
 We published the results from our research in 2004 [Arya M et al 2004 – abstract 
in Appendix, page 309]. 
 
 
SECTION 8.3 
 
THE IMPORTANCE OF THE CXCL12  – CXCR4 AXIS IN TUMOUR 
CELL MIGRATION 
We, and colleague scientists, have elucidated that CXCL12 – CXCR4 interaction 
has a distinctive biological role. Since the publication of the seminal paper in “Nature” by 
Muller A et al 2001, implicating the key role of this axis in the organ-specific metastasis 
of breast cancer, there has been great interest in this pathway, particularly in the 
promotion of cell migration, and the resulting implications for cancer therapy. A 
summary of the pathophysiological role of the CXCL12 – CXCR4 axis in relation to 
cellular migration/ chemotaxis (which is discussed in detail below), is shown in figure 
8.1. 
CXCL12 ligand is constitutively expressed by stromal cells in many tissues with 
highest expression in bone marrow (fibroblasts, osteoblasts, endothelial cells), lymph 
nodes, lung and liver and markedly lower expression levels in the small intestine, skin 
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and skeletal muscle [Bradstock KF et al 2000, Imai K et al 1999, Muller A et al 2001, 
Ponomaryov T et al 2000, Taichman RS et al 2002, Zou YR et al 1998]. Functional 
CXCR4 receptor is found in a wide variety of adult tissues including on peripheral blood 
T lymphocytes [Bleul CC et al 1997], monocytes [Bleul CC 1996 et al], plasma cells 
[Nakayama T et al 2003], subsets of natural killer cells [Hanna J et al 2003], dendritic 
cells [Zoeteweij JP et al 1998], adult CD34+ bone marrow stem/progenitor cells [Aiuti A 
et al 1997], vascular smooth muscle cells [Schecter AD et al 2003], endothelial cells 
[Gupta SK et al 1998], intestinal [Dwinell MB et al 1999] and alveolar epithelial cells 
[Murdoch C et al 1999], microglia, neurons and astrocytes [Zou YR et al 1998].  
 
Figure  8.1: A summary of the pathophysiological role of CXCL12 – CXCR4 interaction 
in cellular migration/ chemotaxis 
CXCL12 – CXCR4
Chemoattraction of leucocytes
Directional migration / chemotaxis and organ specific metastases of various cancers
Chemotaxis and retention of 
circulating haematopoietic 
stem cells to cellular niches 
in bone marrow
Repair of ischaemic tissue injury 
via recruitment of circulating stem 
cells
“Knock-out” mice 
demonstrate heart, 
brain and large vessel 
defects
Embryonic development and 
organogenesis via embryonic 
stem cell migration
Development of 
mechanosensory
posterior lateral line and 
migration of primordial 
germ cells in zebrafish 
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Initial investigations on the CXCR4 receptor concentrated on its role in the 
pathogenesis of HIV infection. In 1996, the field of inflammation and HIV virology 
unexpectedly overlapped due to the discovery that chemokine receptors were identified as 
co-receptors and, that in conjunction with CD4, allowed HIV to infect the host cell [Feng 
Y et al 1996]. Approximately 90% of HIV strains infect using the CCR5 chemokine 
receptor (macrophage tropic) but the virus can mutate to use CXCR4 (T-cell tropic).  
Strains have been identified that can use other chemokine receptors, but all use either 
CCR5 or CXCR4.  
Subsequently, CXCL12 – CXCR4 interaction was discovered to be involved in 
embryonic development and organogenesis. “Knock-out” mice studies have demonstrated 
that mice in which either CXCR4 or CXCL12 genes have been deleted do not develop 
normally and the majority die in utero with defects in heart, brain and large vessel 
development [Zou YR et al 1998, Ma Q et al 1998, Nagasawa T et al 1996, Tachibana K 
et al 1998]. The development of the mechanosensory posterior lateral line and migration 
of primordial germ cells in zebrafish is dictated by CXCR4 expressing cells, which 
respond to a CXCL12-like molecule [David NB et al 2002, Doitsidou M et al 2002]. 
Primordial germ cell migration in murine and fish embryos is also under the influence of 
CXCL12 - CXCR4 interactions and deletion or inhibition of CXCR4 or CXCL12 results 
in significantly decreased migration and ectopic location of the primordial germ cells 
[Ara T et al 2003, Knault H et al 2003]. These results suggest a pivotal role for CXCL12 
– CXCR4 in organogenesis via the control of embryonic stem cell migration. 
Additionally, as these studies demonstrate that CXCR4 is expressed in early foetal 
development, this could partly explain the fact that tumour cells that originate in various 
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organs from the population of transformed or dedifferentiated cells often express cell 
surface CXCR4. This also implies that CXCL12 may influence tumour metastasis via the 
migration of CXCR4 positive tumour cells to specific sites, in a similar manner to its role 
in the migration of embryonic pluripotent stem cells. 
As mentioned earlier, CXCL12 is constitutively secreted by adult bone marrow 
stromal cells. These create cellular niches in which CD34+ haematopoietic stem cells 
(HSCs) and progenitors are retained for growth and differentiation [Fuchs E et al 2004]. 
The chemotaxis or homing of circulating CXCR4 expressing HSCs to the cellular niches 
in the bone marrow, in addition to their subsequent retention in these sites, is controlled 
by CXCL12 [Aiuti A et al 1997, Broxmeyer HE et al 2003, Wright DE et al 2002]. These 
findings have been supported in clinical trials demonstrating that CXCR4 antagonists can 
result in leucocytosis due to rapid mobilization of HSCs [Broxmeyer HE et al 2005, 
DiPersio JF et al 2009, Dugan MJ et al 2010].  Besides HSCs, it has now been realised 
that functional CXCR4 is also expressed on the surface of various normal stem cells for 
different organs and tissues in adults (also referred to as tissue-committed stem cells, 
TCSCs) [Kucia M et al 2005]. Importantly, researchers have currently suggested that not 
only is CXCR4 expressed by embryonic stem cells and TCSCs but the receptor is 
additionally found on the cell membrane of cancer stem cells (CSCs) of various tissues 
and is vital in the homing of these CSCs to their specific metastatic site (following a 
CXCL12 chemotactic gradient) [Gelmini S et al 2008, Kucia M et al 2005, Visvader JE 
and Lindeman GJ 2008]. Thus CXCR4 can be considered a universal marker of all 
groups of stem cells.  
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CXCL12 – CXCR4 interaction is also involved in the repair of ischaemic tissue 
injury, which involves the specific recruitment of circulating TCSCs or progenitor cells. 
Ceradini DJ et al 2004 observed that tissue hypoxia resulted in increased levels of 
hypoxia-inducible factor-1α (HIF-1α) in endothelial cells, which subsequently induced 
CXCL12 expression in the ischemic areas in direct proportion to reduced oxygen tension 
in vivo. Therefore, circulating progenitor/ stem cells migrate to areas of ischaemic tissue 
necrosis due to an increase in CXCL12 expression by endothelial cells, induced by HIF-
1α, to become involved in tissue repair. Once oxygen tension normalises and tissue 
regeneration has occurred expression of CXCL12 decreases [Ceradini DJ et al 2004]. 
Also, distinct niches of hypoxia are present in normal bone marrow that display increased 
levels of HIF-1α induced CXCL12. Circulating CXCR4 positive progenitor cells of 
various tissues (i.e. TCSCs) such as muscle, liver, neural, retinal, renal tubular as well as 
HSCs, all localise within these niches and become mobilised during periods of tissue 
damage – a concept first described by Ratajczak M and colleagues [Ratajczak MZ et al 
2004, Kucia M et al 2004]. Significantly, studies have suggested that hypoxia induces 
CXCR4 expression in tumour cells via HIF-1α (in a similar manner to inducing CXCL12 
in endothelial cells in ischaemic tissue injury) [Dunn LK et al 2009, Schioppa T et al 
2003, Staller P et al 2003, Zagzag D et al 2005]. Initial studies confirming this related to 
the von Hippel-Lindau (VHL) protein, which is the product of the VHL tumour 
suppressor gene, and which promotes degradation of HIF-1α under normoxic conditions 
(figure 8.2). However, under hypoxic conditions, or in renal cell cancers having deletions 
or inactivation of the VHL gene, this process is suppressed and thus HIF-1α levels 
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increase and this promotes tumour cell expression of the CXCR4 receptor (figure 8.2) 
[Pan J et al 2006, Staller P et al 2003, Zagzag D et al 2005].  
 
 
 
 
Figure 8.2: This demonstrates how hypoxia induces CXCR4 expression in renal clear 
cell cancer cells. Under normoxic conditions the VHL protein (a product of the VHL 
tumour suppressor gene) combines with Elongin B and C and promotes proteasomal 
degradation of HIF-1α. However, under hypoxic conditions (or in renal cancer having 
inactivation of the VHL gene), HIF-1α levels increase and this heterodimerises with HIF-
1β, which promotes tumour cell expression of the CXCR4 receptor in addition to several 
angiogenic factors (VEGF, PDGF).  
VHL - von Hippel-Lindau protein, HIF-1 - hypoxia-inducible factor-1, VEGF – vascular 
endothelial growth factor, PDGF – platelet derived growth factor 
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Figure 8.2: The hypoxic control of CXCR4 expression in renal carcinoma 
cells
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In fact, increased levels of CXCR4 in patients with renal clear cell cancers are associated 
with poor prognosis and decreased survival [Staller P et al 2003, Zagzag D et al 2005, 
Wang L et al 2009]. This may explain how CXCR4 becomes expressed during tumour 
development thus allowing the cancer cells to migrate from hypoxic areas, thereby 
 252 
favouring metastasis as the oxygen concentration decreases within the tumour. This also 
demonstrates how the HIF-1 pathway, which is involved in controlling the expression of 
CXCL12 and CXCR4 in the homing of progenitor cells to injured tissues, may have been 
adapted by cancer cells to allow their directional migration down chemotactic gradients to 
specific organs secreting CXCL12, such as the bone marrow and lymph nodes. 
CXCR4 is the most common chemokine receptor expressed in cancers and levels 
of its ligand, CXCL12, are highest in the common sites of metastases of many cancers i.e. 
lung, liver, bone marrow and lymph nodes [Bradstock KF et al 2000, Imai K et al 1999, 
Muller A et al 2001, Ponomaryov T et al 2000, Taichman RS et al 2002, Zou YR et al 
1998]. This suggests that the CXCL12 – CXCR4 axis may be crucial in the organ specific 
metastasis of many cancers.  
In vitro experiments observing the locomotion of individual cells using time-lapse 
monitoring have demonstrated that CXCL12 increases the motility of several human 
tumour cell lines derived from breast cancer, rhabdomyosarcoma and small cell lung 
cancer [Adams GB et al 2003, Libura J et al 2002]. Additionally, neoplastic cells 
migrated extensively in the presence of CXCL12, with CXCL12 increasing the final 
displacement, the average velocity of cell displacement and stimulating the formation of a 
leading edge in migrating cancer cells [Libura J et al 2002]. Many studies have also 
shown that CXCL12 promotes the directional migration or chemotaxis of neoplastic cells 
as well as invasion through Matrigel, endothelial cells, bone marrow stromal, or 
fibroblast monolayers, via the CXCR4 receptor [Balkwill F 2004a and b, Ben-Baruch A 
2008, Zlotnik A 2008]. Also, in cell lines derived from malignancies such as small cell 
lung cancer and osteosarcoma, not only does CXCR4 activation induce migratory and 
 253 
invasive responses, but it also results in activation and signaling of tumour-associated 
integrins that play an important role in tumour adhesion and progression [Hartmann TN et 
al 2005, Huang CY et al 2009]. In laryngeal and hypopharyngeal squamous cell 
carcinoma cell lines, motility and invasiveness were enhanced by CXCL12 acting 
through CXCR4, resulting in upregulation of MMP-13 [Tan CT et al 2008]. Interestingly, 
Bertran E et al 2009 treated hepatoma cells with TGF-β and selected the cells that 
survived its apoptotic effect and underwent epithelial-mesenchymal transition. The 
resultant mesenchymal, de-differentiated, phenotype had significantly elevated levels of 
CXCR4, which enhanced the cells’ migratory abilities in response to CXCL12. 
In vivo studies such as that by Bartolomé RA et al 2009 (using a xenograft mouse 
model) have shown that CXCR4 is required for melanoma metastasis to the lungs 
(specifically in the early phases of melanoma cell arrival in the lungs). Also, transfection 
of a melanoma cell line with CXCR4 redirected this cell line to metastasize to the lung 
instead of the lymph nodes [Murakami T et al 2002]. In pancreatic cancer, the soluble 
protein, pancreatic adenocarcinoma upregulated factor (PAUF), enhanced the metastatic 
potential of pancreatic cancer cells, at least in part, by upregulating CXCR4 expression in 
an orthotopic xenograft mouse model [Lee Y et al 2010]. Using bioluminescent imaging 
to quantify relative volumes of tumour burden after breast cancer cells were injected into 
the left cardiac ventricle, Huang EH et al 2009 indicated that treatment with a CXCR4 
antagonist significantly reduced metastasis as well as primary tumour growth. Also, when 
non-small cell lung cancer cells are grown in SCID mice only 35% of cells in the primary 
tumour expressed CXCR4 compared with 99% of cells in metastases [Phillips RJ et al 
2003]. 
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In addition to in vitro and in vivo experiments there is now an increasing amount 
of evidence from retrospective clinical studies (using tissue samples derived from 
patients) that the CXCL12-CXCR4 pathway is involved in metastasis. Importantly, 
Muller A et al 2001 initially reported strong CXCR4 expression using 
immunohistochemistry in metastatic breast cancer tissue.  This finding has been 
confirmed by Liu Y et al 2010, who demonstrated that high expression of CXCR4 (and 
CCR7) may be associated with lymph node metastasis. Moreover, the expression of these 
receptors served as an indicator of undesirable prognosis in patients with breast neoplasia. 
Also, high CXCR4 overexpression in primary tumours has been shown to be predictive 
of worse outcomes in hormone receptor-positive, node-negative breast cancer patients 
[Chu QD et al 2010]. Surprisingly, in another recent study, microarray gene expression 
analysis and immunohistochemistry revealed that increased expression of CXCL12 but 
not of CXCR4 significantly correlated with disease-free and overall survival in breast 
cancer and that CXCL12 was a strong, independent prognostic marker of this [Mirisola V 
et al 2009]. The group proposed that saturation of the CXCR4 receptor through autocrine 
CXCL12 production reduced chemotaxis towards CXCL12-releasing metastasis target 
tissues thus decreasing the number of breast cancer metastases formed [Mirisola V et al 
2009]. In urological neoplasms, increased levels of CXCR4 in patient renal clear cell 
cancers are associated with poor prognosis and decreased survival [Zagzag D et al 2005, 
Staller P et al 2003]. Additionally, using immunohistochemistry, Wang L et al 2009 
noted that renal cell carcinoma metastasis was associated with higher expression of 
CXCR4 (in comparison to primary tumours and normal tissue) but of particular note was 
the finding by these researchers that the interaction of CXCR4 and its ligand CXCL12 
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resulted in the internalization of CXCR4 from the cytoplasmic membrane. In bladder 
cancer, Nishizawa K et al 2010 identified that CXCR4 expression was induced in high-
grade superficial bladder malignancies, including carcinoma-in-situ and invasive bladder 
tumours. Another group observed consistent expression of CXCR4 mRNA and protein in 
testicular germ cell tumours that accounted for their patterns of relapse in sites of known 
high CXCL12 expression [Gilbert DC et al 2009]. However, these scientists also found 
that expression of CXCL12 in stage I non-seminomas was significantly associated with 
organ-confined disease post-orchidectomy and reduced risk of relapse [Gilbert DC et al 
2009]. They suggested that this may be through the loss of CXCL12 gradients that might 
otherwise attract cells away from the primary tumour. In oesophageal cancer, CXCR4 
expression was identified as an independent variable that was most strongly associated 
with reduced disease specific survival [Kaifi JT et al 2005]. Interestingly, this study also 
showed that CXCR4 correlated with the presence of disseminated, potentially ‘dormant’ 
tumour cells in bone marrow and lymph nodes, implicating the receptor in early 
micrometastatic spread of single tumour cells. Additionally, expression of CXCR4 by 
papillary thyroid carcinoma correlated with indicators of tumour aggressiveness, 
including tumour size, extrathyroidal extension, angiolymphatic invasion and lymph node 
metastasis [Wagner PL et al 2008]. Also of note was the discovery that cytomembranous 
expression of CXCR4 in adenocarcinoma of the lung was an independent risk factor 
associated with worse disease-free survival, whereas nuclear immunostaining of the 
chemokine receptor conferred a survival benefit [Wagner PL et al 2009]. The authors 
suggested that these findings were consistent with a model in which CXCR4 promoted 
tumour cell proliferation and metastasis when present in the cytoplasm or cell membrane, 
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whereas localization of this molecule in the nucleus prevented it from exerting these 
effects. 
 
 
SECTION 8.4 
THERAPEUTIC IMPLICATIONS 
The work in this thesis has demonstrated that the CXCL12 – CXCR4 pathway 
may be important in the organ specific metastasis of prostate cancer and this has been 
validated by other researchers. As discussed, the essential role of the CXCL12 – CXCR4 
axis has additionally been shown to be pivotal in the chemotaxis of other neoplasms to 
specific metastatic sites. Therefore manipulation of this signaling pathway could be of 
therapeutic benefit to patients.  
 
1) Small molecule CXCR4 antagonists 
There have been great difficulties in the development of small molecule 
chemokine receptor antagonists. It was assumed that the search for chemokine receptor 
antagonists would be similar to that of other G-protein coupled receptors, but chemokine 
receptors are not typical of this receptor group. The number of ligands for a particular 
receptor, the ligand size, and the type of interaction between ligands and receptors are 
different [Onuffer J and Horuk R 2002]. Additional reasons for this slow progress include 
differences in affinity of the antagonists for human and animal chemokine receptors 
resulting in problems in the interpretation and relevance of preclinical trials. Another 
problem has been redundancy of the target i.e. several chemokine receptors may be 
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involved in the specific pathway or process of interest, which would mean that more than 
one receptor would have to be inhibited in order to demonstrate efficacy in clinical trials. 
Despite these difficulties, considerable progress has now been made and several small 
molecule chemokine receptor antagonists have now been developed, which may provide 
clinical benefit in cancer management.  
a) Non-peptide CXCR4 antagonists - CXCR4 antagonists were first studied and 
developed in an effort to prevent the entry of the HIV-1 virus into its target cells, as this 
receptor (and CCR5) is known to be a co-receptor used by the HIV-1 virus for entry into 
T cells and macrophages (as already discussed in chapter 1). The bicyclams, in particular 
AMD3100 (plerixafor), are potent specific antagonists of CXCR4. AMD3100, a non-
peptide CXCR4 antagonist, selectively and reversibly antagonizes the binding of 
CXCL12 to CXCR4. The critical role of the CXCR4-CXCL12 receptor-ligand interaction 
for CD34+ haematopoietic stem cell retention in the bone marrow has been discussed. It 
has been shown that AMD3100 can specifically mobilize CD34+ haematopoietic 
progenitor/ stem cells from the bone marrow, which is of considerable clinical benefit as 
a significant number of cancer patients cannot receive high-dose chemotherapy with 
subsequent peripheral blood progenitor cell transplantation because they fail 
haematopoietic stem/ progenitor cell mobilization.  
In phase 3 clinical studies AMD3100 has been demonstrated to act synergistically 
with the established mobilizing agent, granulocyte colony-stimulating factor, for 
autologous stem-cell transplantation in non-Hodgkin's lymphoma and multiple myeloma 
patients [DiPersio JF et al 2009, Dugan MJ et al 2010]. AMD3100 was well tolerated 
with only mild, transient toxicity. Thus, patients can collect more haematopoietic 
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progenitors in fewer apheresis sessions, and patients that previously failed can now 
successfully collect sufficient peripheral blood progenitor cells for transplantation. In 
fact, AMD3100 was recently FDA-approved for stem cell mobilization in combination 
with granulocyte-colony stimulating factor in patients with non-Hodgkin's lymphoma and 
multiple myeloma. CXCR4 antagonists are the most exciting development in the field of 
peripheral blood progenitor cell mobilization for over a decade. 
In promising studies related to solid cancers, administration of AMD3100 has 
been shown to prevent clonogenic growth, VEGF secretion, and intercellular adhesion 
molecule-1 expression of colorectal cancer cells in vitro [Ottaiano A et al 2006]. Also, 
inhibiting CXCR4 with AMD3100 in murine 4T1 cells—a highly metastatic mammary 
cancer cell line and model for stage IV human breast cancer— substantially delayed the 
growth of metastatic 4T1 cells in the lungs of mice [Smith MC et al 2004]. In a mouse 
experiment of liver metastasis, intraperitoneal administration of AMD3100 blocked the 
metastatic potential of colon cancer cells [Matsusue R et al 2009].  
b) Small peptide CXCR4 antagonists - another CXCR4 antagonist, T140 (and its 
analogues TN14003 and TC14012), has also been developed. This is classed as a small 
peptide CXCR4 antagonist. Studies on this 14-residue polypeptide, as well as AMD3100, 
found that each inhibits CXCR4 via different mechanisms. AMD3100 has weak partial 
agonist (CXCL12-like) activity, inducing CXCL12-like G-protein activation in cells with 
this receptor whereas T140 functions as an inverse agonist and does not induce any 
signaling on binding to CXCR4 [Trent JO et al 2003, Zhang WB et al 2002]. Since 
CXCR4 activation by a CXCR4 antagonist may be a disadvantage to the treatment of 
diseases in which CXCR4 activation provides a survival signal (e.g. prostate and breast 
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cancer), T140-derived CXCR4 antagonists might have an advantage over AMD3100. 
T140 CXCR4 antagonists have shown activity in animal tumour models and this provides 
a rationale for future clinical trials of these agents in patients with neoplastic disease 
[Takenaga M et al 2004, Tamamura H et al 2004]. In fact, the T140 analogue, TN14003 
(BKT140), is currently under clinical development for patients with multiple myeloma 
[Burger JA et al 2011]. 
c) Monoclonal antibodies - therapeutic monoclonal antibodies targeting the 
CXCR4 receptor have also been developed but this has proved to be challenging as the 
CXCR4 receptor exhibits conformational heterogeneity, which is responsible for 
differential antibody binding in most cell types. These conformational differences may be 
the result of heterogeneity in post-translational events such as glycosylation [Chabot DJ 
2000], sulfation [Farzan M et al 2002] or phosphorylation [Orsini MJ et al 1999] in 
cancer cells, which would result in structurally distinct forms of CXCR4. Other potential 
possibilities for CXCR4 conformational heterogeneity include changes in cell membrane 
lipid composition (in which the receptor resides), receptor oligomerisation or interaction 
with as yet unidentified molecules. However, neutralisation of CXCR4 using monoclonal 
antibodies has shown potential as a future cancer therapy in animal models of several 
neoplasms including those of the prostate [Engl T et al 2006] and endometrium [Gelmini 
S et al 2009] in which metastasis and progression was significantly impaired. 
d) CXCL12 analogues - CTCE-9908, a peptide analogue of CXCL12, is a 
competitive antagonist of CXCR4. It has been shown to significantly reduce metastasis as 
well as primary tumour growth in mouse models of breast [Hassan S et al 2011, Huang 
EH et al 2009] and prostate cancer [Porvasnik S et al 2009]. In fact CTCE-9908 has now 
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received orphan drug status by the FDA for the treatment of osteogenic sarcoma. 
Importantly, CTCE-9908 is the only CXCR4 antagonist that has been used in clinical 
trials. In a phase I/II clinical trial enrolling 25 patients with metastatic solid cancers, 
which were resistant to standard treatment, CTCE-9908 showed good tolerability. 
Additionally, modest response rates were seen with 6 patients having overall stable 
disease after one cycle of the drug and 1 patient demonstrating a significant reduction in 
tumour size after less than one cycle of treatment [Kavsak PA et al 2009]. 
e) Novel CXCR4 antagonists being developed - small interfering RNAs (siRNA) 
inhibit the expression of a gene by inducing cleavage of the specific mRNA. Using a 
small interfering RNA retrovirus vector driven by human prostate-specific antigen 
promoter and targeting the CXCR4 gene, Du YF et al 2008 demonstrated that CXCR4 
protein expression in LNCaP cells was blocked. In colorectal cancer, siRNA silencing 
CXCR4 expression abrogated CXCL12 induced migration of cells in vitro [Rubie C et al 
2011]. These and other results have suggested great potential for RNA interference based 
therapeutic approaches for use in targeted cancer therapy. 
Small molecular inhibitors of transcriptional coactivation of HIF-1α are also being 
developed. This can result in downregulation of CXCL12 in various tissues and inhibit 
metastasis of CXCR4 positive tumour cells [Block KM et al 2009, Kung AL et al 2004]. 
A single domain antibody is an antibody fragment comprising a single monomeric 
variable antibody domain – these are termed nanobodies. Jahnichen S et al 2010 have 
reported the isolation and characterization of functional VHH-based (i.e. heavy chain) 
nanobodies against CXCR4. Two highly selective monovalent nanobodies, 238D2 and 
238D4, competitively antagonised the chemoattractant effect of CXCL12 in CXCR4 
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expressing Jurkat leukaemia T cells. Only picomolar concentrations of these nanobodies 
was required, which represents the most potent CXCR4 inhibitors described up till now. 
These nanobodies provide a novel and promising method of inhibiting the CXCR4 
receptor in cancer cells. 
 
2. Immunotherapy 
Chemokines may have great potential as agents in cancer immunotherapy. As 
they function physiologically as immunostimulatory molecules (i.e. promotion of 
chemotaxis and the effector function of leucocyte subpopulations), these proteins may be 
used to enhance antitumour immunity in the host. Several approaches have been used in 
the delivery of chemokines, such as CXCL12, into the tumour microenvironment. 
a) Transduction of tumour cells with chemokine genes - as human tumours 
generally elicit only a weak host immune response, it would be greatly advantageous to 
render them immunogenic. Chemokines may be used to modify the tumour 
microenvironment and promote antitumor adaptive immune responses. Fushimi T et al 
2006 showed that adenoviral gene transfer of CXCL12 into murine tumours resulted in 
the attraction of dendritic cells to the tumour and inhibition of tumour growth by 
activation of a cancer specific cellular immune response involving CD8+ cytotoxic T 
lymphocytes. An advantage of using chemokines is that, unlike tumour suppressor genes, 
it is theoretically not necessary for every tumour cell to be transduced.  
b) The administration of tumour vaccine (combining tumour antigen and 
chemokines) - non-immunogenic tumour antigens can be rendered immunogenic when 
fused with chemokines. CXCL10 or CCL7 fusion to lymphoma immunoglobulin resulted 
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in variable regions eliciting leucocyte chemotactic responses in vitro and inducing 
inflammatory responses in vivo. Also, they enhanced protection against tumour 
challenge. Similarly, Zhang T et al 2005 have suggested that CXCL12 may be useful as 
an immunotherapeutic agent for cancer patients when fused with tumour antigen. 
 
3. CXCR4/ CXCL12 as prognostic markers in cancer 
The expression of CXCR4 in many malignancies may be used as a prognostic 
marker. For example, in primary breast cancer it has been shown that high expression of 
CXCR4 is associated with lymph node metastasis and indicates poor prognosis in patients 
with breast tumours [Chu QD et al 2010, Liu Y et al 2010]. Thus, this group of patients 
with high CXCR4 expression may benefit from adjuvant treatment post surgery. In 
human prostate cancer tissue CXCR4 expression is associated with perineural invasion 
[Zhang S et al 2008] and in 35 patient samples CXCR4 protein was an independent and 
superior predictor for bone metastases than Gleason sum [Mochizuki H et al 2004]. In 52 
patients with metastatic prostate cancer, those cancers with high CXCR4 expression had 
poorer cancer specific survival than those with lower levels [Akashi T et al 2008]. These 
results suggest that high CXCR4 expression in prostate cancer is associated with a more 
aggressive phenotype. This can help to guide management as for example those clinically 
localized primary prostate cancers which have a high CXCR4 index may not be suitable 
for active surveillance or focal therapy. Additionally, as discussed previously, expression 
of CXCL12 in stage I non-seminomas was demonstrated to be associated with organ-
confined disease post-orchidectomy with reduced risk of relapse [Gilbert DC et al 2009]. 
This is most likely due to the loss of CXCL12 gradients that might otherwise attract cells 
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away from the primary tumour. These patients may be avoided unnecessary post-
orchidectomy treatments with their associated toxicities. Mirisola V et al 2009 used 
microarray gene expression analysis and immunohistochemistry in breast cancer samples 
from patients and demonstrated that CXCL12 expression by the neoplasms was an 
independent prognostic marker of disease-free and overall survival. The group proposed 
that saturation of the CXCR4 receptor through autocrine CXCL12 production reduced 
chemotaxis towards CXCL12-releasing metastasis target tissues.  
CXCR4 may, in fact, offer a cell surface target for molecular imaging of 
metastases, assisting diagnosis, staging and therapeutic monitoring. Also, non-invasive 
detection of CXCR4 expression of a primary neoplasm may give an indication of 
metastatic potential of the lesion. Interestingly, Jacobson O et al 2011 developed a 
derivative of the CXCR4 peptide antagonist, T140-2D, which was labeled with the 
positron emission tomography (PET) isotope copper-64. The researchers used this agent 
to successfully identify CXCR4 positive tumour xenografts in a mouse model using PET 
imaging. In a similar study, Nimmagadda S et al 2010, reported the development and 
evaluation of [(64)Cu]AMD3100, a positron-emitting analogue of the stem cell 
mobilizing agent plerixafor, to image CXCR4 in human tumour xenografts preselected 
for graded expression of this receptor. This imaging method was evaluated in lung 
metastases derived from human MDA-MB-231 breast cancer cells, and the results 
confirmed the ability of [(64)Cu]AMD3100 to determine CXCR4 expression using PET. 
However, further research with imaging tracers targeting CXCR4 is required due to the 
concurrent high uptake of these substances in metabolic organs such as liver and kidneys. 
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SECTION 8.5 
CONCLUDING REMARKS 
The results from this thesis have implicated the CXCL12 – CXCR4 axis in the 
organ specific metastasis of prostate cancer. CXCL12 - CXCR4 chemokine ligand – 
receptor interaction has additionally been observed to be pivotal in the metastasis of a 
variety of other malignancies. However, the ultimate aim of elucidation of the genetics of 
a tumour is to incorporate it into the clinical treatment of patients i.e. therapeutic 
strategies that are individually constructed for every patient. These personalized 
management strategies based on the molecular profiling of each neoplasm will allow the 
stratification of disease aggressiveness and prognosis and therefore permit the selection 
of appropriate and specific treatment.  
Importantly, during the past 10 years there has been a chemokine revolution in 
cancer and both scientists and physicians are now aware of their crucial role at all stages 
of neoplastic transformation and progression. Great strides have been made in a relatively 
short period in elucidating the often complex relationship between chemokines and their 
role in cancer. The next 5 - 10 years are likely to see further exciting progress in the field 
of chemokine research in relation to cancer but particularly as regards the manipulation of 
various chemokine ligand – receptor pathways for therapeutic intervention in cancer 
patients. There is little doubt that potent new compounds will emerge, which will have 
the ability to influence the migration of CXCR4 positive tumour cells in cancer 
metastasis but will have fewer unwanted effects and complications. These developments 
will translate into significant survival benefits to patients.  
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1. Arya M et al. J Exp Ther Oncol. 2004;4:291-303. 
 
The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in 
prostate cancer metastasis 
 
AIM: Chemokines or chemotactic cytokines are known to be important in the directional 
migration or chemotaxis of leucocytes in conditions of homeostasis and in inflammatory 
or immunological responses. However, the role of chemokines is extending beyond their 
involvement in mediating leucocyte trafficking with an increasing body of evidence 
suggesting these proteins are intimately involved in many stages of tumour development 
and progression. Our aim was to study the role of the CXCL12:CXCR4 chemokine 
ligand:receptor complex in determining the organ-specific metastasis of prostate cancer.  
 
MATERIALS and METHODS: CXCR4 mRNA expression was determined by RT-PCR 
in 3 metastatic prostate cancer cell lines DU145, LNCaP and PC3, the primary prostate 
cancer cell line 1542 CPT3X and the normal prostate epithelial cell lines 1542 NPTX and 
Pre 2.8. This was followed by Taqman quantitative PCR analysis of CXCR4 mRNA in 
these cell lines. Flow cytometry analysis was then used to measure the expression of the 
CXCR4 receptor  protein on the cell surface. The influence of the receptor on cell 
migration was  studied using Transwell, Migration Assays. Finally, Taqman quantitative 
PCR was performed on RNA obtained from laser microdissected fresh primary prostate 
tumour and benign tissue samples from patients.  
 
RESULTS: In DU145, LNCaP and PC3 CXCR4 mRNA expression was approximately 
1000, 400 and 21 times respectively that of 1542 NPTX, Pre 2.8 and 1542 CPT3X. In 
patient primary tumour samples and patient  benign tissue specimens CXCR4 mRNA 
expression was similar to that of the metastatic cell line DU145. Flow cytometry analysis 
showed that significantly higher levels of the CXCR4 receptor were present on the cell 
surface of the 3 metastatic cell lines. Migration studies revealed that chemotaxis of the 
metastatic cell lines PC3 and DU145 was enhanced by CXCL12 ligand and inhibited by 
antibody to CXCR4. CXCL12 did not influence the migration of the normal prostate 
epithelial cell line 1542 NPTX.  
 
CONCLUSIONS: We have demonstrated that human prostate cell lines derived from 
metastases express functional CXCR4 receptor and that CXCL12 ligand enhances their 
migratory capabilities. Also, laser microdissected primary patient tumours and patient 
benign tissue specimens  express CXCR4 mRNA at high levels (it is suggested that post-
transcriptional modification of the CXCR4 receptor plays a major role in regulating 
protein expression). These results suggest prostate cancers may be influenced by the 
CXCL12:CXCR4 pathway during metastasis. This pathway would provide a novel target 
for therapeutic intervention. 
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2. Arya M et al. Tumour Biol. 2007;28:123-31.  
 
Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 
(chemokine ligand-receptor) interaction in cancer cell migration 
 
Chemokines are small, secreted proteins and are now the largest known cytokine family. 
They mediate their effects through a family of G-protein-coupled receptors and were 
initially recognized for their ability to act as chemo-attractants and activators of specific 
types of leucocytes in a variety of immune and inflammatory responses. However, during 
the past 5 years there has been a chemokine revolution in cancer and all scientists and 
clinicians in oncology-related fields are now aware of their crucial role at all stages of 
neoplastic transformation and progression. The most important chemokine ligand-
receptor interaction is that of the CXCL12 (stromal cell-derived factor-1, SDF-1) ligand 
with its exclusive receptor CXCR4; this interaction has a pivotal role in the directional 
migration of cancer cells during the metastatic process. This has been demonstrated by in 
vitro and in vivo experiments in addition to retrospective clinical studies. These findings 
have exciting implications in the field of cancer therapeutics, with several small molecule 
CXCR4 antagonists having been developed, which may provide clinical benefit in the 
therapy of cancer metastasis. Interestingly, it is likely that the effect of the anti-HER2 
antibody [trastuzumab (Herceptin] in breast cancer involves downregulation of the 
CXCR4 receptor. Unfortunately, a major problem is that chemokine receptors are 
expressed in other cells within the body, particularly those of the immune system and it is 
not clear what effects long-term CXCR4 antagonism could have on innate and adaptive 
immunity. However, there is little doubt that the great strides made in elucidating the 
complex relationship between chemokines and their role in cancer will soon translate into 
significant survival benefits for patients. 
 
 
 
 
3. Arya M et al. Expert Rev Mol Diagn. 2005;5:209-19. 
 
Basic principles of real-time quantitative PCR 
 
Real-time quantitative PCR allows the sensitive, specific and reproducible quantitation of 
nucleic acids. Since its introduction, real-time quantitative PCR has revolutionized the 
field of molecular diagnostics and the technique is being  used in a rapidly expanding 
number of applications. This exciting technology has enabled the shift of molecular 
diagnostics toward a high-throughput, automated technology with lower turnaround 
times. This article reviews the basic principles of real-time PCR and describes the various 
chemistries available: the double-stranded DNA-intercalating agent SYBR Green 1, 
hydrolysis probes, dual hybridization probes, molecular beacons and scorpion probes. 
Quantitation methods are discussed in addition to the competing instruments available on 
the market. Examples of applications of this important and versatile technique are 
provided throughout the review. 
 
 311 
4. Arya M et al. Curr Med Res Opin. 2003;19:557-64. 
 
Chemokines: key players in cancer 
 
Chemokines are a family of low molecular weight (8-10 kDa) pro-inflammatory 
cytokines, which bind to G-protein coupled receptors. Their primary function is 
chemoattraction and activation of specific leucocytes in various immuno-inflammatory 
responses. However, new research suggests that they are key players in cancer being 
involved in the neoplastic transformation of cells, promotion of aberrant angiogenesis, 
tumour clonal expansion and growth, passage through the extracellular matrix (ECM), 
intravasation into blood vessels or lymphatics and the non-random homing of tumour 
metastasis to specific sites. In view of the increasing significance of chemokines and their 
receptors in cancers of a variety of types, manipulation of this signalling pathway may be 
important in the development of new anticancer agents. This review provides an 
overview of recent research advances in this field and examines the potential therapeutic 
benefits future developments may bring. 
 
 
 
 
5. Arya M et al. Surg Oncol. 2006;15:117-28.  
 
The metastatic cascade in prostate cancer 
 
Morbidity and mortality due to prostate cancer are mainly a result of prostate cancer 
metastases. After the initial neoplastic transformation of cells, the process of metastasis 
involves a series of sequential steps, which involve neoangiogenesis and 
lymphangiogenesis, loss of adhesion with migration away from the primary tumour and 
entry into the systemic vasculature or lymphatics. Metastatic growth in sites such as 
lymph nodes and bone marrow then involves the specific non-random homing of prostate 
cancer cells. An appreciation and understanding of this metastatic cascade in relation to 
prostate cancer is clinically important in order to stratify men with prostate cancer into 
prognostic groups. Moreover, it is crucial in the future development of therapies that can 
prevent metastases. 
 
 
 
 
6. Arya M et al. Expert Rev Anticancer Ther. 2003;3:749-52. 
 
Expanding role of chemokines and their receptors in cancer 
 
(Editorial – no abstract available) 
 
 
